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Thesis Summary 
Fibrosis can be charactorised as abberent wound healing resulting from an increased presence 
of α-smooth muscle actin (αSMA)-rich, myofibroblasts and a continued influx of immune cell 
mediators.  The pro-fibrotic and pro-inflammatory cytokines TGF-β1 and IL-1β, respectivley, 
have been implicated in fibrotic progression by activating hyaluronan (HA)/CD44-mediated 
pathways. CD44, the principal HA receptor, exists as multiple spliced variants which mediate 
multiple celluar functions through their association with HA.  The aim of this Thesis was to 
investigate the expression and interactions of CD44 variants asociated with fibroblast 
activation induced by TGF-β1 or IL-1β.  
 
Multiple forms of CD44 spliced variants were identified in fibroblasts. Stimulation with TGF-
β1 decreased the expression of all variants, whereas IL-1β-increased global CD44 expression.  
CD44s was the variant identified as essential for both TGF-β1 induction of myofibroblasts and 
IL-1β-induced monocyte binding to fibroblasts.  
 
CD147 is a matrix metaloproteinase (MMP) inducer that mediates receptor interactions within 
the plasma mebrane; and contributes to ECM re-arrangment in response to various stimuli. 
CD147-medaited-αSMA incorporation into F-actin stress fibres that were essential for the 
myofibroblast contractile phenotype.  It associated with CD44s and the EDA-Fibronectin-
associated integrin, α4β7, suggesting that through receptor interaction it mediated the 
mechanotransduction properties required for differentiation.  Decreased expression of CD147 
prevented intracellular activativation of ERK1/2, an essential kinase involved in 
mechanotransdction. 
 
These data suggest that CD44s regulates both a fibrotic and inflammatory response by 
fibroblasts through two separate mechanistic pathways.  It also implicates CD44s in 
mechanotransduction, via its association with CD147. In conclusion, both CD44s and CD147 
are essential mediators of fibrosis and further research into downstream mediators could lead 
to potential therapeutic targets to combat fibrotic progression. 
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Chapter 1 - General Introduction 
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1.1. - Wound Healing 
  
Wound healing can be defined as a highly orchestrated process involving the simultaneous 
collaboration of multiple cell types in wound closure, resulting in the formation of scar tissue.  
The process requires the finely balanced activation of resident and systemic cells, the 
extracellular matrix (ECM) and wound healing mediators, such as cytokines and growth 
factors. Any alteration in surrounding environment conditions can result in dysregulated wound 
healing. The wound healing process is best described in dermal tissue, but a similar process is 
observed in other tissues types, including vital organs.  Under optimal conditions, healthy 
wound healing occurs in four overlapping stages: homeostasis, inflammation, proliferation and 
remodelling (reviewed by Steed 1997).  Figure 1.1. is an adapted schematic overview of these 
wound healing stages. 
 
 
 
 
 
 
 
Figure 1.1. Wound Healing 
The overlapping stages of wound healing include haemostasis which generally occurs between a) initial injury and b) 
coagulation. Damaged vessels undergo vasoconstriction to limit blood loss at the same time that nearby vessels undergo 
vasodilation to allow for the influx of initial mediators including neutrophils, platelets and plasma proteins. Panels c) and d) 
represent the overlapping stages of early and late inflammatory response, respectively. The influx of fibroblasts into the wound 
area is essential for the later stages of wound healing e) proliferation and finally f) the long term remodelling stage. Times 
given for each stage are approximate. Adapted from Beanes et al. (2003). 
 
Haemostasis 
Vasoconstriction 
Vasodilation 
Note – Vasoconstriction 
of damaged vessels and 
vasodilation of nearby 
vessels are overlapping 
stages.  
Polymorphonuclear 
neutrophils 
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1.1.1.-Haemostasis 
  
On initial tissue damage a rapid response results, this limits blood loss and maintains 
homeostasis.  Damage to the cells of the endothelium releases vasoactive amines and lipid 
mediators, including prostaglandins and thromboxanes, triggering damaged blood vessels 
within the wound region to undergo vasoconstriction and reduce local haemorrhaging (Wu et 
al. 1988).  Endothelial cells and platelets activate the coagulation cascade, this results in 
thrombin cleaving soluble fibrinogen to form insoluble fibrin, which together with collagen, 
thrombin and fibronectin form an insoluble clot (Li et al. 2007).  Along with preventing further 
blood loss, the clot acts as a scaffold for platelets and cells migrating into the wound area to 
release growth factors and cytokines into the surrounding region (Baum and Arpey 2005). 
1.1.2. - Inflammation  
 
Overlapping the late stage of coagulation is the early stage of inflammation. Resident mast 
cells release histamines and other vasoactivators, indirectly activating an increased production 
of prostaglandins. These activate blood vessels within the wound to undergo vasodilation and 
become leaky, allowing rapid influx of passing immune cells to the site (Urb and Sheppard 
2012). It should be noted that vasoconstriction of damaged blood vessels and vasodilation of 
other blood vessels within the wound region may happen simultaneously.  Platelets release a 
cascade of cytokines including interleukin 1β (IL-1β), platelet derived growth factor (PDGF), 
transforming growth factor - β1 (TGF-β1) and tumour necrosis factor - α TNF-α (Barrientos et 
al. 2008).  These cytokines, along with products produced from pathogens that have entered 
the wound area, activate an initial immune response from passing neutrophils, monocytes and 
other leukocytes. 
 First to migrate to the site are neutrophils. These polymorphonuclear cells destroy 
bacteria that have entered via the wound using antimicrobial peptides, reactive oxygen species 
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and proteolytic enzymes. They also engulf bacteria and any debris from dead cells by 
phagocytosis, before undergoing apoptosis (Wilgus et al. 2013). Monocytes that have migrated 
to the wound site differentiate into macrophages, which engulf wound debris, pathogens and 
any apoptotic neutrophils at the injury site.  Macrophages release further chemo-attractants and 
growth factors in the wound area. These include PDGF, fibroblast growth factor (FGF-2), TGF-
β1, vascular endothelium growth factor (VEGF); and hepatocyte growth factor (HGF), together 
with a host of pro-inflammatory cytokines such as IL-1β, IL-1α and TNF-α. TGF-β1 released 
by macrophages stimulates nearby fibroblasts and circulating fibrocytes to migrate to the 
wound using the fibril scaffold for adherence (Janis and Harrison 2014).   
1.1.3.-Proliferation 
 
The proliferation stage encompasses multiple overlapping wound healing phases including 
epithelialisation, angiogenesis, granulation tissue formation and collagen deposition.  In this 
stage, epithelial cells at the edge of the wound are stimulated by inflammatory cytokines 
including IL-1 and TNF-α released by macrophages, platelets and fibroblasts, to undergo rapid 
proliferation to form a protective barrier.  Vascular endothelial cells also undergo increased 
proliferation in response to VEGF, FGF and PDGF and form new capillaries from pre-existing 
vessels, thereby re-oxygenating the region. 
 Fibroblasts are continuously activated to migrate into the region by growth factors, such 
as PDGF, TGF-β1 and connective tissue growth factor (CTGF); and by the interaction of cell 
surface integrins with fibronectin (Repesh et al. 1982; Barrientos et al. 2008).  The migration 
of cells into the region is regulated by increased expression of matrix metalloproteinases 
(MMPs), e.g. MMP 1, 2 and 3, which modify the ECM and any cell debris that may prevent 
migration.  This increased MMP secretion results from the activation of TGF-β1 (reviewed by 
Baum and Arpey 2005).  
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 Fibroblast activation by PDGF, Epidermal Growth Factor (EGF) and TGF-β1, induces 
a rapid proliferative response. Further, stimulation by PDGF and other mediators activates 
fibroblasts to lay down a provisional matrix of collagen III, fibronectin and 
glycosaminoglycans (GAGs) (Pierce et al. 1992).  Resident fibroblasts undergo less 
proliferation than migrating fibroblasts and following stimulation by macrophage-secreted 
TGF-β1, they are activated to undergo differentiation to myofibroblasts, cells with a contractile 
phenotype that contribute to wound closure. TGF-β1 activates myofibroblasts to increase 
collagen I synthesis and inhibit MMP activity, via upregulated expression of tissue inhibitors 
of metalloproteinases (TIMPs) (reviewed in Goldman 2004).  This complex stage of wound 
healing results in a provisional scar known as granulation tissue, which is re-organised within 
the remodelling stage.  
1.1.4. –Remodelling 
 
The provisional weaker scar formed from granulation tissue contains a higher percentage of 
collagen III than the original tissue.  In the remodelling phase, which can continue for up to a 
year after initial damage, fibroblasts replace collagen III in the tissue and replace it with 
collagen I.  Further, the remodelled collagen has more structure than the original granulation 
tissue giving it more strength.  However, the new scar tissue only retains 80% of the original 
strength of the tissue, prior to injury (Janis and Harrison 2014).  
1.2 - Fibrosis Overview  
 
Fibrosis is a pathological condition that can affect multiple tissue types including vital organs 
such as the liver, kidneys and lungs (Veeraraghavan et al. 2001; Bataller and Brenner 2005; 
Liu 2006).  There are many underlying conditions that can lead to fibrosis. For example, 
chronic kidney disease (CKD), a progressive fibrotic disease, maybe initiated by various 
inflammatory, metabolic, obstructive or systemic disorders, (reviewed by Meran and Steadman 
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2011).  Regardless of the origin of fibrosis, the result is an accumulation of scar tissue that 
eventually leads to tissue damage and the loss of organ function. In healthy wound healing, 
each phase is mediated by multiple growth factors and cytokines.  However, under fibrotic 
conditions, aberrant expression of these mediators by surrounding cells leads to a non-resolving 
wound healing response. 
1.2.1. – Fibrosis as Dysregulated Wound Healing  
 
Under the normal wound healing conditions described above, the immune response is acute 
and leads to the rapid activation of the innate immune system to eliminate pathogens and 
initiate resolution.  Fibrotic wound responses are often associated with chronic inflammation 
that continues for an extended period of time.  This leads to aberrant tissue repair and a failure 
of scar resolution.  As the inflammatory response continues, normally tightly regulated growth 
factors and cytokines continue to be released and activate surrounding cells to respond 
accordingly.  Since inflammatory mediators are implicated in fibrotic progression, treatments 
commonly used for fibrotic diseases are anti-inflammatories, such as corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs). Both are often used for the treatment of many 
inflammatory diseases that eventually lead to fibrosis, including the genetic disease cystic 
fibrosis (CF) and the autoimmune disease rheumatoid arthritis (RA) (Young et al. 2007; 
Konstan et al. 2010).  Current treatments have proved inadequate in combating fibrotic 
progression, leading to the theory that the immune response is separate from fibrogenesis (Yu 
et al. 2009).  However, it is conceivable that immune response prevention has no effect on 
fibrotic progression, since the aberrant cycle has already begun and fibrotic cells are 
continuously expressing fibrotic mediators. Therefore, anti-inflammatory treatments may 
combat some but not all immune response-related problems. 
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 Wynn (2004) suggests that a more specific treatment may be required, that targets 
fibrotic mediators. A given example is the indirect activation of TGF-β1 by interleukin 13 (IL-
13), which has previously been identified to activate MMP 9, a known activator of pro-fibrotic 
cytokine, TGF-β1 (Lee et al. 2001).  Inhibiting these two cytokines in inflammatory disease 
may prevent further fibrotic progression and targeting these fibrotic mediators indirectly by the 
administration of interferon gamma (IFN –γ) and/or IL-12, may have a more inhibitory in effect 
than current treatments (Wynn, 2004). Both of these cytokines have previously been identified 
to decrease the expression of TGF-β1 and IL-13 in Schistosoma mansoni infection (SMI).  This 
disease is transmitted from flatworms found in fresh water  e.g. Uganda; and the accumulation 
of parasitic eggs in the liver leads to periportal fibrosis (fibrosis that accumulates around the 
hepatic portal vein) in a large percentage of affected people (Wynn et al. 1995).  However, in 
a study by Booth et al. (2004), it was found that patients with high blood levels of IFN-γ and 
IL-12 had a decreased risk of fibrosis from this infectious disease; and suggested that direct 
administration of these cytokines may decrease the percentage of patients with a fibrotic 
response.  
The increased presence of myofibroblasts is a marker for fibrotic progression. The 
contractile phenotype of the myofibroblast is the result of increased expression of α-smooth 
muscle actin (αSMA), which is incorporated into the F-actin cytoskeleton of these cells 
(Gabbiani et al. 1971; Clement et al. 2005). In healthy wound healing, myofibroblasts lay down 
ECM and their contractile phenotype facilitates resolution, following which these cells undergo 
apoptosis. 
In fibrotic tissue, myofibroblasts are continually present and constantly stimulated by 
growth factors and mediators to synthesise and lay down excessive interstitial ECM. This ECM 
accumulation leads to damage to the surrounding tissue and eventual loss of function (reviewed 
in Gabbiani 2003). It is widely accepted that TGF-β1 is responsible for fibroblast to 
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myofibroblast differentiation and is, therefore, a major contributor to fibrotic progression 
(Desmouliere et al. 1993).  Furthermore, TGF-β1 is a powerful chemo-attractant for fibroblasts 
and is, therefore, responsible for their excessive infiltration into damaged regions. Under 
inflammatory conditions, local immune cells, including macrophages secrete TGF-β1 (Wynn 
2008).  Furthermore, removing exogenous TGF-β1 does not inhibit the myofibroblast 
phenotype, due to an autocrine feedback loop that is mediated by hyaluronan; a major ECM 
component (Webber et al. 2009c).  The origins of myofibroblasts of fibrosis are controversial, 
although it is generally agreed that they differentiate from resident or migrating fibroblasts.  
However, a number of studies have associated increased expression of myofibroblasts with 
epithelial to mesenchymal transition (EMT), resulting from a fibrotic environment (Iwano et 
al. 2002).   
MMPs are regulators of ECM turnover that are vital for final wound resolution.  They 
have multiple, sometimes contradictory roles, including activating immune regulators, 
stimulating and inhibiting myofibroblasts; and re-organising the ECM.  MMPs comprise a large 
family of over 20 endopeptidases, with a pro-domain and zinc active site; and they are released 
in a latent form (Ra and Parks 2007). 
There are four known tissue inhibitors of matrix metalloproteinases (TIMPs 1-4) that 
inhibit MMP activity by preventing ECM turnover; and limiting fibrotic progression. However, 
in a study by Yoshiji et al. (2000) transgenic mice that overexpressed TIMP1 were subjected 
to spontaneously-induced, hepatic fibrosis in a carbon tetrachloride (CCl4) model.  The study 
found that transgenic mice overexpressing TIMP1 had a seven-fold increase in fibrosis 
compared, to control mice.  There was a marked increase in fibrotic markers including collagen 
I, IV and αSMA in TIMP1 transgenic mice; and decreased expression of the active form of 
MMP2. It was speculated that this imbalance contributed to fibrotic progression by the lack of 
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ECM degradation that resulted from decreased activity of MMP2 and its continuous inhibition 
by increased levels of TIMP1. 
TIMP3 inhibits not only MMP, but also TNF-α converting enzyme (TACE) (Baker et 
al. 2002). In TIMP3 -/- mice models subjected to unilateral ureteral obstruction (UUO), the 
expression of TNF-α decreased, as did interstitial fibrosis, while inhibition of MMPs and mice 
that had a combined TIMP3-/- TNF-α-/-  knockout had reduced inflammation and fibrosis 
(Kassiri et al. 2009).  Consistent with this study, the induction of lung fibrosis in TIMP3-/- mice 
lengthened the immune response and the influx of neutrophils, indicating that TIMP3 regulates 
the immune resolution (Gill et al. 2010). Interestingly, TNF-α induces TGF-β1 production in 
lung fibroblasts through the activation of the Extracellular Regulated Kinase (ERK) pathway.  
Therefore, increased expression of TNF-α, due to decreased TIMP levels, may ultimately 
contribute to the overall aberrant response observed in fibrosis (Sullivan et al. 2005). 
Similar to TIMP expression, the presence of several MMPs in fibrotic models initiates 
both pro- fibrotic and anti -fibrotic responses.  An anti-fibrotic role for MMP2 was determined 
has been observed in a study showing exacerbated fibrosis in MMP2-/- mice that were subjected 
to two different models of liver fibrosis (Onozuka et al. 2011). Furthermore, TIMP1, TGF-β1 
and PDGF all showed increased expression in MMP2 deficient mice in the fibrotic CCl4 model.  
Therefore, MMP 2 seems to have a regulatory anti-fibrotic role and deletion of its expression 
leads to upregulation of fibrotic mediators.  MMP 3, also known as stromelysin 1, activates 
latent TGF-β1 and has been shown to be pro-fibrotic and upregulated in human idiopathic 
pulmonary fibrosis (Giannandrea and Parks 2014).  Furthermore, a recombinant form of MMP- 
3 introduced into the lungs of rats induced fibrosis; and MMP 3 deficient mice were protected 
from bleomycin-induced pulmonary fibrosis (Yamashita et al. 2011). 
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In conclusion, tight regulation of ECM production and degradation together with 
immune response and mediators is vital for conclusive wound resolution; and any deviation 
from this regulation can result in fibrotic disease.  
 
1.3. – Cells involved in Fibrosis 
 
1.3.1. – The Fibroblast 
 
Fibroblasts are a mesenchymal cell type that display a thin spindle like morphology.  They play 
a key role in maintaining healthy ECM turnover and the structural integrity of renal interstitial 
connective tissue, synthesising many proteolytic enzymes and growth factors.  Fibroblasts are 
a principal cell type involved in restoring ECM homeostasis following tissue damage, moving 
rapidly to the site of injury where they proliferate rapidly and initiate a wound healing response 
(Janis and Harrison 2014). There is no definitive cell marker of fibroblasts. While these 
mesenchymal cells have been identified by vimentin expression, this intermediate filament is 
not exclusive to fibroblasts, making them difficult to identify conclusively (Eriksson et al. 
2009). 
While the fibroblast is ubiquitous to many tissues, these cells display a large degree of 
heterogeneity and tissue specificity. Early studies by Castor et al. (1962) identified that 
fibroblasts extracted from various anatomical sites including dermis, mesothelial and articular 
tissue had different proliferation rates and ECM production. Furthermore, activation of 
fibroblasts is tissue specific.  For example, Smith et al. (1989) identified that thyroid hormone 
triiodothyronine (T3) and synthetic glucocorticoid dexamethasone inhibited dermal fibroblast 
synthesis of hyaluronan (HA), a major ECM component, but in retro-ocular fibroblasts, neither 
hormone affected HA synthesis.  Therefore, the same stimuli can have a different response in 
fibroblasts that are present in different tissue types. Fibroblast populations can also vary at the 
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same anatomical site in injured tissue with the presence of non-contractile fibroblasts, 
contractile myofibroblasts and an intermediate proto-myofibroblast population being 
commonly observed (Tomasek et al. 2002b). 
The origin of fibroblasts is controversial and their abundance is tissue specific.  For 
example, resident fibroblasts are often abundant in connective tissues and when the tissue is 
injured these resident fibroblasts are stimulated to proliferate rapidly and secrete cytokines to 
surrounding regions; making these fibroblasts the principal wound healing population.  
However, in the renal cortex under homeostasis, fibroblasts are comparatively sparse. 
Therefore, following kidney damage, the origin of interstitial fibroblasts involved is not fully 
understood (Meran and Steadman 2011). There are several potential sources for these cells.  
First, numerous studies report that local epithelial cells undergo dedifferentiation to fibroblasts 
in a process described as EMT (Zavadil and Böttinger 2005). Epithelial cells become 
depolarised and lose their tight cell junctions, due to the loss of adherence proteins, including 
ZO1 and cadherin.  The commonly expressed epithelial integrin α6β4 is lost and replaced by 
the mesenchymal integrin, α5β1. These transformations lead to altered actin organisation and 
the release of MMPs that mediate the digestion of the basement membrane and permit cellular 
migration.  Evidence describing this process has mainly been identified in vitro and multiple 
cytokines have been suggested to mediate the process. Most research, however, has focussed 
on and implicated TGF-β1 as a major contributor to EMT.  Research in vivo, however, is limited 
due to the lack of specific markers, although alternative models have been successfully utilised. 
For example, Kim et al. (2006) successfully overexpressed β-galactosidase in lung epithelial 
cells.  Using a pulmonary fibrotic mouse model that over-expressed TGF-β1, they identified 
cells that exhibited mesenchymal markers and were positive for β-galactosidase, indicating 
EMT had taken place.  
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  Other studies have reported that a source of bone marrow stem cells known as 
fibrocytes, that circulate through the blood; are a major source of fibroblasts found at sites of 
tissue damage.  These precursor cells are present in peripheral blood and express markers for 
hematopoietic cells, leukocytes and fibroblast products, including collagen I, III and 
fibronectin (McAnulty 2007).  They do not, however, express markers for 
monocytes/macrophages or neutrophils. Fibrocytes have also been reported to differentiate 
from CD14+ mononuclear cells that enter the wound area with inflammatory cells (Abe et al. 
2001).  Furthermore, it has been shown in vitro that this activation is dependent on T-cells and 
the pro-fibrotic cytokine TGF-β1 (Abe et al. 2001). The importance of these fibrocytes can be 
demonstrated by a study that identified a higher percentage of fibrocytes present in severely 
burned patients compared to control groups, using collagen I as a marker of identification. 
Further, the increased fibrocytes presence correlated with increased TGF-β1 (Bretscher et al. 
2002).  These studies highlight the importance of these stem cells in the maintenance of tissue 
integrity at the site of injury; and may explain the presence of fibroblasts in tissues that have a 
normally sparse fibroblast population.  However, the correlation of their presence with 
increased TGF-β1 may also indicate that they have a role in fibrotic progression. The local 
mesenchymal stem cells that reside in all postnatal tissues has been proposed as a further source 
of fibroblast-like cells (Meirelles et al. 2006). 
 Multiple cytokines/growth factors influence fibroblast behaviour at the site of injury.  
It is well understood that growth factors, including PDGF, FGF and heparan binding-EGF (HB-
EGF), mediate the increases in fibroblast proliferation and increased fibroblast production of 
ECM. Cytokines, including TGF-β1 and members of the interleukin family upregulate 
fibroblast production of VEGF an important mediator of angiogenesis.  Fibroblasts also 
mediate MMP production in the surrounding region, a process known to be vital for ECM 
degradation and re-organisation; and for cellular movement (Asano-Kato et al. 2005). 
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The characteristic fibroblastic spindle morphology results from a cytoskeleton that is 
situated close to the peripheral edge of the cell membrane.  It is well-documented that activated 
fibroblasts undergo a multistage differentiation process (Figure 1.2[A]) that alters this 
cytoskeletal arrangement and results in differentiation to become a myofibroblast.  
1.3.2. – The Myofibroblast  
 
Myofibroblasts are terminally differentiated fibroblasts, that have an increased ability to 
synthesise ECM components.  The principal marker for the presence of myofibroblasts in 
tissues is αSMA, which becomes incorporated into the F-actin cytoskeleton, giving these cells 
a contractile phenotype similar to that observed in a smooth muscle cell (Gabbiani et al. 1971). 
As a result, myofibroblasts exhibit a similar morphology to smooth muscle cells with a 
flattened, irregular shape, an increased cell-ECM association and advanced gap junction 
formation. Furthermore, the cytoskeleton is rearranged and is seen not only around the 
peripheral regions of the cell membrane, as in fibroblasts, but is present throughout the cortical 
regions of the cytoplasm (Sandbo and Dulin 2011).  Under healthy wound healing conditions, 
myofibroblasts participate in tissue repair by replacing the damaged ECM and closing the 
wound site by virtue of their contractile properties.  Conversely, myofibroblasts are not usually 
present in healthy tissue. Under fibrotic conditions, this increased ECM production and 
contractile phenotype leads to damage to parenchymal tissue and eventual loss of tissue 
function, hence this cell type is the principal mediator of fibrotic progression.  
The cytokine, TGF-β1, is widely documented as the principal mediator of fibroblast to 
myofibroblast differentiation.  The proto-myofibroblast represents an intermediate cell 
phenotype between fibroblast and myofibroblasts (Figure 1.2[A]). Under normal conditions, 
fibroblasts have very limited actin-associated cell–cell or cell-ECM contact (Tomasek et al. 
2002b). However, in damaged tissue, normally quiescent fibroblasts acquire a migratory 
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phenotype, in order to re-populate and repair the damaged area.  The proto-myofibroblast can 
be described as an activated fibroblast that results from changes in the mechanical properties 
and organisation of the ECM.  A combination of these ECM alterations and activation by TGF-
β1 results in quiescent fibroblasts acquiring the more contractile phenotype typical of a proto-
myofibroblast.  However, proto-myofibroblasts differ from myofibroblasts, as they do not 
express αSMA.  Instead of αSMA incorporation into the cytoplasmic filaments, proto-
myofibroblasts have cytoplasmic β and γ actin; and consequently generate less contractile force 
than myofibroblasts (Tomasek et al. 2002b; Hinz et al. 2007). 
The ECM component, fibronectin, functions in the contractile phenotype of 
myofibroblasts. In particular, ED-A fibronectin is required to generate the mechanical tension 
required for differentiation to occur.  Increased ED-A fibronectin production is necessary for 
differentiation and this precedes the presence of αSMA at the site of injury, while the 
elimination of ED-A prevents differentiation (Serini et al. 1998). 
This increased mechanical tension in the ECM environment, along with TGF-β1 
activation, leads to alterations in cell–ECM interactions and the formation of mature focal 
adhesions.  Focal adhesions are complexes formed from integrin and integrin-associated 
proteins, such as focal adhesion kinases; and actin-associated proteins, like ezrin, radixin and 
moesin (ERM) (Geiger et al. 2001).  The formation of mature focal adhesion complexes leads 
to a re-arrangement of the actin cytoskeleton, which becomes distributed throughout the 
peripheral and cortical regions of the myofibroblast. How αSMA is incorporated into the F-
actin cytoskeleton is not entirely understood, however, it has been identified that the αSMA 
NH2 terminal peptide sequence, ACEED, is vital for the contractile phenotype of the 
myofibroblast (Hinz et al. 2002). The incorporation of αSMA into actin fibres and the increase 
in intracellular and extracellular tension contribute to the formation of supermature focal 
adhesions, formed from αSMA, tenascin, ED-A fibronectin and α5β1 integrin.  The increased 
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presence of αSMA incorporation results in further stress fibre formation and is central to the 
formation of supermature focal adhesion formation, but also increases the contractile properties 
of the myofibroblast (Hinz et al. 2003). 
 Similar to the fibroblast, the origin of increased myofibroblast numbers in fibrotic tissue 
is controversial.  Multiple cytokines and growth factors have been implicated in fibrotic 
progression and one generally accepted source of myofibroblasts is activation of resident 
fibroblasts by TGF-β1 (Figure 1.2. [B]).  However, circulating bone marrow-derived 
fibrocytes, EMT and activation of resident mesenchymal stem cells (MSCs), have all been 
implicated in the increased myofibroblast presence (McAnulty 2007)  (Figure 1.2. [B]).  
However, as both fibroblasts and myofibroblasts have an increased presence in fibrotic tissue, 
it is not well established if other cell types first transform to fibroblasts and are then TGF-β1-
activated to proto-myofibroblasts and then myofibroblasts, or if the transformation to 
myofibroblast is direct.  Alternatively, fibrocytes, epithelial and stem cells may transform 
directly to proto-myofibroblasts, leading to the continuous presence of this intermediate cell 
type within the damaged tissue.  In a recent study of the fibroblasts/myofibroblasts presence in 
heart tissue by Driesen et al. (2014), it was found that proto-myofibroblasts were able to 
undergo a dedifferentiation process into fibroblasts, as well as differentiate into myofibroblasts.  
However, myofibroblasts did not undergo dedifferentiation and therefore, were terminally 
differentiated.   It is, therefore, conceivable that the continuous presence of proto-
myofibroblasts may account for both the fibroblast and myofibroblast populations found in 
tissue under fibrotic conditions.  
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Figure 1.2 – Myofibroblast Differentiation and Epithelial to Mesenchymal Transition 
[A] Schematic adapted from (Tomasek et al. 2002) illustrates the differentiation process of fibroblasts to 
myofibroblasts (via the intermediate stage of a proto-myofibroblast) and the altered protein expression at each 
stage. Schematic [B] is an illustration of the potential origins of fibroblasts and myofibroblasts in wound healing 
and fibrosis.   
[A] 
[B] 
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1.4 - Extracellular Matrix (ECM) 
 
1.4.1. – Collagens 
 
Collagen family proteins represent the most abundant component of the ECM. Collagens exist 
in the interstitial regions of all parenchymal tissues and contribute to the fibril back bone of the 
ECM, providing structure and strength. All collagens are formed from three polypeptide α-
chains that form a right-handed triple helix.  In the ECM, collagens exist in a range of sizes, 
have different functions and their expression varies between tissue types.  Collagens all have 
repeating proline-rich tripeptide domains, Gly-X-Y, involved in forming the triple helix. 
Currently, 26 collagens have been identified and can be characterised as fibril forming 
collagens (the most abundant group, making up 90% of the ECM), fibril associated collagens 
with interrupted triple helix (FACIT), network forming collagens, anchoring fibrils, 
transmembrane collagens and basement membrane collagens (Gelse et al. 2003).   
Collagen biosynthesis is regulated by 42 genes, some of which have complicated intron-
exon patterns which contributes to the production of multiple mRNA transcripts.  Most 
knowledge of collagen synthesis is focused on the formation of fibril collagens, such as 
collagen I.  Collagen mRNA transcripts link with ribosomal subunits, where an initial 
procollagen helix is formed from the N-terminus to the C-terminus, assisted by enzymes 
peptidyl propyl cis-trans isomerase (PPI) and other collagen specific mediators (Lang et al. 
1987).  Collagen also undergoes posttranslational modifications, including hydroxylation at 
proline and lysine motifs, which thermally stabilize the helix and maintain the structure 
(Cohen-Solal et al. 1986). Procollagens are packaged into vesicles in the Golgi and secreted 
into the ECM, where the C-propeptides and N-propeptides are cleaved by procollagen 
proteases and collagen fibrils are “self assembled” (Prockop et al. 1998).   
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 The function of collagen in the ECM is not limited to structural maintenance.  It is vital 
for cell integrity and cell adhesion; and binds, stores and regulates essential growth factors. For 
example, it has been shown to mediate TGF-β1 activity by its association with the proteoglycan 
decorin (Yamaguchi et al. 1990).  It is well understood that collagen has a major role in the 
wound healing process. However, dysregulated collagen production by resident myofibroblasts 
is also associated with fibrotic progression.  This can be seen in an early study by Zhang et al. 
(1994) in a bleomycin-induced pulmonary fibrosis mouse model, in which an increase in 
procollagen I was observed in fibrotic regions within the lung, together with an associated 
abundance of myofibroblasts. The importance of collagen in regulating and maintaining a 
balanced matrix environment was shown in a study by Zeisberg et al. (2001).  This group’s 
research shows that collagen IV, an important component of basement membranes, is essential 
for the integrity and function of mouse kidney proximal tubular epithelial cells; and that 
damage to the basement membrane or inhibition of collagen IV expression results in increased 
production of TGF-β1 and facilitates EMT. Furthermore, epithelial cells cultivated on collagen 
IV maintained the epithelial phenotype.  Conversely, epithelial cells cultivated on collagen I 
began to spontaneously transdifferentiate into a mesenchymal cell type, hence, showing the 
importance of a balanced collagen expression within the ECM and its contribution toward 
fibrotic progression.     
1.4.2.-Fibronectin 
 
Fibronectin (FN) is an adhesive protein found within blood and the ECM with a molecular 
weight of ~500kDa. In humans it exists in 2 forms, a soluble form that is found in blood plasma 
and an insoluble form that is deposited in the ECM. It is formed from an 8 kb mRNA and has 
two subunits ranging from ~230 kDa to ~270 kDa, that are linked by a disulphide bond to form 
a dimer, and composed of repeating protein units, known as type I, type II and type III.  Proteins 
type I and II stabilise the folding of fibronectin by virtue of two intramolecular disulphide 
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bonds.  In humans, there are 20 known isoforms of fibronectin that result from alternative 
splicing in 3 regions. These are EIIIA, EIIIB and a third at region IIICS that is also known as 
the V region (Singh et al. 2010).  In the ECM, fibronectin forms from soluble to insoluble 
mature fibril bundles that are cell associated and form a network between adjacent cells.  This 
development of insoluble matrix FN was first discovered by McKeown-Longo and Mosher 
(1983).  It was later determined that multiple regions on the fibrinogen dimer were required to 
initiate fibril formation. These include a 70kDa N-terminal domain that also extends through a 
collagen/gelatin binding domain; and the association of cell integrins such as α5β1, with the 
RGD (Arg-Gly-Asp) domain (McKeown Longo and Mosher 1985; Singh et al. 2010).   
The interaction between fibronectin and cells via integrins has a role in regulating cell 
functions, including cell adhesion, migration and differentiation (Serini et al. 1998; Urbich et 
al. 2002).  An example of this is the interaction between integrin α4β7, which associates with 
EDA-fibronectin, a spliced isoform of cellular fibronectin that includes the alternatively spliced 
domain A. The association mediates the differentiation of fibroblasts to myofibroblasts by 
altering the tension of stress fibres and incorporation of contractile αSMA (Kohan et al. 2010).  
Fibronectin also contains binding sites via which it interacts with other ECM components. 
These include a collagen/gelatin binding domain and two or more heparin binding domains 
that mediate the interaction between fibronectin and glycosaminoglycans (Singh et al. 2010).  
1.4.3. - Proteoglycans and Glycosaminoglycans 
 
Proteoglycans are a large family of molecules that have a central protein core covalently bound 
to highly anionic glycosaminoglycan (GAG) side chains. The GAGs are the most common 
heteropolysaccharides in the body and are formed from repeating disaccharide units.  Each 
disaccharide unit consists of either the hexosamine D-glucosamine (GLcN) or D-galactosamine 
(GalN) in combination with an uronic acid. These are either D-glucuronic acid (GlcA) or L-
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iduronic acid (IdoA). The most abundantly expressed GAGs include chondroitin sulphate (CS), 
dermatan sulphate (DS), heparan sulphate (HS) and heparin, which are essential in maintaining 
the structure and function of various tissue types (reviewed by Kjellen and Lindahl 1991). The 
number of GAG chains added onto the core protein can vary between one to more than one 
hundred; and they are usually attached via a tetrasaccharide bridge that contains a single 
glucuronic acid, two galactose residues and a xylose residue (GLAc-Glu-Glu-Xyl). This 
sequence binds to a serine or threonine residue within the protein core to form an O-glycosylic 
bond, although some GAGs, for example keratan sulphate, can form an N-glycosylic bond. The 
variability of these proteoglycans results from a large range of protein cores and the 
arrangement of GAG chains, for example attachment sites usage may vary from cell to cell. 
 Proteoglycans have multiple functions and their negative charge may influence these 
functions.  The anionic charge derives from the addition of sulphate and hydroxyl groups on to 
the GAG chain and results in regulation of the functional properties of proteoglycans.  The 
negative charge creates an osmotic potential and water travels into the surrounding area giving 
a hydrated matrix environment that maintains the required conditions for optimum cell 
interactions (Hardingham and Bayliss 1990) . Furthermore, proteoglycans in the ECM provide 
low viscosity, increased lubrication and compressive strength, making them important in 
synovial joints (Beasley 2012).  They also provide a ridged structure that allows for cell 
attachment, interaction and migration (Wight et al. 1992).  There are four main classes of 
proteoglycans: interstitial proteoglycans, basement membrane proteoglycans, membrane 
bound proteoglycans and granule secretory proteoglycans (of which the major one is serglycin).  
All proteoglycans are placed into groups dependent on function, their distribution in tissue 
types and core protein homology (Kjellen and Lindahl 1991). 
 A different form of GAG is hyaluronan (HA). This ubiquitously expressed GAG exists 
alone as repeating nonsulphated disaccharide units that are not bound to a protein core.  
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1.5. – Hyaluronan: An Overview 
 
HA is a linear polysaccharide formed from repeating disaccharide units of D-glucuronic acid 
and N-acetyl-D –glucosamine (Figure 1.3.). The saccharide units are linked by alternate β1-4 
and β1-3 glucuronic bond units (Weissmann and Meyer 1954).  First discovered in 1934 in the 
vitreous of the bovine eye by Meyer and Palmer (1934), HA has since been recognised as a 
ubiquitously expressed ECM component that is widely abundant in connective tissues, 
including the ocular vitreous, heart valves, skin, synovial joints, neural and skeletal tissue. It is 
also present in much smaller quantities in soft organ tissues, such as the lungs, kidneys and the 
brain, although there is minimal expression of HA within the liver matrix (Fraser et al. 1997). 
 The structure of HA regulates the osmotic potential of the interstitial matrix and 
maintains a continuous hydrated environment and lubrication of joints (Swann et al. 1974). It 
interacts with other ECM components to form strong structural bonds that maintain the stability 
of the matrix environment (Fraser et al. 1997). Along with maintaining homeostasis, HA 
regulates cell-cell and cell-ECM associations, as well as cell proliferation, differentiation and 
migration through its association with cell surface receptors, principally CD44 and RHAMM 
(Evanko et al. 1999; Webber et al. 2009a). The dysregulation of HA metabolism, catabolism, 
ECM distribution and alterations in HA function have a major role in pathology; and have been 
associated with pathological conditions including multiple cancer types, cardiovascular, 
neurological, inflammatory and fibrotic diseases (Itano 2008; Jiang et al. 2011; Albeiroti et al. 
2015; Sherman et al. 2015). 
1.5.1. - HA Biosynthesis  
 
Unlike other GAGs that are commonly synthesised in the Golgi apparatus, uniquely HA is 
synthesised within the inner plasma membrane. HA is synthesised by membrane-bound 
enzymes known as hyaluronan synthases (HASs), that may be classified into class I and class 
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II.  Class I includes eukaryotic HASs, which use UDP-N-acetyl-D-glucosamine and UDP-α-
D-glucuronate as substrates for HA synthesis (Weigel and DeAngelis 2007). There are three 
isoforms of HASs in vertebrates known as HAS1, HAS2 and HAS3, each transcribed from 
discrete autosomal loci on different chromosomes (Spicer and McDonald 1998). 
 The synthesis of HA by HAS enzymes is mediated by the addition of each new sugar 
onto the reducing (UDP) end of the previously added sugar. This allows for the addition of the 
next sugar, via the loss of the covalently bonded UDP residue. The non-reducing end is 
extended and elongated into the peri-cellular space as shown in (Figure 1.3 [B]) (Bodevin-
Authelet et al. 2005).  HA accumulates and forms a peri-cellular matrix or coat around the 
exterior of many cell types (Clarris and Fraser 1968). 
 In a study by Itano et al. (1999), the enzymatic functions of the three HAS isoforms 
were observed in cells transfected with HAS1, 2 or 3 overexpression vectors. Following 
transfection, these workers observed that cells overexpressing HAS1 had a much smaller HA 
peri-cellular coats, compared to cells overexpressing HAS2 or 3.  It was also found that the 
HAS isoforms synthesised HA of different molecular weights. HAS3 synthesised the lowest 
molecular weight HA of ~1 x 10 5– 1 x 106 Da.  HAS 1 and 2 synthesised HA with a larger 
mass ranging between ~2 x 105 – 2 x 106 Da, HAS2 synthesised the largest molecular weight 
HA with a mass at the higher end of the given range. Furthermore, they found the synthesis 
rate and stability of HA produced varied between isoforms, suggesting they all have different 
properties.  Successive subsequent studies have shown different cellular responses are HA size- 
dependent and that induction of HAS gene expression varies between cell types (Craig et al. 
2009; Campo et al. 2010).  In summary, current evidence suggests that the properties and 
functions of each HAS protein may depend on the cellular context in which its corresponding 
gene is expressed. 
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1.5.2. HA Assembly and Hyaladerins  
 
Considering the simplicity of its structure, HA exhibits considerable functional diversity.  
Following synthesis and release by the cell, HA undergoes re-organisation and assembly by 
interstitial hyaldherins, contributing significantly to its functional diversity.  Many hyaldherins 
belong to the link domain family and bind to HA using this link region. These include HA 
receptor, CD44, which mediates multiple HA functions including migration, ECM re-
arrangement and differentiation.  The HA receptor know as lymphatic vessel endothelial 
hyaluronan receptor 1 (LYVE-1), also has a link domain that has been associated with HA 
degradation in lymphatic vessels (reviewed in Day and Prestwich 2002). 
 Tumour necrosis factor stimulated gene 6 (TSG-6) contains a single link domain and is 
widely documented to be involved in the formation of HA peri-cellular matrices.  For example, 
TSG-6 expression is upregulated following TGF-β1 stimulation in myofibroblasts, and is 
important in the formation of the HA peri-cellular coat that maintains cellular phenotype 
(Simpson et al. 2009).  Further, in kidney proximal tubular cells from line HK2, that can be 
activated to undergo EMT using TGF-β1 stimulation in vitro, silencing TSG-6 mRNA 
prevented formation of HA cables (Bommaya et al. 2011).  These HA cables are commonly 
associated with the immune response and bind leukocytes to HA in a process that is CD44-
dependent (de la Motte et al. 1999; Selbi et al. 2006).  Other ECM components with link 
binding domains include the proteoglycans, aggrecan, versican and neurocan. The association 
of these proteoglycans with HA through the link domain forms stabilizing complexes that are 
important in maintaining the structural integrity of tissues (Day and Prestwich 2002). 
 Not all hyaldherins that mediate HA assembly contain a link domain.  Members of the 
Inter α trypsin Inhibitor family (IαI) are non-link domain hyaldherins, comprised of a light 
chain and a varied arrangement of six heavy chains (HCs). The light proteoglycan chain is 
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formed of a chondroitin4-sulphate chain linked to the core protein, bikunin.  Bikunin is widely 
documented as a protease inhibitor, due to the presence of two Kunitz type protease inhibitor 
domains (Xu et al. 1998).  The bikunin domain is often associated with either one or two HCs.  
For example, in pre-α-trypsin inhibitor (PαI), only HC3 is associated with bikunin, while in 
IαI, bikunin is associated with HC1 and HC2.  These linkages take place via an ester bond 
formed between the carboxyl end of the HCs and the chondroitin4-sulphate chain (Enghild et 
al. 1999). One key HC function is the stabilisation of HA matrices.  For example, IαI is essential 
for ovulation, due to its covalent bonding and stabilizing of the HA-rich, ECM.  TSG-6 has 
been widely documented to be required for the transfer of HCs from IαI onto HA, thereby 
facilitating the formation of HA matrices indirectly, as well as directly through its link domain 
(Colón et al. 2009). 
 Another commonly described non-link domain hyaldherin is the receptor for 
hyaluronan - mediated motility (RHAMM), that mediates cellular migration and proliferation 
via its association with HA (Akiyama et al. 2001; Nedvetzki et al. 2004). The precise 
mechanisms of hyaldherin-HA association are presently under intensive study.  However, it is 
well established that these molecules are highly important in maintaining homeostasis; and that 
aberrant expression alters HA assembly and function and can result in disease. 
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[A] 
Figure 1.3. Hyaluronan Synthesis and Structure 
[A] Chemical structure of linear HA polysaccharide formed from repeating disaccharide units. Each disaccharide unit 
is comprised of D-glucuronic acid and N-acetyl-D –glucosamine, linked by alternating β1-4 and β1-3 glucuronic bond 
units (red arrow). Adapted from (http://morebrainpoints.blogspot.co.uk/2013/10/naked-mole-rats-cure-for-
cancer.html). [B] Synthesis of HA in the plasma membrane. (1) Position of HA synthesis in the plasma membrane and 
variable lengths of HA synthesis by HAS 1, 2 and 3. (2) Class 1 eukaryote HAS with six transmembrane domains. (3) 
Addition of saccharide units UDP-GLcNAc and UDP-GlcA at the reducing UDP end of the HA chain by HAS 
enzymes.  HA elongates into extracellular regions at the non-reducing end of the molecule. (1) Adapted from Stridh et 
al. (2012). (2) and (3) adapted from Dr. Paul H. Weigel  
http://www.glycoforum.gr.jp/science/hyaluronan/HA06a/HA06aE.html#III. 
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1.5.3. - HA Degradation  
 
HA production and degradation is a rapid and continuous process. However, the half-life of 
HA varies between tissue types. Hyaluronidases (HYALs) are a family of enzymes that are 
encoded by six HYAL-like sequences at two discrete autosomal loci.  Three HYAL enzymes 
are principally involved in HA degradation in somatic tissue: HYAL1, HYAL2 and HYAL3. 
HYAL1-3 are all located in a cluster at 3p21.3. Three further HYAL-like sequences, clustered 
at 7q31.3, are known as HYAL4, SPAM1 and a HYALP1; and respectively encode proteins 
HYAL4, sperm protein PH-20 and a pseudogene (a gene that is transcribed, but not translated).  
However, the latter three genes are not relevant in somatic tissue and will not be discussed any 
further in this text (Itano et al. 1999; Csoka et al. 2001). 
 HYAL1, also known as plasma hyaluronidase, is found in abundance in multiple tissue 
types and is expressed as a 57 kDa protein.  It is an active acid lysosomal enzyme that can 
degrade HA of any size, usually into tetrasaccharides (Afify et al. 1993).  HYAL2 is also an 
acid active enzyme that functions optimally in an acidic environment, is attached to the plasma 
membrane by a glycophospatidylinositol (GPI) anchor (Rai et al. 2001); and specifically 
cleaves high molecular weight HA into 20 kDa fragments.  The HA receptor CD44 is essential 
to HA degradation by HYAL1 and 2 (Harada and Takahashi 2007).  Using cells that stably 
overexpressed HYAL1, 2 and 3, simultaneously, with the overexpression of the HA receptor 
CD44, it was essential that HA was internalised by CD44 to allow lysosomally-located HYAL1 
to catabolise HA (Harada and Takahashi 2007).  Blocking CD44 activity using antibodies 
prevented HYAL1 function and HA degradation into tetrasaccharides (Harada and Takahashi 
2007). 
 Furthermore, HYAL2 catabolism of HA at the plasma membrane was also shown to be 
CD44-dependent, consistent with previous research by (Bourguignon et al. 2004), that 
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observed that CD44 co-localisation with HYAL2 at the plasma membrane was essential for 
HA catabolism by HYAL2. Interestingly, this study found that the CD44/HYAL2 complex was 
increased in caveolae microdomains, due to optimal environmental pH.  HYAL3 was not 
involved in HA breakdown in the overexpression model. 
 It has previously been suggested that these two enzymes work together in the 
degradation of HA (Csoka et al. 2001). These authors suggest that HYAL2 breaks down large 
exogenous HA into 20 kDa fragments and that these smaller fragment are then internalised and 
further catabolised by HYAL1 enzymes within lysosomes.  However, the aforementioned 
study by Harada and Takahashi (2007), showed that HYAL1 and HYAL2 have the ability to 
degrade HA independently of each other.  (Figure 1.4) is a schematic that shows the generally 
accepted model of internalisation and degradation of HA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. HA Internalisation and Degradation 
Internalisation of HA via CD44 located in caveolae raft regions.  Following internalisation into endosomes, large linear HA is 
broken down into approximately 20 kDa fragments by HYAL2.  Fusion of endosomes with lysosomes containing HYAL1 
leads to further breakdown of HA. Adapted from Dr. Robert Stern 
http://www.glycoforum.gr.jp/science/hyaluronan/HA15a/HA15aE.html. 
CD44 and HAYL 2 are both 
situated within the plasma 
membrane. 
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1.5.4. - HA Involvement in Fibrosis 
 
Increased HA expression and correlation with progression of fibrosis has been observed in 
many tissue types, leading to the suggestion that HA is a marker for fibrotic progression 
(Halfon et al. 2005).  HA accumulation has been associated with inflammatory response 
induction, since upregulated HA synthesis has been observed in inflammatory diseases, such 
as asthma and inflammatory bowel disease (de la Motte 2011; Liang et al. 2011). However, 
different molecular weights of HA regulate both anti-inflammatory and pro-inflammatory 
immune responses. For example, in a study by Nakamura et al. (2004), using T-cell induced 
liver injury in mice, injection with high molecular weight HA (HMW-HA) of ~900 kDa, a 
significant reduction in expression of pro-inflammatory cytokines was seen, including, TNF-α 
and IFN-γ; indicating an anti-inflammatory role for HMW-HA.  Conversely, HMW-HA that 
has been depolymerised to fragmented or low molecular weight HA (LMW-HA) elicits a pro-
inflammatory response in inflammatory diseases, such as rheumatoid arthritis (RA).  It is not 
understood how LMW-HA mediates this pro-inflammatory response.  However, it is known 
that LMW-HA can mediate intracellular signalling through multiple receptors, including CD44 
(Termeer et al. 2002; Wolny et al. 2010; Kouvidi et al. 2011). 
 HA molecules also cross-link to form cables between adjacent cells that facilitate 
leukocyte binding. This cross linking is achieved by the HCs of IαI and pre-α inhibitor (PαI) 
being covalently linked to HA, a process known to be facilitated by the hyaldherin, TSG-6.  It 
has been proposed by Day and de la Motte (2005), that cables act as an anti-inflammatory 
mediator by binding leukocytes and preventing the activation of receptors on resident cells, 
thereby preventing the release of pro-inflammatory cytokines. It is thought that CD44 receptors 
on the plasma membrane of leukocytes form clusters and internalise a proportion of the HA 
cables to facilitate binding. Furthermore, it has been shown that the HA peri-cellular coat can 
mediate the activation of resident cells by leukocytes. For example, it was previously 
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determined by Selbi et al. (2004), that HA cables were formed between unstimulated, adjacent 
cells proximal tubular cells. In addition, monocytes were shown to bind to the cables via CD44.  
The association of the monocytes with the HA cables prevented the association and subsequent 
activation of the cells by monocytes. 
 In a later study, it was reported that removal of HA from the cell surface lead to 
increased association of monocytes with the intracellular adhesion molecule 1 (ICAM-1). This 
increased association resulted in upregulation of TGF-β1 promoter activity that was ICAM-1 
dependent (Zhang et al. 2004). Moreover, TGF-β1 has previously been shown to activate 
epithelial to mesenchymal transition in these cells. Therefore, the HA cables seem to play a 
role in preventing and limiting an inflammatory and fibrotic response (Zhang et al. 2004).   
As well as indirectly mediating fibrotic progression through a dysregulated immune 
response, HA contributes directly to a pro-fibrotic response. Under fibrotic conditions, HA 
oligomers have been shown to interact with RHAMM and mediate fibrosis via increasing 
inflammation, migration and angiogenesis.  Using a HA oligomer targeting HA/RHAMM 
association, Tolg et al. (2012) found that preventing HA binding to RHAMM significantly 
decreased the presence of fibroblasts within rat wounds.  Furthermore, they suggested that the 
reduction in cell migration results from interference with the required RHAMM association 
with focal adhesion kinases. A previous study by Webber et al. (2009b), found that association 
of HA with principal receptor CD44 is central to the formation of a peri-cellular coat. 
Moreover, this HA peri-cellular coat was essential for both differentiation and maintaining the 
myofibroblast phenotype. The host laboratory has previously identified the importance of the 
HA/CD44 interaction in both inflammatory and fibrotic regulation (Meran et al. 2008a; 
Simpson et al. 2009; Midgley et al. 2013).  Two cytokines that are known to mediate CD44/HA 
regulation of pro-fibrotic and pro-inflammatory responses are TGF-β1 and IL-1β, respectively. 
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1.6. – Transforming Growth Factor–β (TGF-β) and Fibrosis 
 
1.6.1. - Transforming Growth Factor-beta (TGF-β) 
 
There are three isoforms of TGF-β known as TGF-β1, β2 and β3. These multifunctional 
cytokines are members of the transforming growth factor super family (TGFSF).  All three 
isoforms are transcribed from different genes and play roles in embryogenesis, cellular 
regulation and progression of diseases, including cancer, heart disease and fibrosis (Lawrence 
1996). 
 TGF-β is secreted ubiquitously by multiple parenchymal cell types and infiltrating 
leukocytes in a latent form that is biologically inert.  Latent TGF-β is secreted as a large protein 
with a range of 390-412 amino acids in length. To become activated, it is cleaved to produce a 
pro-region known as a latency-associated protein (LAP) and active mature TGF-β.  The LAP 
can be released or re-organised to allow for exposure of the TGF-β receptor binding site. There 
are multiple proteases reported to cleave latent TGF-β including plasmin, thrombospondin-1 
and MMP-2 and -9 (Yu and Stamenkovic 2000; Robertson et al. 2015). Furthermore, 
environmental changes including pH and increased temperature can release the LAP 
association from the active region.  TGF-β1 is the most studied member of the isoforms and it 
is widely acknowledged that it is a major mediator of wound healing and fibrosis. 
1.6.2. -Transforming Growth Factor-β1 (TGF-β1) 
 
TGF-β1 is encoded by the TGF-β1 gene at 19q13. The three subtypes of TGF-βR (TGF 
Receptor) are known as types I, II and III. TGF-β1 signalling requires both type I and type II 
receptors. TGF-βRIII (also known as betaglycan) is a proteoglycan with approximately 10 kDa 
of N-linked glycan chains, together with chondroitin sulphate and/or a heparan sulphate chains.  
Betaglycan exists in both soluble and plasma membrane-bound forms, both of which bind 
members of the TGF-β superfamily and other ligands, including basic fibroblast growth factor 
31 
 
(bFGF) (Andres et al. 1989; 1992). The membrane bound form does not have an active 
intracellular signalling domain, but forms dimers with both TGF-βRII and TGF-βRI (Henis et 
al. 1994; Zhang et al. 2010).  In this way both soluble and membrane bound TGF-βIII forms 
act as accessory proteins, providing a reservoir of ligands that can present or restrict TGF-β 
superfamily member association with TGF-βRI and II (Andres et al. 1989; Zhang et al. 2010). 
Initially, TGF-β1 interacts with TGF-βRII prior to interaction with TGF-βRI, the 
phosphorylation of a threonine residue in a glycine/serine domain in TGF-βRI by TGF-βRII 
results in intracellular signalling. In the absence of TGF-βRII, there is no signal from TGF-
βRI, indicating the importance of this complex formation (Feng and Derynck 1996). 
The type I receptor that is associated with TGF-β1 signalling has been identified as an 
activin-like kinase receptor (ALK-5). Activation of this receptor following TGF-β1 binding 
activates the downstream SMAD pathway, resulting in the translocation of SMAD proteins to 
the nucleus where they form complexes and mediate gene regulation. In mammals, SMAD2 
and 3 are TGF-β/activin receptor dependent, the other SMADs are bone morphogenic protein 
(BMP)-dependent. 
BMP cytokines also represent a subfamily of the TGF-β superfamily.  TGF-β1 induced 
SMAD regulation has previously been shown to be anti-proliferative, and therefore has a 
tumour suppressive role (Seoane 2006).  By contrast, TGF-β1 induction of ERK1/2 has a role 
in EMT, contributing to tumour progression (Xie et al. 2004), and TGF-β1:receptor interactions 
are therefore cell specific. Similarly, stimulation of dermal fibroblasts with TGF-β1 results in 
increased cellular proliferation, but oral fibroblasts stimulated with TGF-β1 have an anti-
proliferative response (Meran et al. 2008b).  
TGF-β1 has also been associated with cellular regulation of the ECM, integrin 
expression and increased production of protease regulators; and thus acts as a major mediator 
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of cell-ECM contact. TGF-β1 activation increases fibroblast expression of fibronectin, collagen 
I and HA, all of which are important in cell differentiation, migration and adhesion (Streuli et 
al. 1993).  However, not only fibroblasts are activated by TGF-β1 to produce ECM components.  
For example, TGF-β1 activation of SMAD2 and 3 through TGF-βRI in corneal endothelial cells 
increased their production of laminin and fibronectin (Usui et al. 1998). 
Regulation of cellular TGF-β1 expression is also commonly mediated by ECM 
components.  For example, in an early study by Streuli et al. (1993), the basement membrane 
(BM) was determined to be important in regulating cellular TGF-β1 expression. In the absence 
of the BM, TGF-β1 promoter activity increased significantly.  Furthermore, when epithelial 
cells were in contact with a BM that was either endogenously synthesised or added 
exogenously, the activity of the promoter significantly decreased. 
TGF-β1 also regulates cellular synthesis of proteases, including MMPs, and therefore 
indirectly modulates ECM arrangement and turnover. For example, TGF-βR complexes 
activate downstream SMAD and co-SMADs, these transcription factors have been shown to 
target the TGF-β1 inhibitory element (TIE) within the promotor regions of MMP 1 and MMP 
3, thereby, regulating their expression.  Furthermore, MMP gene expression varies depending 
on the cell type and location (Brinckerhoff and Matrisian 2002; Burrage et al. 2006).  Therefore, 
TGF-β1 expression and the ECM work synergistically to maintain a tightly regulated cellular 
environment and disruption of this homeostasis may result in disease. 
1.6.3. – TGF-β1 Induced HA/CD44 in Fibrosis 
 
Under normal conditions in damaged tissue, TGF-β1 mediates a healing response by 
activating phenotypic transition of resident fibroblasts to myofibroblasts. Early studies 
determined that TGF-β1 stimulation of fibroblasts resulted in altered morphology, resulting 
from increased αSMA expression and subsequent increase in contractile force (Serini and 
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Gabbiani 1999; Vaughan et al. 2000).  Multiple studies have shown a distinct change in 
fibroblast morphology, following TGF-β1 stimulation, from a thin spindle-like morphology to 
the three dimensional polygon structure; typical of myofibroblasts. Furthermore, F-actin re-
arrangement also alters in myofibroblasts and actin bundles show an increased thickness 
resulting from αSMA incorporation (Desmoulière et al. 1993; Hinz et al. 2001; Tomasek et al. 
2002a; Evans et al. 2003b).  Interestingly, removal of TGF-β1 does not reverse this 
morphology, indicating that the differentiation process is stable and non-reversible (Evans et 
al. 2003a; Webber et al. 2009b).  The morphological change is associated not only with 
upregulated αSMA expression, but also an increased presence of ECM components, including 
collagen I, II, III and fibronectin (Ignotz and Massague 1986; Varga et al. 1987; Evans et al. 
2003b). It has long been determined that TGF-β1 interaction with its receptor, ALK5, activates 
the phosphorylation of downstream SMAD proteins (Heldin et al. 1997; Goumans et al. 2002). 
Interestingly, the overexpression of SMAD3 in fibroblasts induces terminal differentiation in 
a TGF-β1-independent manner. However, overexpression of SMAD2 does not activate a 
differential change, suggesting that SMAD3 activation regulates cell morphology (Evans et al. 
2003b).  
An important feature of the myofibroblast’s role in fibrotic progression is its excessive 
production of ECM components (Hinz 2007). In fibrotic tissue, collagen is the major ECM 
component laid down by myofibroblasts and can be used as a further marker of fibrotic 
progression (Rosenberg et al. 2004; Fontana et al. 2008). In order for fibroblasts to increase 
collagen production independent of TGF-β1, the over expression of SMAD2, SMAD3 and Co-
SMAD4 was required. Furthermore, silencing any of these SMADs individually prevented 
differentiation, highlighting the importance of this complex in gene transcription associated 
with myofibroblast differentiation (Evans et al. 2003b). 
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The association of increased HA expression in scar tissue with fibrotic progression is 
well-documented. TGF-β1 stimulation increases HA metabolism, leading to an accumulation 
of both intracellular and extracellular HA and the formation of a peri-cellular coat (Eddy 1996; 
Jenkins et al. 2004).  Terminally differentiated myofibroblasts exhibit a HA peri-cellular coat 
assembled from crosslinking of linear HA (Webber et al. 2009a).  HA is tethered by 
hyaldherins, such as HC from IαI and PαI, which are localised by association with TSG-6 (Selbi 
et al. 2006).  TSG-6 gene expression is elevated following TGF-β1 stimulation.  Interestingly, 
inhibition of TGF-β1 receptor, ALK5, decreased TSG-6 expression; and in recent unpublished 
data it was determined that the transcriptional expression of TSG-6 was also SMAD3- 
dependent.   
In dermal fibroblasts, peri-cellular coat assembly is central to the maintenance of the 
myofibroblast phenotype. By contrast, the rapid, non-scarring healing of the oral mucosal 
membrane results from a fibroblast population with different myofibroblastic differentiation 
properties.  Comparison of non-scarring oral fibroblasts with scar forming dermal fibroblasts 
reveals different transcriptional expression of HAS isoforms. HAS1 is not expressed in oral 
fibroblasts and HAS2 expression decreases in the presence of TGF-β1.  By contrast, scar-
forming dermal fibroblasts express HAS1 and HAS2 and expression of both increases in TGF-
β1-induced myofibroblasts (Meran et al. 2007). 
HAS2 siRNA silencing and depleting the cytoplasmic pool of UDP-glucuronic using 
4MU, prevents myofibroblast differentiation in dermal fibroblasts, but TGF-β1 
phosphorylation of the SMAD pathway is not affected (Webber et al. 2009c).  Therefore, the 
formation of the HA peri-cellular coat is essential for myofibroblast differentiation.  The lack 
of a HA peri-cellular coat prevents TGF-β1- induced myofibroblast differentiation in oral 
fibroblasts, therefore, the synthesis and arrangement of the peri-cellular coat is central to the 
differentiation process (Webber et al. 2009c).  HA accumulation occurs simultaneously with 
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the secretion of HYAL1 and 2, but the expression of both these HA degrading enzymes is 
decreased in myofibroblasts.  A subsequent decrease in HA degradation might also favour 
accumulation of HA in fibrotic disease (Jenkins et al. 2004).  
Increased dermal fibroblast proliferation is also thought to be central to scar formation 
and hence, fibrotic progression. Analysis of proliferation in dermal and oral fibroblasts 
stimulated with TGF-β1 has shown an anti-proliferative response in oral fibroblasts, compared 
to increased proliferation in dermal fibroblasts (Meran et al. 2008b) Although both cell types 
are activated by TGF-β1 through the SMAD pathway, but different expression patterns of the 
genes encoding HA-associated proteins, including aggrecan and versican were observed 
(Meran et al. 2008b).    
    The interaction between HA and receptor CD44 is central to both fibroblast 
differentiation and proliferation; and this HA/CD44 interaction is TGF-β1-dependent. Co-
localisation of CD44 with epidermal growth factor receptor (EGFR) is also central to both 
fibroblast proliferation and differentiation.  In oral fibroblasts, the involvement of CD44 is not 
required for an anti-proliferative response, but in dermal fibroblasts, the upregulation of HA is 
associated with the increased  interaction of CD44 and EGFR; and HA mediates the co-
localisation between the two receptors. Furthermore, the overexpression of HAS2 in oral 
fibroblasts can reverse the anti-proliferative response and drive proliferation.   
 A similar response can be observed in aged dermal fibroblasts.  These cells have 
impaired differentiation properties resulting from decreased HAS2 expression, limited HA 
peri-cellular coat assembly and downregulation of TSG-6.  There is also a failure of HA to 
associate with CD44 and a decreased expression of EGFR, preventing the CD44/EGFR 
association essential for αSMA induction.  This inability to undergo differentiation may 
contribute to non-healing wounds, which are commonly associated with age or disease.  
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However, overexpression of HAS2 alone is not enough to restore the myofibroblast phenotype 
observed in young dermal fibroblasts.  Simultaneous overexpression of EGFR with HAS2 is 
required to recover the differentiation properties of aged fibroblasts to myofibroblasts 
(Simpson et al. 2009; 2010).     
The association of HA-mediated CD44/EGFR results in the phosphorylation of EGFR 
and subsequent downstream activation of ERK1/2. The activation of ERK1/2 happens in a 
biphasic manner, with early and late phase activations. The proliferative response is associated 
with the late activation of ERK1/2 and is TGF-β1/HA/CD44/EGFR dependent. It is not 
observed in oral cells that exhibit an anti-proliferative response, due to limited HA synthesis 
(Meran et al. 2011a). A similar HA/CD44/EGFR response has been observed in fibroblast-
myofibroblast differentiation; and TGF-β1 induction of this complex formation activates 
downstream ERK1/2 followed by calmodulin kinase II (caMKII), which is phosphorylated in 
a similar biphasic pattern as upstream ERK1/2 (Midgley et al. 2013).  Recent work has shown 
that EGFR is present within caveolin lipid raft regions in both fibroblasts and myofibroblasts.  
Conversely, CD44 is more mobile in fibroblasts and is present inside and outside lipid raft 
regions (Midgley et al. 2013).   However, the motility of CD44 throughout the plasma 
membrane is significantly decreased in myofibroblasts, resulting from its association with 
EGFR within lipid raft regions. Dysregulation of HAS2, CD44 or EGFR expression results in 
loss of downstream ERK1/2 and CAMK-II phosphorylation; and subsequently a loss of αSMA 
induction (Midgley et al. 2013). Therefore, it has previously been determined that the pro-
fibrotic cytokine, TGF-β1 mediates fibrosis through the continuous activation of the SMAD2/3 
and co-SMAD4 pathway simultaneously, with the HA/CD44/EGFR pathway, both of which 
are required for differentiation (Figure 1.3) and proliferation of resident fibroblasts. 
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1.7 – Interleukin-1 β (IL-1β) and Fibrosis 
 
1.7.1. – Interleukin-1 
 
IL-1 was purified several times and given multiple names, including endogenous pyrogen, 
lymphocyte activating factor and thymocyte proliferating factor. In 1979, it was given the 
uniform name of IL-1(Aarden et al. 1980). Two forms of the three identified members of the 
IL-1 family are agonistic while one is antagonistic. All have been identified as sharing 
approximately 20-25% amino acid sequence homology (Burger et al. 2006; Brocker et al. 
2010).  Respectively, these are IL-1α and IL-1β; and a receptor antagonist known as interleukin 
receptor antagonist protein (IRAP) also abbreviated to (IL-1Ra) (Stylianou and Saklatvala 
1998). 
TGF-BR 
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HA 
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Figure 1.5. TGF-β1 mediated fibroblast –myofibroblast differentiation. I 
Interaction of TGF-β1 with TGF-βR activates the downstream SMAD pathway. Simultaneously, HA modulates the movement 
of CD44 through the plasma membrane where it co-localises with EGFR and becomes locked into caveolae lipid rafts.  This co-
localisation results in EGFR phosphorylation and the subsequent downstream activation of ERK1/2 and CAMK-II, both of 
which are essential for increased production of αSMA, HAS2 and TSG-6.  The upregulation of HAS2 increases HA synthesis, 
and HA is rearranged on the cell surface to form a peri-cellular coat.  The coat is formed from crosslinking of HA to hyaldherins 
such as HCs from IαI and PαI, which is facilitated by TSG-6.  The HA coat maintains the myofibroblast phenotype, and αSMA 
becomes incorporated into the F-actin cytoskeleton to give the myofibroblast its contractile phenotype. 
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 There are two identified receptors to IL-1 proteins known as IL-1R1, an 80 kDa protein 
that has a long cytoplasmic tail; and IL-1R2, a 60 kDa protein that has a short cytoplasmic tail 
(Wesche et al. 1997; Arend et al. 1998).  Interaction of IL-1 proteins with IL-1R2 does not 
activate a signalling pathway and, therefore, IL-1RII is often referred to as a decoy receptor.  
The activation of both IL-1α and IL-1β occurs via association with the IL-R1 and its association 
with an IL-1 receptor associated protein (IL-1R AcP); and this complex is required for 
intracellular signalling (Dinarello 1991; Arend 2002). The IL1-Ra isoform also associates with 
the IL-1R1, but fails to activate intracellular signalling and acts as a regulator of IL-1 signalling 
(Arend et al. 1998). 
 IL-1α and IL-1β are produced mainly by inflammatory cells, including monocytes and 
macrophages.  However, they are also commonly secreted by fibroblasts, endothelial and 
epidermal cells (Dinarello 1988).  Both isoforms are synthesised as 31 kDa pro-IL1 and cleaved 
into their 17 kDa active form (Krumm et al. 2014).  IL-1β is cleaved in the plasma membrane 
by a protease named IL-1β converting enzyme (ICE) and is secreted in its active mature form 
(Thornberry et al. 1992).  IL-1β is largely involved in inflammatory responses, and has also 
been widely accepted to have a major role in wound healing and fibrosis (Arend 2002). 
1.7.2. – IL-1β and Inflammation 
 
IL-1β is a potent inflammatory mediator that has an increased expression in disease tissue. The 
promoter region of the IL-1β gene contains a typical TATA region along with binding sites for 
NFκB, Activating Protein 1 (AP1), cAMP response element binding protein (CREB), NF-IL6 
and novel nuclear factor NF-βA.  Stimuli that induce pathways that regulate the transcription 
of pro-IL-1β mRNA include IL-1β itself, TNF-α and toll like receptor ligands, such as 
lipopolysaccharides (found on gram-negative pathogens), that activate the toll like receptor 
pathway. IL-1β induces several genes via the activation of intracellular signalling pathways, 
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including the activation of NF-κB (biding sites for which are often found within promoter 
regions of inflammation-associated genes), AP1 and mitogen activated kinase (MAPK) p42 
and p44, i.e. the ERK1/2 pathway (Liacini et al. 2002) 
Increased IL-1β expression has been observed in the synovial fluid of arthritic joints, 
the skin of patients that suffer from fibromyalgia, as well as ulcerative colitis and 
neurodegenerative diseases (Gan et al. 2002; Salemi et al. 2003; Granet et al. 2004; Koprich et 
al. 2008).  This increased expression results in further activation of other inflammatory 
mediators and cytokines that results in a further influx of inflammatory cells. In acute tissue 
damage, IL-1β activates IL-6, a potent inflammatory mediator. However, in IL-1β-/- mice, the 
acute phase response usually observed in local tissue damage is prevented, as there is no 
activation of IL-6 (Fantuzzi and Dinarello 1996).  In degenerative disease, there is increased 
expression of MMPs that contributes to degradation of local tissue.  In tendonopathy, increased 
expression of IL-1β correlates with the increased expression of MMP-13 (collagenase-3), an 
MMP that has been linked to osteoarthritis, rheumatoid arthritis and peridontal disease; and 
silencing IL-1β mRNA expression decreases expression of MMP-13 (Sun et al. 2008). 
Blocking signalling pathways of transcription factors NF-κβ, AP-1 and mitogenic kinase 
proteins prevented the upregulation of MMP-1, MMP-8 and MMP-13, all of which have been 
implicated in arthritic progression (Sun et al. 2008).  Furthermore, IL-1 stimulation increased 
phosphorylation of kinase pathways, including P38, ERK1/2 and JNK, upregulated MMP 
expression, which is known to contribute towards cartilage degeneration in arthritis (Liacini et 
al. 2002).   
In wound healing, the initial response by pro-inflammatory cytokines contributes 
towards the regulation and activation of other wound healing mediators.  When this response 
is continuous, it leads to multiple dysregulated wound healing.  For example, diabetes is often 
associated with non-healing wounds, due to dysregulation of wound healing mediators. The 
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induction of IL-1β under hyperglycemic conditions has previously been identified in some cell 
types, including macrophages (Lachmandas et al. 2015). Analysis of IL-1β expression in 
diabetic non-healing wounds by Mirza et al. (2013), found that macrophages exhibit a pro-
inflammatory response inhibited by IL-1β.  Inhibiting the IL-1β pathway in diabetic mice 
resulted in an increase in wound healing associated with a change in resident macrophage 
phenotype (Mirza et al. 2013). 
Increased expression of IL-1β has also been associated with fibrotic progression. In a 
study by Kolb et al. (2001), the effects of increased IL-1β expression were analysed using an 
adenovirus that transiently overexpressed IL-1β in rat lungs.  In response to overexpression of 
IL-1β, there was increased expression of pro-fibrotic cytokines, PDGF and TGF-β1, as well as 
an upregulated expression of pro-inflammatory cytokines, IL-6 and TNF-α. All of these 
mediators have previously been determined to have increased expression in fibrotic 
progression.  Furthermore, the increase in IL-1β was associated with tissue damage, due to the 
increase in TGF-β1, which subsequently lead to the increased myofibroblast numbers and ECM 
components, fibronectin and collagen.  Increased expression of IL-1β, therefore, regulates 
expression of other fibrotic mediators and matrix production. 
A further example of this regulatory role of IL-1β and TGF-β1 has been described in 
pancreas fibrosis (Aoki et al. 2006). This group determined that both IL-1β and TGF-β1 
activated each other in an autocrine loop.  The activation of TGF-β1 by IL-1β was associated 
with ERK1/2 activation, but the activation of IL-1β by TGF-β1 was associated with SMAD3 
activation. The continuous secretion and auto-induction of cytokines mediates an effect on 
multiple resident cell types.  For example, in a study by Campo et al. (2012), the stimulation 
of rheumatoid arthritis synovial fibroblasts (RASF) with TNF-α increased the expression of 
HYAL enzymes, oxidative species, CD44 and multiple immune response mediators, including 
IL-1β. These workers concluded that increased expression of HYAL enzymes resulted in 
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continuous HA degradation and the formation of HA oligomers.  The association of these HA 
oligomers with CD44 stimulated transcription factor NF-κB, which increased the expression 
of many pro-inflammatory mediators. This association of HA with CD44 has previously been 
shown to activate NF-κB through protein kinase C (PKC) (Fitzgerald et al. 2000).  NF-κB then 
upregulates further fibrotic mediators, including IL-6, TNF-α, TGF-β1, IL-1β; and matrix 
degrading MMPs (Tak and Firestein 2001; Liacini et al. 2002).  
1.7.3. - IL-1β Induction of HA/CD44 Mediated Monocyte Binding 
 
The association of HA and CD44 has previously been described to be important in 
TGF-β1-induced, fibroblast to myofibroblast differentiation.  The association of HA/CD44 also 
has a role in maintaining a monocyte/macrophage presence at the site of injury by an 
association with fibroblasts. Macrophages are a principle mediator of wound healing, they not 
only engulf bacteria and debris at the site of injury, but also release cytokines and growth 
factors into the damaged region (Laskin et al. 2011) .  These cytokines activate resident cells 
to mediate wound closure. Comparatively few macrophages at this site originate from resident 
tissue, the rest are derived from blood borne monocytes that then differentiate to mature 
macrophages (Martin and Leibovich 2005).  The consistent presence of 
monocyte/macrophages results in increased proliferation, migration and differentiation of 
resident cells that are associated with fibrotic progression (Lech and Anders 2013; Xue et al. 
2015). 
IL-1β is a principal cytokine released by monocytes/macrophages that induces the 
expression of TGF-β1 by fibroblasts and surrounding cells; and thereby activates fibroblast 
differentiation to myofibroblasts via HA/CD44 association.  Therefore, IL-1β can indirectly 
act in a pro-fibrotic way.  However, IL-1β stimulation has also been shown to have a direct 
effect in fibrosis by its continued association with resident monocytes (Meran et al. 2013).  This 
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process is also mediated by HA interactions with CD44. Similar to TGF-β1 induction of peri-
cellular coat formation seen in myofibroblasts, the activation of fibroblasts by IL-1β results in 
the formation of a HA coat, which is also synthesised by HAS2.  However, by contrast with 
TGF-β1 induction, the HA forms a spiked matrix characterised by cell membrane protrusions 
(Meran et al. 2013).  The association of HA with CD44 is essential for this coat assembly. 
However, unlike the TGF-β1-induced peri-cellular coat observed in myofibroblasts, the IL-1β 
induced coat does not require TSG-6 activity, suggesting that other hyladherins are involved 
in maintaining the coat structure (Meran et al. 2013).  
Meran et al. (2013) also concluded that the IL-1β-dependent HA spikes on protrusions 
of the plasma membrane were ICAM-1 dependent; and the association of ICAM-1/CD44 was 
essential for monocyte binding. ICAM-1 is a transmembrane receptor that stabilises cell-cell 
interactions and it has previously been shown that its association with HA activates intracellular 
signalling of NF-κβ and AP-1 (Oertli et al. 1998).  Furthermore, as ICAM-1 is an adhesion 
receptor, it is often associated with facilitating leukocyte migration.  Therefore, its ability to 
bind resident cells is essential for the movement of leukocytes into an inflamed region, but also 
for intracellular activation and response (Walpola et al. 1995). 
Similar to the observed CD44 and HAS2 upregulation, both ICAM-1 mRNA and 
surface protein expression are induced by IL-1β stimulation (Ledebur and Parks 1995; van der 
Velden et al. 1998).  In unstimulated fibroblasts, ICAM-1 and CD44 are diffuse throughout the 
membrane. However, after stimulation with IL-1β, both ICAM-1 and CD44 co-localise within 
the HA-rich membrane protrusions.  Unlike TGF-β1-induced myofibroblasts that result from 
the co-localisation of CD44 with EGFR in lipid raft regions, the co-localisation of CD44 with 
ICAM-1 is lipid raft independent and the association happens outside of raft regions, within 
the membrane (Meran et al. 2013). 
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Inhibiting the expression of HAS2 or CD44 and preventing or degrading the HA coat 
decreased the ability of IL-1β-induced fibroblasts to bind monocytes. Therefore, CD44/HA 
association is essential for this cellular function (Meran et al. 2013).  Co-localisation of CD44 
with ICAM-1 also activated downstream ERK1/2 (Figure 1.4 [A&B]).  Silencing CD44 
expression prevented intracellular phosphorylation of ERK1/2, highlighting the importance of 
CD44 in modulating intracellular signalling (Meran et al. 2013).  Since CD44 is associated 
with the cytoskeleton, the activation of ERK1/2 may be an important signal in the modulation 
of the cell membrane protrusions. 
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1.8. -CD44 Regulation of Fibrosis 
 
The CD44 transmembrane receptor exists in multiple isoforms that have marked variability in 
function (Ponta et al. 2003). Dysregulation of CD44 splice variants has been implicated in 
multiple diseases, including many cancers. As described in this chapter, the association of 
[A] 
ICAM-1 IL-1R1 CD44 
HA IL-1 
CD44 
HA 
ERK1/2 
IL-1RAcP 
IL-1β stimulated fibroblast 
Monocyte 
Hyaluronan 
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1/2 
CD44/ICAM-1  
co-localisation 
Spiculated protrusions 
Nucleus 
Intracellular 
signalling 
[B] 
Figure 1.6. Activation of HA spiculated protrusions by IL-1β promotes monocyte binding 
[A] IL-1β activation of fibroblast monocyte binding by HA/CD44/ICAM-1 mediated spiculated protrusions. Formation 
of a complex of IL-1β, IL-1R1 and IL-1RAcP activates intracellular signalling.  At the same time, CD44 moves through 
the membrane and associates with ICAM-1 resulting in the activation of downstream ERK1/2 and the subsequent 
formation of the HA spiculated protrusions involved in monocyte binding. [B] IL-1β stimulated fibroblast, the location 
on the plasma membrane of CD44/ICAM-1 and the binding of monocytes to spiculated HA. 
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CD44 with HA is central to the TGF-β1-induced, fibroblast to myofibroblast differentiation, 
and to IL-1β- induced monocyte binding. However, the CD44 splice variants involved in these 
HA mediated functions, or if multiple spliced variants are required for the maintenance of the 
myofibroblast phenotype or the regulation of monocyte binding, is not known.  Furthermore, 
CD44 associates with other receptors in various cell types and induces multiple functional 
properties in various cells, via its association with HA (Wielenga et al. 2000; Wang and 
Bourguignon 2006).  One such receptor is the MMP inducer, EMMPRIN/CD147, which has 
previously been shown to associate with CD44 and EGFR in breast cancer cells.  This 
association leads to an increase in invadapodia on breast cancer cells in a CD44/HA-dependent 
manner (Grass et al. 2013).  Furthermore, this CD147/CD44/EGFR association activates 
downstream ERK1/2 in a similar mechanism that is observed in fibroblast–myofibroblast 
differentiation and IL-1β induced monocyte binding. Investigation of a role for CD147 in 
fibroblast activation will be one of the aims of this Thesis. A more detailed description of 
CD147 is given in Chapter 5. 
The work in this Thesis aims to identify which CD44 spliced isoforms are expressed 
and involved in TGF-β1-induced, fibroblast-myofibroblast differentiation and IL-1β-induced 
monocyte binding.  Furthermore, interaction of CD147 with CD44 and the role of this 
interaction in mediating these differentiation or monocyte binding responses was also 
investigated. 
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1.9 –Specific Aims 
 
The principal aims are to:- 
 Investigate the effects of TGF-β1 and IL-1β on CD44 spliced variant expression. 
 Determine the involvement of CD44 variants in myofibroblast differentiation and 
inflammatory cell interactions. 
 Elucidated the role of CD147 in fibroblast differentiation and monocyte binding. 
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Chapter 2 - Methods 
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2.1 – Materials 
All materials were purchased from Sigma-Aldrich (Poole, UK), GIBCO/Thermo-Fisher 
Scientific (Roskilde, Denmark) or Life Technologies (Paisley, UK), unless otherwise stated. 
2.2 – Cell Culture 
2.2.1 – Primary Cells  
All experiments were carried out using primary Human Lung Fibroblasts (HLFs) (no. 
AG02262 Coriell Institute for Medical Research, NJ, USA) within a passage range of 6-10.  
Fibroblasts were cultured in Dulbeccos Modified Eagle Medium and Nutrient Mixture F-12 
Ham’s Medium (DMEM/F12, 1:1 ratio), was supplemented with 2mM L-glutamine, 
100units/ml penicillin, 100g/ml streptomycin, 10% foetal bovine serum (FBS, Biological 
Industries Ltd., Cumbernauld, UK). Cells were incubated at 37C in 5% CO2. Fresh growth 
medium was added to cells every 3-4 days until cells had grown to confluent monolayers.  Cells 
were growth arrested in serum-free medium for 48h, prior to all experiments. This allowed for 
cell cycles to synchronise. 
2.2.2. – U937 Cell Line 
The U397 (human histiocytic lymphoma cell line) was purchased from ATCC (Manassas,VA). 
U937 cells were cultured in RPMI-1640 medium, supplemented with 2mM L-glutamine, 
100units/ml penicillin, 100 g/ml streptomycin, 10% FBS. Cells were incubated at 37C in 5% 
CO2, until the cells reached a high cell density. 
2.2.3. - Cellular Sub-Culture 
Fibroblast were grown to confluent monolayers in 75cm2 tissue culture flasks.  Cells were then 
treated with a phosphate buffer saline solution (PBS), containing 0.05% w/v trypsin, 0.53mM 
EDTA and incubated at 37C for 1-2 minutes, until cells became detached from the flask.  An 
equal volume of FBS was then used to neutralise the trypsin and the cell suspension was 
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centrifuged for 5 min at 1500rpm, at room temperature.  The subsequent pellet was suspended 
in 50 ml of DMEM/F12 containing 10% FBS.  To continue culture expansion, the cell 
suspension was split with a 1:3 ratio into sterile 75cm2 tissue culture flasks.  
U937 cells were grown to a high density in 75cm2 tissue culture flasks. To expand the culture, 
the cell suspension was diluted 1in 10, using fresh RPMI medium containing 10% FBS, before 
being placed into a sterile 72 cm2 tissue culture flask.  Any remaining unused cells were 
cryogenically frozen and stored, as described in section 2.2.6. 
2.2.4. - Cell Stimulation 
Following a 48 h growth arrest period, fibroblasts were incubated in serum–free DMEM/F12 
containing either TGF-1 (10ng/ml) or IL-1 (1ng/ml) (R&D Systems, Abingdon, UK).  
Unstimulated control fibroblast were incubated in fresh serum-free medium at the time of 
stimulation, unless otherwise stated.  Individual experimental conditions are described in each 
subsequent results chapter.   
2.2.5. – Cell Storage and Retrieval 
Cells that we not required for subsequent experiments were cryogenically stored.  Briefly, 
following subculture, cells were centrifuged to form a pellet.  The pellets of fibroblasts or U937 
cultures were taken from a 75cm2 flask and re-suspended in 1 ml of a solution containing 10% 
dimethyl sulphoxide (DMSO), 30% FBS and 60% DMEM or RPMI, respectively.  1 ml of 
solution was then transferred to a cryogenic vial (Thermo-Fisher Scientific) and stored at 80C 
for 24 h.  Cells were stored long-term in liquid nitrogen at -196C.    
2.2.6 – Cell Counting 
Cells were counted using a Beckman Coulter Particle Count and Size Analyzer. For each cell 
count, 20 µl of cell suspension was added to 20 ml of Coulter® Isioton® II Diluent.  Each cell 
count gave an average of two separate counts.  This was repeated three times.  An average of 
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these three counts was then calculated and the cell quantity calculated using the following 
equation. 
Average cell count x2000 = cell/ml 
2.3 -Alamar Blue Assay 
Alamar Blue is a redox indicator that incorporates a fluorometeric growth indicator. Cellular 
metabolism is monitored by a colour change that occurs when the environment is reduced (red 
colour) from its oxidative state (blue colour).  The increase in reduction is correlated to the 
metabolic efficiency of the cells in their environment.  To assess experimental conditions on 
the cell viability, fibroblasts were seeded into 6-well culture plates.  At the experimental 
endpoint the medium was removed from each well and replaced with 1 ml of fresh serum-free 
medium, containing 10% v/v Alamar blue (Invitrogen/Thermo-Fisher Scientific). A negative 
control containing just medium and 10% Alamar blue was placed in an empty well. Samples 
were then incubated for 1 h at 37C, 5% CO2. 100µl of conditioned medium from each well 
(i.e. each sample) was then placed into a Microfluor 96-well plate (Thermo-Fisher Scientific).  
Detection was performed using fluorescent spectroscopy (Fluostar Optima Spectrometer), with 
wavelengths of 540nm excitation and 590nm emission. The fluorescent values of the control 
sample (containing only medium and Alamar blue) were subtracted from each sample to give 
a final arbitrary fluorescent unit. 
2.4. – Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
2.4.1.-RNA Isolation 
To analyse gene expression, total RNA was extracted following each experiment according to 
TRIzol® manufacturers’ protocol (Ambion; Life Technologies).  Briefly, cells were lysed using 
1 ml of Trizol® per well of a 6-well tissue culture plate.  To extract cells from smaller well 
plates, the volumes were scaled down accordingly.  The subsequent supernatant was then 
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transferred into a 1.5 ml micro-centrifugation tube.  Samples were then left at room temperature 
(RT) for 5 min to allow for dissociation of any nucleoprotein complexes. 200 µl of chloroform 
was added to each sample and thoroughly vortexed, before being left at room temperature for 
5 min.  The samples were then centrifuged at 12,000rpm for 15 min at 4ºC.  Following 
centrifugation, the sample separated into three distinct phases a lower red phenol phase, a white 
interphase and a top aqueous phase.  The aqueous phase containing RNA only was carefully 
pipetted into a freshly labelled Eppendorf.  500 µl of isopropyl alcohol was added to each 
sample and vortexed.  Following an incubation period of 15 min at room temperature, samples 
were centrifuged at 12,000rpm for 10 min at 4ºC.  The subsequent pellet was then washed with 
75% ethanol before being vortexed and re- centrifuged at 7500rpm 4ºC for 5 min.  This wash 
step was repeated twice more.  The ethanol was removed and the pellet was air dried for 10 
min.  16 µl of RNase-Free Water was added to solubilise the pellet.  Purified RNA samples 
were quantified (ng/l), using a Nanodrop 3300 (Thermo Scientific). The volume required for 
1 g of sample was quantified using the following equation:        
1 / (Total RNA ng/l) /1000 
2.4.2. -Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Reverse transcription (RT) of purified RNA samples was carried out using the random primer 
method. All stages throughout the RT procedure were carried out on ice.  Briefly, 1 µg of RNA 
(made up to a final volume of 10 µl with RNase-free, deionised H2O), was placed into a RT-
PCR reaction tube with 10 µl of the following reaction mixture:  10X random primers (2.0 l), 
25X 100mM deoxynucleotide triphosphates - dNTPs (0.8 l), MultiscribeTM reverse 
transcriptase (1.0 l), RNase inhibitor (1.0 l), 10X RT buffer (2.0 l) and nuclease free dH2O 
(3.2 l).  A negative control consisting of 10 µl of RNase-free, deionised H2O only and 10 µl 
of the reaction mix was carried out for each experiment. All reagents used were from a high 
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capacity cDNA Reverse Transcription Kit (Life Technologies). Reverse transcription was 
carried out using a (PTC-225, Peltier Thermal Cycler, Bio-Rad Laboratories, Berkely USA).  
Cycle conditions were as follows: 25C for 10 min, to allow the random primers to anneal to 
the RNA. This was followed immediately by an extension stage of 37C for 120 min, in order 
to allow reverse transcriptase to attach the free dNTPs.  A final dissociation stage of 85C for 
5 min was used to separate the template strand from the final cDNA strand and denature the 
reverse transcriptase. Following RT, the cDNA was diluted with 60 l of RNase-free de-
ionised H2O and stored at -20ºC until further use. 
2.5. - Real Time - Quantitative Polymerase Chain Reaction (RT-qPCR) 
2.5.1 -Taqman Gene Expression qPCR  
Following RT-PCR, samples were analysed using qPCR. Each reaction had final volumes of 
20 µl, consisting of 4 µl of cDNA, 10µl of Taqman Fast Universal PCR master mix (x2 No 
AmpErase UNG; Applied Biosystems), 5 µl nuclease-free dH2O and 1 µl of a Taqman gene 
expression primer and probe (Applied Biosystems, see Table 2.1.) A negative control 
containing RNase-free de-ionised H2O in place of the cDNA, was carried out for each 
experiment.   An rRNA 18S target was used as an endogenous control and amplified 
simultaneously with the gene target to be used as a reference gene. Expression analysis was 
carried out using the ViiA-7 Real Time PCR System (Applied Biosystems). 
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2.5.2. -Power SYBR Green qPCR 
Following RT-PCR, samples were analysed using qPCR. Each reaction had final volume of 20 
µl, consisting of 4 µl of cDNA, 10 µl of Power SYBR Green PCR Master Mix (Applied 
Biosystems), 4.8 µl of RNase-free dH2O and 0.6 µl of 10µM custom-designed forward, primer 
and 0.6µl of 10µM custom-designed, reverse primer.  All custom-designed primer sequences 
are given in (Table 2.2.). RNase-free dH2O was used in the place of the cDNA for a negative 
control for each experiment.   GAPDH was used as an endogenous control and amplified 
simultaneously with the gene target. Expression analysis was carried out using the ViiA-7 Real 
Time PCR System.  
2.5.3. -Relative Quantification 
Relative quantification was calculated using the comparative CT method.  The CT value (the 
threshold cycle where the amplification is in the linear range of the amplification curve) of the 
standard endogenous control reference gene was subtracted from the CT value of the target 
gene in order to obtain a delta CT (dCT) value. The mean dCT was then calculated for control 
experiments.  The relative quantification (RQ) for the experimental target genes was then 
calculated using the mean of the control experiments with the following equation. 
Primer target Primer Identity Number 
TNFA1P6 (TSG6) 
(Applied Biosystems) 
Hs0113602_m1 
TGF-β1 
(Applied Biosytems) 
Hs0017127_m1 
PTPRC (CD45) 
(Applied Biosystems) 
HS00236304 
αSMA (ACTA2) 
 (Applied Biosystems) 
HS_00426835_gl 
18s Ribosomal RNA 
(Applied Biosystems) 
Catalog. No. 4319413E 
Table 2.1. Primer targets and identity number for Taqman gene expression assay 
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2^- (dCT(Experimental Target) - dCT(Mean Control Group) )   
2.7. - Small Interfering RNA (siRNA) 
Transient transfection was carried out using either custom designed siRNA that targeted 
specific CD44 variants or a specific siRNA to CD147.  For siRNA targeted regions of CD44, 
see methods section in Chapter 4. Fibroblasts were grown to 50-60% confluence in 6-well 
plates in DMEM/F12 containing 10% v/v FBS, before growth arrest in serum-free DMEM/F12 
for 24 h. Two solution were made for transfection, the first contained 100µl per sample of 
OPTIMEM transfection medium and the specific target siRNA (33nm; final concentration.).  
The second contained 100µl of OPTIMEM transfection medium and Lipofectamine 2000 (1:50 
dilution; Invitrogen).  The two solutions were incubated at room temperature for 45 min, 
combined and mixed thoroughly. 800µl of OPTIMEM transfection media was added to the 
solution for each sample, this gave a final transfection solution volume of 1 ml per well.  The 
cells were incubated in 5% CO2 at 37ºC for 6 h. 1 ml of fresh DMEM/F12 containing 20% v/v 
FBS was then added to each well and samples were incubated for a further 24 h.  Following 
transfection, the medium was removed and fresh serum-free DMEM/F12 was added 1 ml/well 
to growth arrest cells for 48 h, prior to experimentation.   A negative control scrambled siRNA 
I.D. AM4613 (Ambion) was carried out simultaneously for all transfection experiments (a 
nonsense sequence, bearing no resemblance to known human mRNA sequence).  
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Target Primer sequence 
CD44s Forward 5’-GCTACCAGAGACCAAGAC-3’ 
Reverse 5’-GCTCCACCTTCTTGACTCCC-‘3 
CD44v2 Forward 5’-CCTGCTACCACTTTGATGAGC-’3 
Reverse 5’-GTGTCTTGGTCTCCAGCCAT-‘3 
CD44v3 Forward 5’ -TGCTACCAGTACGTCTTCAAAT-‘3 
Reverse 5’-GTGTCTTGGTCTCTGGTGCT-‘3 
CD44v4 Forward 5’-CTGCTACCATTTCAACCACACC-‘3 
 Reverse 5’-TGGTCTCAGTCATCCTTGTGG -‘3 
CD44v5 Forward 5’-CAGAATCCCTGCTACCAATGT-’3 
Reverse 5’-TCTTGGTCTCTTGTGCTTGTAGA-’3 
CD44v6 Forward 5’-TGCTACCATCCAGGCAACTC-’3 
Reverse 5’-GGAATGTGTCTTGGTCTCCAGC-‘3 
CD44v7 Forward 5’-GAATCCCTGCTACCACAGCCTC- ‘3 
Reverse 5’-TCTCCCATCCTTCTTCCTGCTT-’3 
CD44v8 Forward 5’-ATGTGTCTTGGTCTGGCGTT-’3 
Reverse 5’-TCCCTGCTACCAATATGGACTC-‘3 
CD44v9 Forward 5’-CAGAATCCCTGCTACCAAGC-‘3 
Reverse 5’-ACTGGGGTGGAATGTGTCTT-‘3 
CD44v10 Forward 5’-TCCCTGCTACCAATAGGAATGA-‘3 
Reverse 5’-TAAGGAACGATTGACATTAGAGTTG-‘3 
CD147 Forward 5’- CAGAGTGAAGGCTGTAAGTCG-‘3 
Reverse 5’-TCGGAGGAACTCACGAAGAA-’3 
GAPDH Forward 5’-CCTCTGATTCAACAGCGACAG-’3 
Reverse 5’-TGTCATACCAGGAAATGAGCTTGA-’3 
EDA-Fibronectin 
(EDA-FN) 
Forward 5’GCTCAGAATCCAAGCGGAGA’3 
Reverse 5’-CCAGTCCTTTAGGGCGATCA-‘3 
 
 
 
Table 2.2. - Custom designed primer sequences used for Sybr Green qPCR analysis 
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2.6. - Touch-Down Conventional PCR (TD-PCR) 
To determine the expression of larger CD44 variants, touch-down conventional polymerase 
chain reaction (TD-PCR) was used, to prevent unselected hybridisation.   Following RNA 
extraction and reverse transcription (described in section 2.4) the resulting cDNA was 
amplified using custom-designed primers, to amplify CD44 variants (Table 2.3.), according to 
the Phusion® DNA Polymerase Kit protocol (Bio-RAD Laboratories).  Briefly, 2µl of cDNA 
was added to a solution containing, 1 µl of dNTPs (10mM), 2.5 µl of each 10mM primer 
(forward and reverse), 10 µl of Phusion® buffer and 0.5 µl of DNA polymerase to an 
appropriate PCR tube.  RNase-free dH2O was added to each sample to give a final volume of 
50 µl.  Samples were amplified using an ATC-225, Peltier Thermal Cycler.   The calculated 
melting temperature (Tm) +10ºC was used as the initial starting annealing temperature, the 
temperature was then decreased by 1ºC for each additional cycle for the first 10 cycles. The 
temperature then remained consistent for the remaining 22 cycles.  Each PCR reaction was run 
for a total of 32 cycles.  Following amplification, the samples were mixed with a gel loading 
dye (Qiagen, Manchester, UK) and pipetted into wells of a 1% agarose gel, containing ethidium 
bromide.  Flatbed electrophoresis was used to separate DNA amplicons.  Gels were submerged 
in 1X Tris-acetate buffer solution containing ethidium bromide.  Electrophoresis was run at 
90V for 1 h.  Bands were visualised and extracted from the gel using an Ultra Violet (UV) 
trans-illuminator.  DNA was isolated from the extracted bands using a QIAquick Gel 
Extraction Kit (Qiagen) and quantified using a Nanodrop 3300 (Thermo-Fisher Scientific).  
Product were confirmed by using 5ng/µl for DNA sequencing (BioCore Sequencing, Central 
Biotechnology Services, Cardiff University, UK). 
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2.7. - Lipid Raft Analysis 
 
Caveolae raft analysis was performed using a Caveolae/Raft Isolation Kit (Sigma - Aldrich), 
in order to determine the localisation of membrane proteins in fibroblasts or myofibroblasts.  
Briefly, fibroblasts were grown to approximately 80% confluence in DMEM containing 10% 
v/v FBS at 37ºC and 5% CO2 in 6-well plates.  Cells were then growth arrested in serum-free 
DMEM/F12 for 48 h.  Cells were incubated in serum -free DMEM/F12 containing TGF-β1 
(10ng/ml) or serum-free DMEM/F12 alone (control samples) for 72 h.  Cells were lysed in 1ml 
of ice cold lysis buffer containing 1% v/v Triton X- 100 and 1% v/v of protease inhibitor 
cocktail (PIC). Cells were harvested using a cell scraper and incubated on ice for ~30 min, 
before transfer into a pre-cooled 2ml Eppendorf. Lysed samples were centrifuged at 450rpm 
for 5 min at 4ºC and the supernatant was discarded. The cell pellet was carefully washed twice 
in ice-cold PBS, before re-suspension in 1ml of lysis buffer, containing 1% Triton–X100 and 
1% PIC. Samples were stored at -80ºC until use.    
Target Primer sequence 
Common forward 
primer 
5’TCAATGCTTCAGCTCCACCT’3 
CD44S Reverse 5’CAAAGCCAAGGCCAAGAGGGATGC’3 
CD44v2 Reverse 5’CAGCCATTTGTGTTGTTGTGTGAA’3 
CD44v3 Reverse 5’CCTTCATCATCATCATCAATGCCTGATCC’3 
CD44v4 Reverse 5’TTTGAATGGCTTGGGTTCCACTGG’3 
CD44v5 Reverse 5’GCTTGTAGAATGTGGGGTCTCTTC’3 
CD44v6 Reverse 5’GAATGGGAGTCTTCTTTGGGTGTT’3 
CD44v7 Reverse 5’CCATCCTTCTTCCTGCTTGATGAC’3 
CD44v8 Reverse 5’GTCATTGAAAGAGGTCCTGTCCTG’3 
CD44v9 Reverse 5’TGTCAGAGTAGAAGTT’3 
CD44v10 Reverse 5’TGGAATCTCCAACAGTAACTGCAGT’3 
Table 2.3. Primer targets and sequences used for touch-down PCR analysis. 
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2.7.1. - Preparation of Density Gradient 
 
The density gradient consisting of 5 layers was created using OptiPrep Medium (Sigma-
Aldrich).  These were (starting from the lowest layer) 35%, 30%, 25%, 20% and 0% and made 
up to 1ml with lysis buffer. All stages were carried out on ice.  1 ml of the pre-prepared 35% 
OptiPrep solution was added to a pre-cooled ultracentrifugation tube. 1ml of each subsequent 
gradient layer was carefully pipetted onto the previous layer, until the final top gradient layer 
of 0% OptiPrep lysis buffer was level with the top of the tube.  Samples were then centrifuged 
at 200,000 x g for 14 h at 4ºC, using a Optima-Max ultracentrifuge (Beckman Coulter).  
Fractions were then carefully collected into 500µl aliquots.  Each fraction was placed into a 
pre-chilled pre-labelled Eppendorf. The fractions were labelled 1-9, in accordance with their 
removal from the ultracentrifugation tube.  To precipitate the protein from each fraction, 
samples were treated with 10% trichloroacetic acid (TCA) and left for 30 min on ice. Samples 
were the centrifuged at 12,000rpm for 10 min, until a pellet was formed.  The subsequent pellet 
was washed in 50:50 ethanol/ether and the resulting protein from each fraction was then 
analysed by Western blot. 
2.8. - Protein Analysis 
 
5.8.1. – Immunocytochemistry 
Immunocytochemistry (ICC) was used to analyse αSMA stress fibre formation and the co-
localisation of CD147 with CD44, EGFR and the integrin α4β7.  All ICC experiments were 
carried out in 8-well Permanox chamber slides (Nunc; Thermo-Fisher Scientific)  On 
completion of each experiment, cells were fixed using 200 µl of a 4% paraformaldehyde 
solution for 10 min and then washed using PBS. For intracellular analysis, cells were treated 
with 0.1% (v/v) Triton X-100 and left for 5 min at room temperature.  Analysis of membrane 
receptors did not require Triton X-100 treatment. The cells were then washed three times with 
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200 µl per well of 0.1% (w/v) Bovine Serum Albumin (BSA)/PBS and left for 5 min on a STR6 
platform shaker (Stuart scientific, UK). This wash stage was repeated twice more.  Samples 
were blocked using 200µl of 1% (w/v) BSA/PBS per well for 30 min, to prevent unspecific 
binding.  Samples were then washed and treated with 200µl of the appropriate primary antibody 
(Table 2.4), overnight at 4ºC. Following a further wash stage, samples were treated with a 
secondary antibody conjugated to a fluorescent tag (Table 2.5.), for 1 h at room temperature.  
Samples were washed and the chamber wells were removed.  Samples were left to air dry and 
slides were then mounted using Vector Shield mounting media for fluorescence containing a 
DAPI nuclear stain (Vector Laboratories Inc. Birlingane. UK). Samples were visualised and 
examined under UV-light, using a Leica Dialux 20 Fluorescent Microscope (Leica Microscope 
UK Ltd, Milton Keynes, UK). For F-actin and lipid raft visualisation, a phalloidin conjugate  
Alexa Fluor® 555 (Sigma-Aldrich) and Cholera toxin B subunit conjugated with Alexa Fluor® 
548 (Invitrogen) were used (Table 2.4). 
 
 
 
 
 
 
 
 
 
 
 
Antibody Type and Host Dilution 
Anti-EGFR(528) 
Merck Millipore 
Monoclonal –Mouse 1:25 
Anti-CD44(A020) 
Merck Millipore 
Monoclonal – Rat 1:100 
Anit-CD147 
BD Pharminogen 
Polyclonal –Mouse 1:50 
Anti-α-SMA 
(Sigma) 
Monoclonal –Mouse 1:100 
Phalloidin – Conjugate 
Alexa Fluor 555 
(Sigma) 
N/A 1:100 
Cholera –Toxin subunit B-
conjugate Alex Fluor 548 
(Invitrogen) 
N/A 1:100 
Figure 2.4 - Primary antibodies and dilutions used for ICC analysis. 
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5.8.2. - Protein Extraction  
 
All experiments that required protein analysis were carried out in 6-well cell culture plates.  
Cell were dissociated from the plate using a cell scraper, before being pipetted into a 1.5 ml, 
pre-chilled, pre-labelled, Eppendorff tube.  Samples were centrifuged at 8,000rpm at 4ºC for 
10 min, until a pellet was formed.  The supernatant was then discarded and the remaining pellet 
was treated with 200µl of lysis buffer (pH 7.4) (±0.1), containing 10 µl of (100mM) sodium 
orthovanadate (Na3VO4), 10µl of (200mM)  phenylmethylsofonyl floride (PMSF) 200mM and 
10µl of protease cocktail inhibitor.  All reagents were included in a Radio Immunoprecipitation 
Assay (RIPA) Kit (Santa Cruz, Biotechnology, U.S.A.).  Samples were vortexed for 1 min and 
then re-centrifuged at 8,000 rpm at 4ºC, for 10 minutes.  The subsequent supernatant was 
transferred into a fresh Eppendorff.  Samples were stored at -80ºC until further analysis.  
5.8.3. - Protein Quantification 
 
All extracted protein was quantified using Bradford Assay method (Bio-Rad Laboratories Inc.). 
Samples were diluted 5µl to 125µl Bradford Assay.  Quantification was performed using 
absorbance spectroscopy (Fluostar Optima Spectrometer), with wavelengths of 620nm 
excitation and 590nm emission. A standard of BSA serial dilution was used as a reference for 
sample concentrations. 
 
Antibody Type and Host Dilution 
Anti-mouse-IgG 
AlexaFlour 488 (FITC) 
Polyclonal -Goat 1:500 
Anti - Rat-IgG 
AlexaFlour 555 (TRITC) 
Polyclonal -Goat 1:500 
Figure 2.5. - Secondary antibodies and dilutions used for ICC analysis. 
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5.8.4. - Co-Immunoprecipitation (Co-IP) 
 
Following protein extraction, Co-Immunoprecipitation (Co-IP) was carried out using 
MagnaBind Goat anti-Mouse IgG magnetic beads or Pierce Protein G Magnetic Beads 
(Thermo-Fisher Scientific), depending on analysis. Briefly, beads were washed 3 times in PBS 
before use.  10 µg of primary antibody (Table 2.6), was added to 200µl of beads and incubated 
at 4C for 2 h. The beads/antibody complex were then washed with PBS to remove any 
unattached antibody.  5 µg of sample was then added to the beads/antibody complex and 
samples left on a roller overnight. Samples were further washed 3 times with PBS, proceeded 
by a single wash with a 1% (v/v) Nonidet P40 detergent solution (Sigma-a 
Aldrich).  The beads were then transferred to a fresh pre-labelled Eppendorff tubes.  Beads 
were dissociated from the antibody sample complex by boiling for 5 min at 95C, under 
reducing conditions. The beads were then removed using a magnetic holder and co-precipitated 
proteins were identified using SDS-PAGE/Western Blot analysis. 
5.8.5. -SDS-PAGE/Western Blot Analysis 
 
Following protein extraction and quantification, protein separation and identification was 
performed by SDS-PAGE/Western blot, using a BioRad Mini Protein II apparatus (Bio-Rad 
Laboratories).  30 µg of sample was boiled at 95C for 5 min with an equal volume of reducing 
buffer (pre-prepared and containing 0.8ml glycerol, 1.6ml 10% (w/v) SDS, 0.4ml β-
Mercaptoethanol and 0.05% Bromophenol Blue). The total volume of sample/reducing buffer 
was loaded into the wells of a 7.5% polyacrylamide gel.  Each experiment was carried out 
alongside 10 µl of a ColourPlusTM Prestained Protein Ladder, Broad Range (New England 
Biolabs, UK). To separate the proteins, electrophoresis was carried out at 100V for 20 min 
followed by 150V for 40 min under reducing conditions.  Following electrophoresis, samples 
were transferred at 100V for 1 h onto a nitrocellulose membrane (GE Healthcare, UK).  In 
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order to prevent non-specific binding, the nitrocellulose membrane was blocked with 5% (w/v) 
skimmed milk in 0.5% (v/v) Tween/PBS for 1 h.  The membrane was then washed in 0.1% 
(v/v) Tween/PBS three times for 5 min.  The primary antibody of interest (Table 2.6.) was 
diluted in 0.1% (v/v) Tween/PBS, containing 1% (w/v) BSA and incubated with the membrane 
at 4C, overnight.  The membrane was then washed before the addition of the secondary 
antibody, conjugated to horseradish peroxidase (HRP) (Table 2.7) diluted in 0.1%(v/v) 
Tween/PBS containing 1% (w/v) BSA. Following a further wash step the Enhanced 
Chemoluminecense (ECL) method was used to visualise the samples. Briefly, the membrane 
was treated with ECL reagent (GE Healthcare) and left to react for 1 min.  HyperFilm X-ray 
film (GE Healthcare) was then placed onto the membrane and left to expose for a pre-
determined time.  The film was developed using a Curix-60 developer (AGFA Healthcare, 
Greenville SC, USA). 
 
 
 
 
 
 
 
 
 
Antibody Type and Host Dilution 
Anti-Phospho-p44/p42(ERK1/2) 
(T202/Y204) 
(Cell Signalling Technology) 
Monoclonal-Mouse 1:1000 
Anti-CD44(A020) 
(Merck Millipore) 
Monoclonal – Rat 1:500 
Anit-CD147 
(BD Pharminogen) 
 
Polyclonal -Mouse 1:2000 
Anti-Caveolin-1 
(Sigma-Aldrich) 
Polyclonal -Rabbit 1:1000 
Anti-EEA-1 
(BD Biosciences) 
Monoclonal-Mouse 1:1000 
Anti-GAPDH 
(SantaCruz) 
Monoclonal-Mouse 1:5000 
Anti-ICAM-1 
(SantaCruz) 
Monoclonal-Mouse 1:1000 
Table 2.6 – Primary antibodies used for Western Blot analysis 
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 2.9. -Collagen Gel Analysis 
Collagen type I (5mg/ml) sourced from rat tails (Gibco) was diluted to 4mg/ml.  Briefly, 8ml 
of collagen was added to (1ml) 10xPBS, (0.20ml) 1M NaOH, and 0.8ml (dH2O). The 
subsequent solution was then slowly mixed to achieve the optimal pH 7.0.  The gel was pipetted 
into 6-well plates and incubated at 37C for 40 min, until the gel was firm. The gels were then 
washed using culture medium before fibroblasts were seeded and left to adhere in DMEM/F12 
containing 10% FBS. Following a 24 h growth period, fibroblasts were then growth arrested in 
serum-free medium for 48 h, before being transfected with siRNA targeting CD147 or a 
scrambled negative control.  Following a 48 h growth arrest period, cells were stimulated with 
TGF-β1 (10ng/µl). Control (non-stimulated) fibroblast cultures were used as experimental 
controls (0h). Subsequent time points were 72 h and 144 h. Gel contraction was measured using 
Image J processing program (National Institutes of Health, Bethesda, Maryland, USA).  
2.10. - Statistical Analysis 
Data is displayed as ± s.d. (Standard deviation) or ± s.e.m. (Standard error of mean) dependent 
on the number of experimental repeats. Statistical analysis was carried out using the one way 
ANOVA of variance followed by the unpaired student’s t test.  Graph Pad (version 6) was used 
for each graphical analysis. *P=<0.05 was considered significant.   
Antibody Type and Host Dilution 
Anti-mouse-IgG (HRP) Polyclonal –Goat 1:5000 
Anti-Rabbit-IgG (HRP) Polyclonal -Goat 1:5000 
Anti - Rat-IgG (HRP) Polyclonal –Goat 1:5000 
Table 2.7. – Secondary antibodies used for Western Blot analysis 
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Chapter 3- The Effects of Transforming Growth Factor- β 
(TGF-β1) and Interleukin -1 β (IL-1β) on CD44 Spliced 
Variant Expression 
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3.1 - Introduction 
 
3.1.1. CD44 
 
CD44 is a transmembrane glycoprotein that regulates cell adhesion, migration, proliferation, 
differentiation and signalling (Kosaki et al. 1999; Legg et al. 2002; Ito et al. 2004; Meran et al. 
2011b; Midgley et al. 2013), through its interaction with hyaluronan.  First identified in 1983 
in human white blood cells (Gallatin et al. 1983), CD44 is encoded by a single highly conserved 
gene that is located on chromosome 11 at p13 (Gao et al. 1997). A combination of alternative 
splicing and posttranscriptional modification leads to multifunctional isoforms (known as 
CD44 variants), of the protein being expressed with a large molecular weight range of 80-
200kDa.   
3.1.2. - CD44 Transcription 
 
In humans, nineteen exons encode for CD44 pre-mRNA.  The first five exons (1-5) and the last 
five exons (15-19) are common to all the CD44 variants.  The variability of CD44 is the result 
of alternative splicing of ten exons (6-14) that are situated between these constant regions. 
(Figure 3.1. [A]).  The simplest CD44 variant has only the common exons translated into 
protein and is known as CD44 standard or CD44s.  This is the most abundant of all the CD44 
variants and is present in most cell types.  Conversely, much less expressed is the largest CD44 
variant, this has all the variable exons translated into protein and is known as CD44 (v2-10).    
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Figure 3.1 – Schematic of CD44 Exon and Protein Structure. 
Exon arrangement of CD44 [A], shows the exons that code for the corresponding region of the protein [B].  [A] indicates (exons 1-5) and (15-16) code for the amino domain, (exon 17) codes 
for the transmembrane region and part of (exon 17) and all of (exon 19) code for the cytoplasmic domain. Exon 18 is not often present and its insertion results in the translation of a stunted 
cytoplasmic region. 
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3.1.3. CD44 Protein Structure 
 
All CD44 variants express three domains; an extracellular domain, a transmembrane domain 
and a cytoplasmic tail region. CD44s contains only these regions and, therefore, is the smallest 
protein with a molecular mass of 80-95kDa.  The CD44 size variation is due to the insertion of 
a stem region between the extracellular domain and the transmembrane region that results from 
the translation of exons within the variable region of the gene (Figure 3.1[B]).  
3.1.3.1. - The Extracellular Domain 
 
The extracellular domain, also known as the amino terminal domain or the hyaluronan-binding 
domain, is a globular structure that is encoded by the common exons (1-5 and 15-19) (Figure 
3.1. [A]). This domain regulates the interaction of CD44 with the ECM, including its primary 
ligand hyaluronan. Two known binding domains have been located in the amino terminal of 
CD44. The first is the link domain (amino acids 32-132), which has homology with the cartilage 
link protein and also contains a hyaluronan-binding motif.  The second is the hyaluronan 
binding site that is situated away from the link domain (amino acids 150-158)  (Peach et al. 
1993). The amino domain also mediates binding of other ECM proteins, such as collagen, 
laminin and fibronectin (Wayner and Carter 1987; Faassen et al. 1992; Jalkanen and Jalkanen 
1992).  In order to maintain the correct folding of both the link domain and the HA binding 
domain, the amino terminal is folded and stabilised by four highly conserved cysteine residues 
that form disulphide links; inhibition of these results in an inability of HA to bind to CD44 
(Day and Sheehan 2001).  A stem region links the amino domain to the transmembrane region 
in CD44s. In CD44 variants, however, this stem region can be extended by the incorporation 
of variable spliced exons. 
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3.1.3.2. - The Stem Region 
 
The variation of CD44 is the combined result of the insertion of spliced variable, exon products 
into the stem region and specific post-translational modifications within this region. This 
combination allows for multiple products/variants to be produced from a single gene. 
3.1.3.3. - Alternative Splicing 
 
The exact mechanism of alternative splicing is not fully understood; however, it is generally 
accepted that spliceosomes play a role in determining the final exon expression of mature 
mRNA. Spliceosomes are large complexes that are composed of five small nuclear 
ribonucleoproteins (snRNP) U1, U2, U4, U5 and U6 and numerous polypeptides, that modulate 
the removal of non-coding introns from pre-mRNA by recognising poor consensus sequences 
within the intron-exon boundary; allowing exons to ligate and form mature mRNA. In a similar 
process, alternative splicing removes exons using a combination of poor consensus sequence 
and recognition of splice sites.  There are four categories of consensus sequences (known as 
cis-regulatory elements), identified as exonic splicing enhancers (ESEs), exonic splicing 
inhibitors (ESIs), intronic splicing enhancers (ISEs) and intronic splicing inhibitors (ISIs).  
These sequences are identified by splicing regulators (SRs), such as SR factors and 
heterogeneous nuclear ribonucleoproteins (hnRNPs reviewed by Jurica and Moore 2003; Chen 
and Manley 2009).  Splicing regulators are subjected to extensive post-transcriptional 
modifications and either promote or inhibit splicing through a combinatory effect (Mayeda et 
al. 1993).  Dysregulation of alternative splicing can be the consequence of either a Cis-Acting 
or a Trans-Acting mutation.  A Cis-Acting mutation is either an acquired or inherited mutation 
of splice sites, or the addition of new splice motifs and defective protein translation.  Trans- 
Acting mutations are associated with defective splicing machinery and regulators (Brinkman 
2004). 
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3.1.3.4. – Post-Transcriptional Modifications of CD44 Variants 
 
The interaction between CD44 and the ECM is highly dependent on modifications in the amino 
terminal and the stem region. The standard form of CD44 alone has large N-linked and O-
linked glycosylations and GAG modifications that increase the molecular mass of the protein 
from 37kDa to 80-95kDa.  The majority of N-glycosylation’s are within the amino domain 
situated close to the link region.  However, the O-linked glycosylation and GAG modification 
sites are situated closer to the carboxyl terminal of the amino domain (Naor et al. 2009). The 
addition of spliced exons into the stem region in CD44 variants further increases these 
glycosylation and GAG modifications. For example, CD44 v3 contains the heparan sulphate 
site which binds to heparin binding proteins (Bennett et al. 1995); and CD44 v6 exhibits a 
binding site for hepatocyte growth factor (HGF) and vascular endothelial growth factor 
(VEGF) (Tremmel et al. 2009). HA binding is usually induced after some form of external 
stimulus that switches CD44 from its inactive to active form. This is thought to be modulated 
by N-linked glycosylations (Lesley et al. 1995).  Whether CD44s or a CD44 spliced variant 
interacts with HA varies depending on cell type (Stamenkovic et al. 1991; He et al. 1992). 
3.1.3.5 - The Transmembrane Domain 
 
The transmembrane domain is encoded by exon 17 (Figure 3.1[A]); and is composed of 23 
hydrophobic amino acids and a single cysteine residue.  The exact role of the transmembrane 
region in modulating CD44 binding with ECM ligands is not entirely understood.  It is known, 
however, to play a role in modulating the CD44-HA association in the cell membrane through 
its cysteine residue (Liu and Sy 1997).  Preventing this CD44 clustering using chimera 
CD4/CD44 molecules has been shown to down regulate the HA-CD44 interaction (Liu and Sy 
1997). Furthermore, the transmembrane region has been associated with the interaction with 
lipid raft regions in the cell membrane (Neame et al. 1995; Perschl et al. 1995).  This indicated 
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that the transmembrane region may also be involved in the ability of CD44 to act as a co-
receptor with other transmembrane receptors.  As many of these receptor associations happen 
within lipid raft regions, it indicates that the transmembrane region may play an important role 
in controlling CD44 interactions and signalling.  
3.1.3.6. – CD44 Cytoplasmic Domain Phosphorylation and the Cytoskeleton Interaction. 
 
The cytoplasmic domain is encoded partially by exon 17 and all of exon 19 (Figure 3.1 [A]) 
of the CD44 gene and is ~70 amino acids in length. It contains a constitutively expressed 
phosphorylated region at Ser325, which when mutated dysregulates cell migration (Peck and 
Isacke 1998).  Phosphorylation at this site has been shown to be regulated by calmodulin kinase 
II (CaMKII) and protein kinase C (PKC).  The activation of PKC has been shown to play a role 
in the cytoplasmic domain association with the cytoskeleton, by switching phosphorylation of 
Ser325 to Ser219.  This results in a dissociation of the cytoplasmic tail from ezrin, a component 
of the cytoskeleton (Legg et al. 2002).  
The intracellular partner proteins that modulate the association of CD44 with the 
cytoskeleton are ankyrin, ERM proteins, ezrin, radixin, and moesin and merlin.  Ankyrin is a 
protein linker that is known to associate with spectrin; a component of the cytoskeleton. The 
importance of CD44/ankyrin binding has not been fully investigated, but it is known that 
blocking the ankyrin binding site situated between amino acid 305 and 355 on the cytoplasmic 
tail prevents the HA/CD44 association within the amino domain (Lokeshwar et al. 1994); 
indicating it may play an essential role in ligand binding and, therefore, HA-dependent cell 
adhesion, migration and differentiation. The ERM proteins regulate the linking of F-actin in 
the cytoskeleton to receptors within the plasma membrane making them essential for cell 
morphology and multiple cell functions, including cell migration, adhesion and signalling. 
ERM proteins are a subfamily within the band 4.1 superfamily, that consist of a ~300 amino 
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acid FERM (four point one ezrin, radixin, moesin) domain at the N-terminus and a F-actin 
binding site at the C-terminus (Algrain et al. 1993).   CD44 interacts with ERM proteins 
(Tsukita et al. 1994) in vitro and in vivo, using a binding domain situated between the 
transmembrane region and the ankyrin binding domain (Yonemura et al. 1998).  Furthermore, 
a similar motif can be found in cytoplasmic regions of other transmembrane proteins, including 
members of the intercellular adhesion molecule (ICAM) family, (Heiska et al. 1998).  Inactive 
ERM proteins fold together through the interaction of the N-terminal and the C-terminal 
preventing the interaction of protein sites in a homotypic association or with each other in a 
heterotypic association (Gary and Bretscher 1993). ERM proteins are activated by binding to 
the phospholipids in the plasma membrane (Hirao et al. 1996); and phosphorylation has been 
observed of a conserved threonine residue in the C-terminal by kinases, including, Rho-kinase 
(Matsui et al. 1998), PKCα (Ng et al. 2001); and PKCθ (Pietromonaco et al. 1998). Finally, 
merlin, which is an ERM related protein, exhibits similarity to the ERM proteins, however, it 
does not have an F-actin binding domain in the C-terminus.  Moreover, merlin associates with 
the ERM proteins and both work as a molecular switch.  Interestingly, it is the 
dephosphorylated form of merlin that binds with the CD44 cytoplasmic tail. This in turn 
prevents the interaction of CD44 with the cytoskeleton, due to the lack of an F-actin binding 
site.  Furthermore, when CD44 associates with hyaluronan, merlin becomes phosphorylated, 
dissociates and the ERM proteins link CD44 with the cytoskeleton.  Therefore, the ERM-merlin 
complex acts as a mediator of HA-dependent cellular functions (Morrison et al. 2001). 
 The interaction between the cytoskeleton and the cytoplasmic domain of CD44 variants 
is not well understood.  It is, however, known that the epithelial form of CD44 (CD44v6-10) 
along with CD44s, does interact with both ERM proteins and ankyrin and that the association 
of these two region varies in their binding affinity (Lokeshwar et al. 1994; Tsukita et al. 1994). 
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In a review by Bourguignon et al. (1998), it was suggested that isoforms of CD44 have different 
affinities with ankyrin/ERM, which may mediate differences in intracellular signalling. 
3.1.4. – Alternative Splicing of CD44 Variants in Cell Types 
 
Early investigation of CD44 variant expression in different cell types identified that CD44s 
was widely distributed in multiple tissues and that the different isoforms of CD44 varied 
between cells of hematopoietic lineage (Dougherty et al. 1991).  Moreover, transfection of a B 
cell line with both CD44s and epithelial CD44v8-10 altered the adhesion properties of the cell 
(Stamenkovic et al. 1991),  indicating that each variant has a different role. Multiple studies 
have examined the expression of CD44 variants in normal tissues and found them to be less 
abundant and have more specific functions, compared to standard CD44. For example, studies 
using specific CD44 variant antibodies have shown CD44v9 to be expressed in nearly all 
epithelial cell types.  The expression of CD44v6 and v3 has been detected in squamous or 
glandular epithelium and CD44v4 expression has shown to be limited to epidermis or 
oesophageal tissue (Terpe et al. 1994; Fonseca et al. 2000).  Larger CD44 variants have been 
detected in keratinocytes, including CD44v2-10, v3-10, v4-10, v6-10 and v8-10; and this 
expression changed after keratinocytes had terminally differentiated into corneocytes (Hudson 
et al. 1995).   
More recently, due to an extended knowledge of defective splicing at the pre-mRNA 
level, more studies have focused on the dysregulated expression of CD44 variants in cancer, 
with the aim of using altered expression as a marker for cancer growth and its progression.  In 
the prognosis of cancer, the upregulation of CD44s has been linked to Non-Hodgkinson 
lymphoma and has been shown to be a useful marker for prognosis. The upregulation of CD44s 
correlates with increased HA deposition and enhanced migration and metastasis (Horst et al. 
1990). In a review by Bourguignon et al. (1998), CD44v5 was linked to colon rectal 
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progression, CD44v9 was deemed a positive marker for gastric carcinoma and CD44v7/8 was 
a marker for cervical cancer progression. 
 More recent research of CD44 and its role in tumour growth shows that overexpression 
of CD44s in the metastatic breast cancer cell line, MCF7, induced increased proliferation, 
migration and invadapodia in vitro. This was confirmed in vivo, where high levels of CD44s 
correlated with increased invadapodia and liver metastasis (Ouhtit et al. 2007). The co-
expression of CD44v10 with CD44s results in the inability of CD44s to form clusters within 
the cell membrane. This cluster formation usually enhances the CD44/HA binding affinity. 
However, CD44v10 interacted with CD44s decreasing CD44s/HA binding affinity.  This 
decrease in binding is thought to initiate metastatic progression (Iida and Bourguignon 1997). 
Isoforms containing v3 been have found to be associated with breast and head and neck cancer; 
and are thought to increase the expression of MMPs, known mediators of invadapodia and 
migration in metastasis.   The variant CD44v3,8-10 has a heparin binding domain that was 
shown to preferentially interact with VEGF and therefore, it is implicated in angiogenesis 
(Wang et al. 2007). 
The research into CD44 variants in cancer is extensive, however, there is limited 
knowledge about their expression and role in fibrosis. Previous studies in our laboratory have 
identified that total CD44 is highly expressed in fibroblasts and that this expression is down 
regulated upon TGF-β1 stimulation, but upregulated by IL-1β (Meran et al. 2011b; Meran et al. 
2013).  What is not known is which individual CD44 variants are expressed in fibroblasts or 
how this expression alters when they are stimulated with these two cytokines.   
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3.2 -Chapter Aims 
 
The aims of this chapter are: 
 
1)  Determine CD44 variant expression in unstimulated fibroblasts. 
2)  Investigate the effect of TGF-β1 stimulation on CD44 variant expression.  
3) Analyse the effect of IL-1β stimulation on CD44 variant expression. 
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3.3. – Methods 
 
3.3.1. - Analysis of CD44 Spliced Variants 
 
The transcriptional expression of the CD44 variants was analysed by two methods: 
i) Analysis of single variant expression 
In order to identify any variants that existed as a distinct single exon between the two common 
regions, primers were designed to overlap the 3’ end of exon 5 with the 5’ end of each selected 
target exon of the variable region (Figure 3.2 [A]).  (This was the forward primer. The 3’ end 
of the target was then overlapped with the 5’ end of exon 15 as the reverse primer) (Figure 3.2 
[B]). Each exon product has a corresponding variant name, which is outlined in (Table 3.1). 
Amplified targets were then quantified using QPCR, as previously described in Chapter 2. 
ii) Analysis of large transcript variant expression 
To investigate the expression of larger spliced variants, a forward primer located between the 
exon-exon boundary of exons 3 and 4 of the 5’ constant region was used (Figure 3.3. [A]). A 
panel of reverse primers, each specific to a sequence in each of the variable exons (6-14), 
enabled the identification of variants between the regions v2-v10 (Figure 3.3. [B]).  A final 
reverse primer in exon 17 was located in the transmembrane region and enabled the 
identification of CD44s.  
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[A] 
No Exon CD44s 
Exon 6 v2 
Exon 7 v3 
Exon 8  v4  
Exon 9 v5 
Exon 10 v6 
Exon 11 v7 
Exon 12 v8 
Exon 13 v9 
Exon 14 v10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[B] 
 
[C] 
 
Primer Design for single exon expression variants 
5 15 
5 15 
5 15 6 
5 15 7
 8
5 15 9 
5 15 10
5 15 11 
5 15 12 
5 15 13 
5 15 14 
Table 3.1 – Corresponding exon expression with variant 
    5 
Forward primer overlapped exon 5 in the 
common region and the exon of interest. 
15 
Reverse primer over lapped exon 15 in the 
common region and the exon of interest. 
Figure 3.2. - Final Target Sequence and Corresponding Nomenclature of Single CD44 Variants 
To enable a more detailed analysis of CD44 expression a preliminary investigation was carried out to examine the expression of 
single exons between the common regions.  Custom primers were designed to target variants that express one of the variable exons 
(6-14) between the common regions.  Final target products are indicated in schematic [A].  The corresponding nomenclature of 
CD44 variant to exon expressed is indicated in table 3.1 [B].  Primers were designed to span the exon boundary of the common 
region and the variant of interest.  Forward primers overlapped the 3’ end of exon 5 in the common region with the 5’ end of the 
exon of interest.  Reverse primers overlapped the 5’ end of exon 15 with the 3’ end of the exon of interest [C]. 
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Figure 3.3. - Primer Design for Analysis of Large CD44 Spliced Variants 
A common forward primer located in exon 5 was used for all targets [A].  A panel of reverse primers that were located within spliced variant exons (6-14) were used 
to amplify CD44 spliced variants (v2-v10) [B].  An additional reverse primer was located in exon 17 [C] was used to identify CD44 standard. 
Reverse primer 
[C] 
Constant forward primer 
                   [A] 
v2       v3       v4       v5      v6       v7        v8        v9          v10        
 
5` 
3` 
6 
7 
8 
9 
10 
11 
12 
13 
14 
5` 
3’ 
    
1 2 3 54 6 7 8 9 10 11 12 13 14 15 16 17 19
18 
[B] Panel of reverse primers located 
within each variable exon 
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3.4. - Results 
 
3.4.1 – The Expression of Single Exon CD44 Variants in Fibroblasts. 
 
Total CD44 expression has previously been described, using a CD44 primer that targeted 
multiple exon - exon boundaries within the CD44 variable stem region. This enabled the 
amplification of multiple isoforms. Using this primer, TGF-β1 decreased total CD44 expression 
in fibroblasts over time (Meran et al. 2011b).  Conversely, IL-1β stimulation increased total 
CD44 expression (Meran et al. 2013).   
A preliminary analysis of basal CD44 variant expression was carried out to investigate 
if the CD44 variants containing single exons between the common regions were expressed in 
fibroblasts. Initial analysis indicated that all the CD44 variants were expressed in fibroblasts 
with the exception of v5. To estimate how abundant the basal expression of each variant was 
in fibroblasts, the DCT values were subtracted from the final CT value 40 and analysed (Figure 
3.4.).  The highest expressed variant was CD44 standard, followed by variants v3, v6 and v10.   
CD44 variants that were least expressed were v2, v7 and v9.  Table 3.2 shows the CT 
expression range of CD44 variants, which corresponds to these findings.  
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3.4.2 – The Effect of TGF-β1 and IL-1β Stimulation on CD44 Variant Expression. 
 
To investigate how the cytokines TGFβ1 and IL-1β affected CD44 variant expression, 
fibroblasts were stimulated with TGF-β1 (10 ng/ml) or IL-1β (1 ng/ml) over a time course of 
0-72 h. Control samples were treated with serum-free medium alone and extracted 
simultaneously at each time-point. Total RNA was extracted and samples were analysed using 
Basal Expression Range (CT values) Variant 
20-25 Standard 
25-30 v3<v10 < v6 
30-35 v8<v4<v7<v9 <v2 
Figure 3.4. – Preliminary Analysis of CD44 Variant Expression in Fibroblasts. 
Fibroblasts were grown to confluence and total RNA was extracted.  Analysis of fibroblast expression of 
CD44 variants that had one exon between common regions was done using qPCR and the primer 
combinations that were previously described in Figure 3.2.1.  Graph shows the DCT expression of variants 
subtracted from the total CT number (40). Data is shown as ±SD from two separate experiments. l n=2 
Sample. 
  
Table 3.2. – CT Expression of CD44 Variants in Basal Fibroblasts 
Table shows the different expression of CD44 variant in unstimulated fibroblasts. The total cycle number for 
qPCR amplification was 40 and all the variants were expressed with in this range with the exception of v5.  
CD44s was the highest expressed variant in basal fibroblast and amplified within the range of 20-25 CT.  All 
the variants amplified are stated in the table in order of amplification. 
C D 4 4
4
0
 C
T
 -
D
C
T
C D 4 4 s v 2 v 3 v 4 v 6 v 7 v 8 v 9 v 1 0
0
5
1 0
1 5
2 0
2 5
3 0
3 5
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qPCR, described in chapter 2. Analysis of CD44 variants was carried out using the primers 
previously described (Figure 3.3.). 
 Preliminary analysis suggested that TGF-β1 stimulation of fibroblasts decreased the 
expression of all CD44 variants.  After 12 h of stimulation with TGF-β1, the expression of 
CD44 standard, v2, v3, v4, v6, v8, v9 and v10 all decreased, when compared to control 
fibroblast expression (Figure 3.4. [A-E&H-I]).  Expression of CD44 v7 was unchanged, 
compared to control fibroblasts at all the time-points (Figure 3.4. [F]).   
Stimulation of fibroblasts with the pro-inflammatory cytokine IL-1β increased all the 
variants after 6 h of stimulation, compared to control fibroblasts (Figure 3.5. [A-I]).   
Interestingly, CD44v10 had the highest increase of 9-fold at the 6 h time point (Figure 3.5. 
[I]).  However, CD44s, the most expressed variant in fibroblasts, increased by only 4-fold 
(Figure 3.5. [A]). CD44v2 increased the least of all the variants by 2-fold at 6 hours (Figure 
3.5. [B]).   The expression of CD44v7 did not peak until 24 h, therefore, it was the only variant 
that did not exhibit its highest expression at 6 h (Figure 3.5. [F]).  After 72 h, all the variants 
had an expression equal to or below basal level control fibroblasts, with the exception of CD44 
v2 and v7. This preliminary data suggested that there was some variability in the response of 
CD44 variant expression following IL-1β stimulation.  
Using the observations made during this experiment, the time-points used for the 
subsequent investigations were 72 h for TGF-β1 stimulation and 6 h for IL-1β induced 
stimulations. 
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Figure 3.4. - The Effect of TGF-β1 Stimulation on CD44 Single Variant Expression 
Human lung fibroblasts were grown to 80% confluence in 6-well plates and growth-arrested in 
serum-free medium for 48h.  Cells were stimulated with TGF-β1 (10ng/ml) or fresh serum-free 
medium was added to control cells.    Cell were extracted at different time-points over 72 h. 
The extraction time-points were 0 h (this was immediately after stimulation of TGF-β1 or the 
addition of fresh serum free medium in control samples) 6, 12, 24, 48; and 72 h.  Total RNA 
was extracted, as described in Chapter 2.   QPCR was used to quantify the expression of a 
single CD44 exon between the common regions, using primers previously described in section 
3.2 and (Figure 3.2.1.)  The relative CT method was used for analysis.  Each graph represents 
the expression of a single CD44 variant over the 72 h time course. Graph compares control 
sample expression (open bars) against cells stimulated with TGF-β1 (black bars) at each of the 
time-points. Comparative exon expression between common regions with co-responding 
variant names are:  [A] CD44s (no exon), [B] v2 (exon 6), [C] v3 (exon 7), [D] v4 (exon 8), 
[E] v6 (exon 10), [F] v7 (exon 11), [G] v8 (exon 12), [H] v9 (exon 13), [I] v10 (exon 14).  
Sample were normalised to control samples at each of the respective time point. Data shown is 
preliminary data, experimental N=1, sample N=3.  
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Figure 3.5. - The Effect of IL-1β Stimulation on CD44 Single Variant Expression 
Human lung fibroblasts were grown to 80% confluence in 6-well plates and growth-arrested in 
serum-free medium for 48h.  Cells were stimulated with IL-1β (1ng/ml) or fresh serum-free 
medium was added to control cells.    Cell were extracted at different time points over 72 h. 
The extraction time points were 0 h (this was immediately after stimulation of IL-1β or the 
addition of fresh serum-free medium in control samples) 6, 12, 24, 48; and 72 h.  Total RNA 
was extracted, as described in Chapter 2.  QPCR was used to quantify the expression of a single 
CD44 exon between the common regions, using primers previously described in section 3.2 
and (Figure 3.2.1).  The relative CT method was used for analysis.  Each graph represents the 
expression of a single CD44 variant over the 72 h time course. Graph compares control sample 
expression (open bars) against cells stimulated with IL-1β (black bars) at each of the time- 
points. Comparative exon expression between common regions with co-responding variant 
names are:- [A] CD44s (no exon), [B] v2 (exon 6), [C] v3 (exon 7), [D] v4 (exon 8), [E] v6 
(exon 10), [F] v7 (exon 11), [G] v8 (exon 12), [H] v9 (exon 13), [I] v10 (exon 14).  Sample 
were normalised to control samples at each of the respective time-point. Data shown is 
preliminary data, experimental N=1, sample N=2.   
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3.4.3. -The Effect of TGF-β1 and IL-1β on Large CD44 Spliced Variants 
 
To identify CD44 variants that expressed multiple exons between the common regions, a panel 
of reverse primers and a common forward primer was used as described in (Figure 3.3.). 
Fibroblasts were grown to 80% confluence and growth-arrested for 48 h.  Fibroblasts were 
stimulated with TGF-β1 (10ng/ml) for 72 h or IL-1β (1ng/ml) for 6 h. Control fibroblasts were 
treated with fresh serum-free medium. A further set of control samples were extracted, prior to 
treatment directly following growth arrest to assess experimental conditions.  
  Separate amplification of the constant forward primer (Figure 3.3[A]) with the reverse 
primer that targeted a region within exon 17 (Figure 3.3[C]) and primers located within exons 
6, 7 and 8 figure 3.3[B], all amplified a single product.  (Figures 3.6 [A-D]) and (Figure 3.7 
[A-D]) bands (1-4) were identified using DNA sequencing as (1) CD44s, (2) CD44v2, (3) 
CD44v3 and (4) CD44v4.  TGF-β1 stimulation decreased the expression of CD44s (1), CD44v2 
(2) and CD44v3 (3) at 72 h compared to control fibroblasts (Figure 3.6 [A-C]). The expression 
of CD44v4, however, did not alter after stimulation of TGF-β1, compared to controls (Figure 
3.6. [D].) Stimulation with IL-1β (Figure 3.7 [A-D]) bands (1-4) increased the expression of 
CD44s (1), CD44v2 (2), CD44v3 (3) and CD44v4 (4), after 6 h.    
 As previously seen, variant 5 did not amplify and was not affected by either TGF-β1 or 
IL-1βstimulation (data not shown).   
(Figure 3.6 [E-H]) and (Figure 3.7 [E-H]) are the products of reverse primers located within 
exons 10, 11, 12 and 13. Using these reverse primers with the constant forward primers 
multiple products were identified, bands (5-11).  These were CD44v6 (5), CD44v 6-7 (6), 
CD44v8 (7), CD44v6-8 (8), CD44v9 (9), CD44 v8-9 (10) and CD44v6-9 (11).  Bands 5, 6, 8, 
10 & 11 show a sequential base pair increase of approximately one exon in length, respectively. 
Starting from exon 10/v6 (5), each reverse primer is located in an upstream variant exon.  Each 
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of the sequential variants increased by one exon, indicating that they were all different length 
amplicons of the same product. The final reverse primer located within exon 14 (Figure 3.6 
[I]) and (Figure 3.7 [I]), amplified one band that was determined to be CD44v10 (12).  As 
previously seen with the other variants, all of the amplicons decreased when treated with TGF-
β1 (Figure 3.6 [E-I]) and increased when treated with IL-1β (Figure 3.7[E-I]). 
An additional set of primers was used to amplify the largest target.  A forward primer that 
overlapped the 3' of exon 5 in the common region with the 5' end of exon 10/variant 6; and a 
reverse primer that overlapped the 5' end of exon 15 in the common region and with the 3' end 
of exon 14 /variant 10. This is a combination of the previously designed primers described in 
(Figure 3.2. [C]).  A large amplicon of approximately 720bp was identified (Figure 3.6. [J]) 
and (Figure 3.7. [J]) band (13).  The amplicon size was larger than the expected product size 
of 480bp stated in (Table 3.5 and Table 3.9). This was due to the continued amplification of 
the product into exon 5 and exon 15 in the common region from the forward and the reverse 
primers. DNA sequencing of this band identified the amplicon to be CD44v6-10 (see Appendix 
1). Consistent with previous results, this largest target had a decreased expression following 72 
h stimulation with TGF-β1 decreased and showed an increase after 6 h IL-1β treatment. 
Details of the expected amplicon length, reverse primer used, and identified product are given 
in (Tables 3.2-3.5) for TGF-β1 and (Tables 3.6-3.9) for IL-1β amplicons.  
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Figure 3.6. - TGF-β1 Effects on Large CD44 Spliced Variant Expression 
To identify the expression of large variants that contained multiple exons between common 
regions, fibroblasts were grown to 80% confluence and growth-arrested for 48 h. Cell were 
then stimulated with TGF-β1 (10ng/ml) for 72 h.  Control fibroblasts were treated with serum- 
free medium for the same time period as treated fibroblasts.  A further control group was 
extracted at 0 h, prior to the addition of medium.  Total ribosomal RNA was extracted and 
samples were reverse transcribed, as described in Chapter 2.  Touch down PCR was used to 
amplify CD44 variant targets, using the combination of primers described in Figure 3.2.2. 
cDNA was separated on a 0.5% agarose gel containing ethidium bromide, using electrophoresis 
at 100v for 90 min.  Bands were visualised and extracted under a UV light. DNA was extracted 
from each gel band using a QIAquick Gel Extraction Kit (Qiagen) and sequenced.  Figures [A-
I] show photos of the final gels.  Lane 1 are control fibroblasts that have been extracted 
immediately after the 48 h growth arrest period.  Lane 2 is control fibroblasts treated with 
serum-free medium.  Lane 3 is TGF-β1 stimulated fibroblasts.  Both Lanes 2 and 3 were 
extracted at 72 h.   
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Band Number Exon position of Reverse Primer Target Size Identified Product 
1 Exon 17 391bp CD44 Standard 
2 Exon 2 441bp CD44 v2 
3 Exon 3 420bp CD44v3 
4 Exon 4 388bp CD44v4 
500bp- 
1000bp- 
1000bp- 1000bp- 
1000bp- 
500bp- 
500bp- 500bp- 
TGF-β1 TGF-β1 TGF-β1 TGF-β1 
[A] [B] [C] [D] 
-   -     + -   -     + -   -     + -   -     + 
1 
2 3 
4
4 
1        2         3 1        2         3 1        2         3 1        2         3 
Table 3.2. – Shows the reverse primer position, the expected product size and the product identified for each of 
the bands (1-4). 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band Number Exon position of Reverse Primer Target Size Identified Product 
5 Exon 6 424bp CD44v6 
6 Exon 7 573bp CD44 v6-7 
7 Exon 8 408bp CD44v8 
8 Exon 8 674bp CD44v6-8 
9 Exon 9 402bp CD44v9 
10 Exon 9 469bp CD44v8-9 
11 Exon 9 757bp CD44v6-9 
Table 3.3. – Shows the reverse primer position, the expected product size and the product identified for each 
of the bands (5-11). 
1000bp- 1000bp- 
1000bp- 1000bp- 
500bp- 
500bp- 
500bp- 
500bp- 
TGF-β1 TGF-β1 TGF-β1 TGF-β1 
[E] [F] [G] [H] 
 
-   -     + -   -     + -   -     + -   -     + 
6 
8 11 
5 
7 10 
1        2         3 1        2         3 1        2         3 1        2         3 
9 
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Band 
Number 
Exon position of 
forward Primer 
Exon position 
of reverse 
primer 
Target 
size 
Identified 
Product 
13 Exon5/Exon 10 
boundary 
Exon 15/Exon 
14 boundary 
720bp CD44v6-10 
Band 
Number 
Exon position 
of Reverse 
Primer 
Target 
Size 
Identified 
Product 
12 Exon 14 489 CD44v10 
 
1000bp- 
1000bp- 
500bp- 500bp- 
[I] [J] 
12 
TGF-β1 -    -       + -    -       + 
1            2          3 1            2          3 
Table 3.4. – Shows the reverse primer position, the expected 
product size and the product identified for band (12). 
Table 3.5. – Shows the reverse primer position, the expected product size and 
the product identified for band (13). 
 
TGF-β1 -    -       + 
13 
95 
 
 
Figure 3.7. - IL-1β Effects on Large CD44 Spliced Variant Expression 
To identify the expression of large variants that contained multiple exons between common 
regions, fibroblasts were grown to 80% confluence and growth-arrested for 48 h. Cell were 
then stimulated with IL-1β (1ng/ml) for 6 h.  Control fibroblasts were treated with serum-free 
medium for the same time period as treated fibroblasts.  A further control group was extracted 
at 0 h, prior to the addition of medium.      Total ribosomal RNA was extracted and samples 
were reverse transcribed, as described in Chapter 2.  Touch down PCR was used to amplify 
CD44 variant targets, using the combination of primers described in Figure 3.2.2. cDNA was 
separated on a 0.5% agarose gel containing ethidium bromide, using electrophoresis at 100v 
for 90 min.  Bands were visualised and extracted under a UV light. DNA was extracted from 
each gel band using QIAquick Gel Extraction Kit (Qiagen) and   sequenced.  Figures [A-I] 
show photos of the final gels.  Lane 1 are control fibroblasts that have been extracted 
immediately after the 48 h growth arrest period.  Lane 2 is control fibroblasts treated with 
serum-free medium.  Lane 3 is IL-1β stimulated fibroblasts.  Both Lanes 2 and 3 were extracted 
at 72 h. 
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Band Number Exon position of Reverse Primer Target Size Identified Product 
1 Exon 17 391bp CD44 Standard 
2 Exon 2 441bp CD44 v2 
3 Exon 3 420bp CD44v3 
4 Exon 4 388bp CD44v4 
1000bp- 1000bp- 
1000bp- 
1000bp- 
500bp- 500bp- 
500bp- 
500bp- 
IL-1β IL-1β IL-1β IL-1β -    -       + -   -     + -    -       + -   -     + 
[A] [B] [C] [D] 
1 
2 
3 4 
1            2          3 1            2          3 1            2          3 1            2          3 
Table 3.6. – Shows the reverse primer position, the expected product size and the product identified for each of 
the bands (1-4). 
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Band Number Exon position of Reverse Primer Target Size Identified Product 
5 Exon 6 424bp CD44v6 
6 Exon 7 573bp CD44 v6-7 
7 Exon 8 408bp CD44v8 
8 Exon 8 674bp CD44v6-8 
9 Exon 9 402bp CD44v9 
10 Exon 9 496bp CD44v8-9 
11 Exon 9 757bp CD44v6-9 
IL-1β 
500bp- 
1000bp- 
1000bp- 
500bp- 
IL-1β 
500bp- 
1000bp- 1000bp- 
IL-1β IL-1β 
500bp- 
[E] [F] [G] [H] 
5 
6 
7 
8 
9 
10 
11 
-    -       + -    -       + -    -       + -    -       + 
1            2          3 1           2         3 1            2          3 1            2          3 
Table 3.7. – Shows the reverse primer position, the expected product size and the product identified for each of 
the bands (5-11). 
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Band 
Number 
Exon position of 
forward Primer 
Exon position of 
reverse primer 
Target 
size 
Identified 
Product 
13 Exon5/Exon 10 
boundary 
Exon 15/Exon 
14 boundary 
720bp CD44v6-10 
Band 
Number 
Exon position of 
Reverse Primer 
Target 
Size 
Identified 
Product 
12 Exon 14 489bp CD44v10 
Table 3.8 – Shows the reverse primer position, the 
expected product size and the product identified for band 
(12). 
1000bp- 
1000bp- 
500bp- 
500bp- 
IL-1β IL-1β 
[I] 
12 
13 
-   -     + 
1            2          3   1           2          3 
-   -       + 
Table 3.9 – Shows the reverse primer position, the expected product size and 
the product identified for band (13). 
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3.5. - Discussion 
 
This chapter aimed to identify which CD44 variants were expressed in fibroblasts and how the 
cytokines TGF-β1 and IL-1β, affected their expression.  A summary of all the variants identified 
is given in (Figure 3.8).  A preliminary investigation to examine the expression of CD44 
variants that had only one spliced exon between common regions, found that all the CD44 
variants from CD44v2 up to CD44v10 were expressed in fibroblasts, with the exception of 
CD44v5.     
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – Summary of CD44 variants identified to be expressed in fibroblasts 
Diagrams show the CD44 variants identified to be expressed in fibroblasts.  Figure [A] shows a summary of the CD44 variants 
containing only one single exon from the stem region between common regions Identified using qPCR.  Figure [B ] shows the 
final identification of the  large CD44 spliced CD44v6-10 using Touch down PCR. 
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preliminary data in this chapter indicates that CD44s is the highest expressed variant in lung 
fibroblasts. It is well documented the CD44s is the most abundant and widely distributed 
isoform of CD44 and the most commonly associated with HA binding functions (Bourguignon 
et al. 1998). Therefore, it could be speculated that CD44s may be the principle receptor 
involved in CD44/HA mediated functions in fibroblasts. 
 However, this study also suggests that CD44 variants v3, v6 and v10 are highly 
abundant in fibroblasts (Table 3.1.)  Variants of CD44 all have the same HA binding domains 
within the extracellular region, but they display a different HA binding affinity.  However, the 
variants CD44v3 v6 and v10 have all been documented to have an increased interaction with 
HA in cancer progression; and be associated with migration and increased proliferation 
(Bourguignon et al. 1998; Afify et al. 2009). Fibroblasts are the principle mediator in wound 
healing. Resident fibroblasts migrate to the damaged region and undergo increased 
proliferation, preceding differentiation to a myofibroblast.  Therefore, the high expression of 
these isoforms may contribute to increased CD44/HA interactions and facilitate these 
functions. CD44 variants v2, v4, v7, v8 and v9 were all expressed in fibroblasts, although to a 
lesser extent (Table 3.1.).  These variants, with the exception of variant 2, have all previously 
been documented to have an increased expression in cancer cells, indicating that they also can 
interact with HA (Iczkowski et al. 2003; Zen et al. 2008; Lau et al. 2014).  
The pro-fibrotic cytokine, TGF-β1, is a major contributor to fibrotic progression.  Our 
research has previously shown that TGF-β1-activated fibroblasts differentiate to myofibroblasts 
in a HA/CD44/EGFR-dependent manner. The HA/CD44 interaction moves CD44 through the 
membrane into lipid rafts, where it associates with EGFR.  This complex formation initiates an 
intracellular signalling cascade through ERK1/2 and the differentiation process (Midgley et al. 
2013).  
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 The effect of TGF-β1 on CD44 variant expression in fibrosis is not well researched. It 
is known that overexpressing CD44v3 inhibited the expression of TGF-BR1 and downstream 
activation of TGF-β1 in CD44 knockout/knockin mice. This led to the prevention of tubular 
damage and increased proliferation of tubular epithelial cells, preventing fibrotic progression 
in obstructive nephropathy. Furthermore, overexpression of CD44s increased TGF-β1 
expression and fibrotic progression (Rampanelli et al. 2014). In addition, upregulated CD44v6 
and v9 have been observed in pulmonary fibrosis, compared to normal lung tissue (Kasper et 
al. 1995). More recently, our group has shown that total CD44v7/8 expression is significantly 
decreased in TGF-β1-induced myofibroblasts, compared to an increased expression observed 
in fibroblasts stimulated with BMP-7.  Further, stimulation of myofibroblasts with BMP-7 has 
been observed to reverse the fibrotic effect probably by the internalization of HA and 
prevention of TGF-β1 induced signalling (Midgley et al. 2015).  
To elucidate how TGF-β1 regulates CD44 variants in differentiating fibroblasts, a 
preliminary study investigated the expression of CD44 variants containing only one exon 
between common regions after TGF-β1 activation.  This study is consistent with previous 
findings in our group and shows that CD44s and all the variant isoforms CD44v2 to v10 had a 
reduced expression after 72 h (this is the time the cells were deemed to be myofibroblasts), 
with the exception of CD44v7 which had no variation in expression throughout the time course.  
Why CD44 expression in myofibroblasts is attenuated is undetermined. One 
explanation may be that the HA/CD44 interaction alters in myofibroblasts, compared to 
fibroblasts.  In fibroblasts, CD44 is diffuse throughout the plasma membrane when TGF-β1 
induces differentiation, CD44 is moved into clusters by HA resulting in the formation of a 
TSG-6/HA/CD44-dependent peri-cellular coat (Webber et al. 2009c; Midgley et al. 2015).  
This different orientation of CD44 alters the affinity of the HA/CD44 complex, a factor that is 
known to alter the cellular response (Iida and Bourguignon 1997).  As the functions of a 
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fibroblast are different to a myofibroblasts, it may suggest that this reduction alters signalling 
pathways that mediate the cell functions. 
A continued inflammatory response plays a role in the underlying pathology of fibrotic 
progression by mediating the influx of healing mediators to the site of injury, including 
monocytes/macrophages and fibroblasts. The association of fibroblasts with 
monocytes/macrophages has been previously demonstrated to play a role in fibrogenesis.  
Recent evidence has implicated the pro-inflammatory cytokine, IL-1β, in the induction of 
fibroblast-monocyte binding in a HA/CD44-dependent manner.   After IL-1β stimulation, 
fibroblasts form cell membrane protrusions that associate with linear spikes of HA.  CD44 is 
central to this formation and accumulates within the protrusions and associates closely with 
ICAM-1 mediating monocyte binding (Meran et al. 2013). 
IL-1β induced the expression of all the CD44 variants identified in this preliminary 
study after 6 h. As seen in fibroblasts and myofibroblasts, CD44v5 was not detected.  
Previously, it has been shown that both TGF-β1 and IL-1β upregulate CD44v5 in cervical 
adenocarcinoma (Ibrahim et al. 2006).  In this study, both these cytokines failed to stimulate a 
CD44v5 product. Therefore, it may suggest that this variant is not expressed in fibroblasts or 
myofibroblasts.  CD44v10 had the highest increase of nearly 9-fold, comparative to control 
fibroblast following IL-1β stimulation. In inflammatory conditions, cell migration plays a 
pivotal role. CD44v10 has been associated with upregulated cell migration to a similar extent 
as that seen by CD44s in cancer (Bourguignon et al. 1998).  Therefore, the large increase in 
this variant following stimulation with pro-inflammatory IL-1β may suggest an increased 
migratory response.   Interestingly, CD44v7, v8, and v9, which were deemed to be the least 
expressed variants in fibroblasts, exhibited a higher fold increase comparative to the more 
highly expressed variants, CD44s CD44v3 and v6. However, these latter variants already have 
a high basal expression and therefore, an increase may not be as noticeable. The increase of 
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CD44 variants in inflammatory disease is well-researched. For example, in rheumatoid arthritis 
synovial fluid, there is a high expression of CD44 isoforms containing v6 and v9; and v3, v6 
and v7 containing isoforms are largely associated with inflammatory bowel disease (Hale et al. 
1995; Rosenberg et al. 1995b; Wittig et al. 2000).  Moreover, due to the high expression of 
CD44s on lymphoid cells, it has long been established that upregulation of the standard CD44 
plays a role in inflammatory diseases (Jalkanen et al. 1986; Haynes et al. 1991).  This study, 
therefore, presents data in line with previous work that states that CD44 is upregulated under 
inflammatory conditions. 
  Larger CD44 spliced variants have mostly been identified in association with cancer.  
The increased insertion of amino acids into the stem region results in further potential 
glycosylation.  This alters the association of CD44 with ECM components and hence, changes 
the cell properties.  The large variant identified in fibroblasts in this study, CD44v6-10 has 
been shown to have a lower affinity for HA binding, compared to the standard form of CD44.  
Furthermore, the upregulation of this variant has been observed to delay lymphoma 
progression.  It does this as it undergoes a significantly higher shedding than CD44s.  
Moreover, this shed form interacts with CD44s to prevent HA binding mediating HA/CD44s 
interactions that are associated with cancer progression (Bartolazzi et al. 1995). Therefore, it 
may be speculated that the decreased expression of CD44v6-10 in myofibroblasts and 
increased expression in IL-1β-stimulated fibroblasts have a role in regulating CD44/HA 
interactions in these mechanisms that contribute to the overall function.  
This chapter aimed to identify which CD44 variants are expressed in fibroblasts and determine 
how stimulation with TGF-β1 and IL-1β affected the overall expression of each variant.  The 
next aim was to determine which of the CD44 variants are involved in the TGFβ1-induced 
HA/CD44/EGFR mechanism and the IL-1β-induced HA/CD44/ICAM-1 pathways. 
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Chapter 4 -The Role of CD44 Variants in Myofibroblast 
Differentiation and Inflammatory Cell Interactions 
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4.1-Introduction 
 
The work described in Chapter 3 profiled the expression pattern of cluster of differentiation 44 
(CD44) spliced variants in fibroblasts and demonstrated how the stimulation by the pro-fibrotic 
cytokine, TGF-β1, or the pro-inflammatory cytokine, Interleukin-1β (IL-1β), affected variant 
expression.  The overall effect of TGF-β1 was decreased expression of all variants, whereas in 
contrast, IL-1β increased the expression of all the variants examined. 
 Previous research has shown the interaction of HA with CD44 to be central to TGF-β1- 
induced fibroblast to myofibroblast differentiation, wherein a re-localisation of membrane- 
associated CD44, resulted in the co-localisation of CD44 with epidermal growth factor receptor 
(EGFR) in cholesterol-rich lipid raft regions.  The CD44/EGFR association was an essential 
process for downstream Extracellular regulated kinase 1/2 (ERK1/2) activation and 
upregulation of hyaluronan synthase 2 (HAS2) and αSMA gene transcription in this pathway.  
This re-localisation of CD44 was dependent on HA and may also orchestrate the formation of 
the HA peri-cellular coat that maintains the myofibroblast phenotype (Webber et al. 2009a; 
2009c; Midgley et al. 2013).  Silencing total CD44 expression was previously shown to inhibit 
the expression of α smooth muscle actin (αSMA) following TGF-β1 stimulation (Midgley et 
al. 2013). 
  A similar role for HA/CD44 has been described in IL-1β-induced monocyte binding.  
Fibroblasts stimulated with IL-1β formed HA/CD44-modulated cell membrane protrusions. 
CD44 and intercellular adhesion molecule-1 (ICAM-1) re-distributed through the cell 
membrane and co-localised within these protrusions, activating downstream ERK1/2 
signalling. Using a siRNA to all CD44 mRNAs, fibroblasts failed to form HA protrusions, they 
lost CD44/ICAM-1 co-localisation, downstream ERK1/2 activation and monocyte binding 
(Meran et al. 2013). 
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Although it has been established that CD44 has a critical role in both TGF-β1 induction 
of αSMA and IL-1β-induced monocyte binding, which of the CD44 variants mediates the 
functional outcomes has not yet been investigated.  In the previous chapter, there were CD44 
variants identified in fibroblasts that had more abundant levels of expression than others.  This 
suggested that these CD44 variants (CD44s, v3, v8, v6 and v10), may have an important role 
in the regulation of fibroblast function.  These variants have previously been reported to bind 
HA and regulate important cellular functions, excluding CD44v8, which currently has an 
unknown role (Bourguignon et al. 1998).  The role of the larger variant, CD44v6-10, that was 
identified will also be investigated as this splice variant was previously described to regulate 
HA interactions (Bartolazzi et al. 1995).  
It is hypothesised that there may be one or more specifically highly expressed CD44 
variants that have roles central to myofibroblast differentiation, or the induction of pro-
inflammatory fibroblasts.  
 
4.2 – Chapter Aims 
 
The objectives of this chapter are:- 
1) To determine which of the CD44 variants previously identified, have roles in the 
HA/CD44 induction of αSMA upregulation, following TGF-β1 activation. 
2) To investigate which CD44 variants have roles in HA/CD44-dependent monocyte 
binding, following IL-1β stimulation. 
 
 
 
107 
 
4.3 – Methods 
 
4.3.1. – Custom-designed siRNA 
 
Custom-designed, short interfering ribonucleic acids (siRNA), were designed to target specific 
CD44 variants.  The variants found to have the highest expression in fibroblasts were CD44s, 
v3, v10, v6 and v8 (Table 3.2).  In order to silence CD44 variants v3, v10 and v8, siRNAs were 
designed to be situated within variant-specific exons (Figure 4.1. [A] (1-3)).  The siRNA to 
silence CD44v6 was designed to overlap the common region exon 5 with exon 10/v6 (Figure 
4.1. [B](1)).  The siRNA to CD44s targeted the overlap of the exon boundaries, bridging the 
two common regions; exon 5 and exon 15 (Figure 4.1. [C](1)). 
In the previous chapter, the larger CD44 splice variant, CD44v6-v10, was found to be 
expressed by fibroblasts.  To examine the effect of this variant on TGF-β1-induced, fibroblast 
to myofibroblast differentiation and IL-1β- induced monocyte binding, multiple custom siRNA 
were designed to target distinct regions within CD44v6-10.  Firstly, a siRNA to CD44v7/8 was 
designed.  This siRNA overlapped the exon 11 and exon 12 boundary, as shown in (Figure 
4.1. [B](2)). Furthermore, the siRNAs that were designed to target CD44v6, v8 and v10, also 
targeted regions within CD44v6-10 (Figure 4.1. [B] (1, 3 & 4)). 
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Figure 4.1. – Custom-designed siRNA for CD44v knockdown 
Schematic shows target regions of custom-designed siRNA to CD44 variants.  Figure [A] shows the targeted regions of siRNA against (A1) CD44 v3, (A2) CD44v8; and (A3) CD44v10.  
These primers were designed to target regions within the exons 7, 12 and 14, respectively. To silence the larger variant, CD44v6-10, multiple siRNAs were designed  to confirm knockdown 
Figure [B].These were a siRNA that overlapped exon 5 within the common region with exon 10/CD44v6 B(1); and a siRNA targeted the exon-exon boundaries of exon 11 and 12/ 
(CD44v7/8)(B2).  The siRNA to v8 (B3) and v10 (B4), also targeted regions in CD44v6-10.  The siRNA designed to targeting CD44s targeted overlapped the exon-exon boundary between 
common region exons; 5&15. (C1). 
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4.4 – Results 
 
4.4.1 – TGF-β1-Induced Myofibroblast Differentiation 
 
To identify the time-point at which myofibroblast differentiation was complete, fibroblasts 
were stimulated with TGF-β1 and αSMA expression was analysed over a time course of 24-72 
h, using quantitative polymerase chain reaction (qPCR).  (Figure 4.2. [A]), demonstrates the 
gradual increase of αSMA mRNA expression over 72 h. A significant increase was observed 
at 72 h. αSMA protein expression was observed at 72 h, using immunocytochemistry 
(previously described in chapter 2). The change in cell morphology and formation of αSMA 
stress fibres, a known characteristic of the myofibroblast phenotype was observed and is shown 
in (Figure 4.2. [C]). Unstimulated fibroblast controls are shown in (Figure 4.2. [B]), where 
there is a distinct lack of αSMA and stress fibre formation.  These data correspond with 
previous research in our group that has identified 72 h as a time-point at which myofibroblasts 
are completely differentiated (Evans et al. 2003b; Webber et al., 2009a). Therefore, all 
subsequent analysis of myofibroblast induction was performed following 72 h of TGF-β1 
stimulation.    
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Figure 4.2. – TGF-β1 Induction of α Smooth Muscle Actin. 
To determine the time-point of complete differentiation from fibroblast to myofibroblast, the expression of αSMA was analysed over 
a time course of 72 h, using qPCR [A].  Fibroblasts were grown to 80% confluence, before growth arrest.  Cells were treated with TGF-
β1 (10ng/ml) or serum-free medium alone (control samples). Data represents the mean of 3 separate experiments ± SEM. Statistical 
analysis used the one way ANOVA, followed by the Student’s unpaired t-test.  Immunocytochemistry was used to visualise αSMA 
protein and stress fibre formation, following 72 h of TGF-β1 (10ng/ml) stimulation. Cells were grown to 50% confluence before growth 
arrest in serum-free medium.  Cells were then treated with TGF-β1 (10ng/ml) or with fresh medium for controls for 72 h.  Cells were 
then fixed before being analysed using immunocytochemistry. Figure [B] is representative of control fibroblast populations that lack 
αSMA and stress fibres.  Figure [C] is representative of TGF-β1 stimulated myofibroblasts.  An IgG control was used to show antibody 
specificity Figure [D]. Samples were visualised using a Lecia Dialux 20 Fluorescent Microscope. Original magnification X 400.   
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4.4.2. – IL-1β-Induced Monocyte Binding 
 
The ability of fibroblasts to bind monocytes following IL-1β has previously been shown in our 
laboratory, in a CD44-dependent manner (Meran et al. 2013).  In order to assess the role of 
CD44 variant expression on IL-1β-stimulated monocyte binding, it was necessary to identify a 
highly sensitive assay for monocyte binding. CD45 is a specific marker of leukocytes.  Figure 
4.2 [A] shows qPCR analysis of CD45 expression in unstimulated and IL-1β-stimulated 
fibroblasts, compared to the expression of CD45 by U937 (1x106 cells /ml).  There was limited 
detectable expression of CD45 in unstimulated fibroblasts or fibroblasts treated with IL-1β, 
compared to U937 cells.  Therefore, all further experiments assessing monocyte binding were 
analysed using CD45 as a marker of monocyte numbers. 
To identify an optimum time-point for monocyte binding, following growth arrest, 
fibroblasts were stimulated with IL-1β or serum-free medium alone (control samples), over a 
72 h time course. At each of the indicated time-points between 24 and 72 h, U397 cells (1x106 
cells/ml) were added to IL-1β-stimulated and unstimulated (control) fibroblast cultures and 
incubated for 4 h.  Unattached monocytes were removed by washing with PBS; and remaining 
cells were assessed for mRNA expression using qPCR.  (Figure 4.3.[B])  shows a significant 
increase in  monocyte binding, compared to control fibroblasts, with an optimum time of 72 h 
which was the time point used for all subsequent experiments.  
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Figure 4.3. – IL-1β Induction of Monocyte Binding 
Data [A] shows the expression of CD45 in 1 µg of total cell cDNA in unstimulated and IL-1β-stimulated fibroblasts, 
compared to U397 positive control cells.  Fibroblasts were grown to 80% confluence and growth-arrested.  Cells 
were incubated in serum-free medium alone (controls) or serum-free medium containing IL-1β (1ng/ml), for a 
further 72 h. As a positive control, U397 cells (1x106 cells /ml) were also included.   CD45 expression was analysed 
using qPCR.  Figure [B] shows the assessment of monocyte–binding over 72 h.  Fibroblasts were grown to 80% 
confluence, prior to growth arrest. Cultures were then treated with serum-free medium alone or serum-free medium 
containing IL-1β (1ng/ml).  At each time point, U397 cells (1x106cells/ml) were added to the control fibroblasts 
(white bars) and IL-1β-stimulated fibroblasts (black bars) and incubated for 4 h.  Unbound monocytes were washed 
using PBS.  CD45 was analysed using qPCR. Statistical analysis was carried out using the ANOVA followed by 
the Student’s unpaired t-test.  Results are displayed as the mean of three individual experiments ± SEM. *P<0.05, 
**P<0.01, ***P<0.001. 
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4.4.3. -CD44 Variant Involvement in αSMA Expression and Monocyte Binding 
 
Using a siRNA that targeted global CD44 expression in fibroblasts, our laboratory has 
previously shown that CD44 is required for both TGF-β1-induced fibroblast to myofibroblast 
differentiation and IL-1β-induced fibroblast to monocyte binding (Webber et al. 2009b; Meran 
et al. 2013; Midgley et al. 2013).  However, it is not understood which of the CD44 variants 
are involved in these processes.   
The efficiency of knockdown by each custom-designed siRNA (Figure 4.1) was 
assessed (see; Figure 4.4. [A&B], Figure 4.5. [A&B], Figure 4.6. [A-C] and Figure 4.7. [A-
C]). All control fibroblasts transfected with the custom-designed siRNA to CD44 had a 
decreased expression of CD44 targets, when compared to fibroblasts transfected with the 
negative scrambled control (Figure 4.4. [A&B]) and (Figure 4.6. [A-C]). IL-1β-stimulated 
fibroblasts, transfected with the custom designed siRNA to CD44, also had knockdown of 
targeted CD44 variants (Figure 4.5. [A&B]) and (Figure 4.7. [A-C]).   
 Following knockdown of CD44v3 and v8, αSMA expression and monocyte 
binding were assessed (Figure 4.4[C-D]) and (Figure 4.5[C-D]).  These CD44 variants were 
both highly expressed in quiescent fibroblasts (Table 3.2). It was, therefore, important to 
investigate the effects of silencing them on both pathways.  TGF-β1 induction of αSMA 
expression was not affected in samples transfected with siRNA to CD44v3 (Figure 4.4 [C]) or 
CD44v8 [D]), when compared to samples transfected with the scrambled siRNA. Fibroblasts 
stimulated with IL-1β showed no significant difference in monocyte binding between samples 
transfected with siRNA to CD44v3 (Figure 4.5 [C]), when compared to fibroblasts transfected 
with scrambled siRNA control. Interestingly, unstimulated control fibroblasts transfected with 
a siRNA to CD44v8 had a significant increase in monocyte binding, compared to scrambled 
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controls Figure 4.5. [D]. These data suggest that the fibroblast expression of CD44v8 may 
have a regulatory role in monocyte binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] 
[B] 
[C] [D] 
Figure 4.4 – Transfection with siRNA to CD44v3 and v8 had no Effect on αSmooth Muscle Actin Induction in 
Myofibroblasts. 
To investigate the effect of silencing CD44v3 and v8 on αSMA induction in myofibroblasts, fibroblasts were grown to 50-
60% confluence.  Cells were transfected with either a siRNA to CD44v3, CD44v8 or a negative scrambled siRNA (control 
samples).  Following a growth arrest period, cells were treated with TGF-β1 (10ng/ml) or serum-free medium alone (control 
samples) for 72 h.  Data [A] and [B] show the knockdown of CD44v3 and CD44v8, respectively, at the experimental end-
point.  Unstimulated control cells (black bars) were compared to TGF-β1 (10ng/ml) stimulated cells (white bars). The 
knockdown of each variant was compared to a negative scrambled control.  The expression of αSMA after significant 
knockdown of CD44v3 and v8 are shown in graphs [C] and [D].  Data shows the αSMA expression of control unstimulated 
fibroblasts (black bars) against TGF-β1 (10ng/ml) stimulated cells (grey bars). Data is displayed as the mean of three separate 
experiments ± SEM. Statistical analysis was performed using the one way ANOVA, followed by the unpaired Student’s t-test.  
N/S= not significant, *P <0.05, **P<0.01, ***P<0.001. 
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Figure 4.5 – Transfection with siRNA to CD44v3 had no Effect on Monocyte Binding, Although, 
siRNA to CD44v8 Increased Monocyte Binding in Control Fibroblasts 
To investigate the effect of silencing CD44v3 and v8 on IL-1β induction of monocyte binding, fibroblasts were 
sub-cultured in 6-well plates, until 50-60% confluence.  Cells were transfected with either a siRNA to CD44v3, 
CD44v8 or a negative scrambled siRNA control. Following growth arrest, cells were treated with IL-1β (1ng/ml) 
or serum-free medium alone (control samples) for 72 h.  Data [A] and [B] show the knockdown of CD44v3 and 
CD44v8, respectively, at the experimental end-point.  Unstimulated control cells (black bars) were compared to 
IL-1β (1ng/ml) stimulated cells (white bars). The knockdown of each variant was compared to a negative scrambled 
control.  The expression of CD45 after significant knockdown of CD44v3 and v8 are shown in graphs [C] and [D].  
Data shows the CD45 expression of control unstimulated fibroblasts (black bars) against IL-1β (1ng/ml)- 
stimulated, cells (grey bars). Data is displayed as the mean of three separate experiments ± SEM. Statistical analysis 
was performed using the one way ANOVA followed by the unpaired Student’s t-test. N/S = not significant, 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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Previously in Chapter 2, it was determined that CD44v6 and v10 were highly expressed 
in quiescent fibroblasts. The larger CD44 variant (CD44v6-10) contains the exons that encode 
smaller variants: CD44 v6, v8 and v10.  The siRNA used to target CD44v6, v8 or v10 also 
silence the mRNA expression of CD44v6-10; (see Figure 4.1.).  However, using siRNAs that 
are designed to target CD44v6, v8 or v10 gives two possible outcomes to the results: 
1) The result is due to siRNAs targeting the single variants CD44v6, v8 and v10. 
2)  Any observed results are from the siRNA targeting the larger CD44v6-10. 
 To clarify involvement, a further siRNA was designed to target the exon-exon boundaries of 
exons 11/12 (also known as CD44v7-8), that would only effect the expression of the larger 
variant and not CD44v6, v8 or v10.   
Following successful knockdown of CD44v6, v7/8 and v10, the effect of silencing these 
variants on myofibroblast differentiation and monocyte binding were analysed. Preliminary 
data comparing myofibroblasts transfected with the scrambled siRNA to samples transfected 
with siRNA to CD44v6 and v10, showed no difference in αSMA expression (Figure 4.6. 
[D&F]).  This indicated that these two variants did not appear to have a role in regulating 
αSMA.  Furthermore, these data suggest that the larger spliced variant CD44v6-10 also has no 
role in TGF-β1-induced αSMA, due to collateral knockdown.  To confirm this, the effect of 
siRNAv7/8 on αSMA expression was assessed (Figure 4.6[B]). Comparing cells transfected 
with siCD44v7/8 to those transfected with the scrambled control, indicated that there was no 
effect on induction of αSMA.  Therefore, this combined preliminary data along with the data 
from siRNA CD44v8 analysis, where no effect on induction of αSMA was also seen, suggests 
that CD44v6-10 does not play a role in TGF-β1 upregulation of αSMA. 
Figure 4.7 [A-B] shows the preliminary analysis of siRNA to CD44v6 and v10 and the 
effects on monocyte binding. Knockdown (Figures 4.7. [D]) CD44v6 and (Figure 4.7. [F]) 
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CD44v10 suggest that these variants, do not have a role in CD44-dependent, monocyte binding. 
Similarly, these data suggest that the larger variant, CD44v6-v10, also has no role in monocyte 
binding.  Conformational experiments using siRNA against CD44v7/8 (Figure 4.7. [E]) 
showed there was no difference in CD45 expression, following silencing of CD44v7/8.  This 
preliminary data is in line with the observations made when fibroblasts were transfected with 
siRNA to v6, v8 and v10. Therefore, using the analysis of these combined data, it may be 
assumed that the larger CD44v6-10 has no role in CD44-dependent, fibroblast-monocyte 
binding. 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. – CD44v6, v7/8 and v10 Knockdown Had no Effect on αSmooth Muscle Actin. 
Custom-designed siRNA to CD44v6, v7/8 and v10, were used to analyse the effects of silencing CD44v on TGF-β1- induced αSMA.  A negative scrambled siRNA was 
used in control samples to ensure siRNA specificity.   Following growth arrest, cells were treated with TGF-β1 (10ng/ml) or serum-free medium alone (control samples) for 
72 h. mRNA expression was analysed using qPCR. Data [A-C] show the knockdown of CD44v6, v7/8 and v10, respectively. TGF-β1-stimulated cells (white bars) and 
control cells (black bars). The expression of αSMA after siRNA CD44v6, 7/8 and v10 are shown in graphs [D-F], control unstimulated fibroblasts (black bars) against TGF-
β1 (10ng/ml)-stimulated cells (grey bars). Data is representative of two separate experiments ± S.D. 
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   [A] [B] [C] 
[D] [E] [F] 
Figure 4.7. – CD44v6, v7/8 and v10 Knockdown Had no Effect on Monocyte Binding. 
 Custom designed siRNA to CD44v6, v7/8 and v10 were used to analyse the effects of silencing CD44v on IL-1β-induced monocyte binding. A negative scrambled siRNA 
was used in control samples.   Following growth arrest, cells were treated with IL-1β (1ng/ml) or serum-free medium (control samples) for 72 h.  Total RNA was extracted 
and samples were reverse transcribed before analysis by qPCR, as described in chapter 2. Data [A-C] show the knockdown of CD44v6, v7/8 and v10, respectively, IL-1β 
stimulated cells (white bars) and control cells (black bars).  The expression of CD45 (the monocyte marker) after siRNA CD44v6, 7/8 and v10, are shown in graphs [D-F].  
Data shows the CD45 expression of control unstimulated fibroblasts (black bars) against IL-1β (1ng/ml) stimulated cells (grey bars). Data is representative of ±S.D. of two 
separate experiments. 
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4.4.4. - Standard CD44 (CD44s) Decreases αSMA Expression in Myofibroblasts and 
Reduces Fibroblasts Ability to Bind Monocytes 
 
The standard form of CD44, was the highest expressed of all the CD44 variants identified 
(Table 3.2). Therefore, the effect of siRNA targeting CD44s on αSMA induction and IL-1β- 
induced monocyte binding was investigated.  The mRNA expression of αSMA was assessed 
in myofibroblasts that had been transfected with a siRNA to CD44s (Figure 4.8.).   There was 
a significant decrease in αSMA expression in TGF-β1–stimulated fibroblasts transfected with 
siRNA against CD44s, compared to TGF-β1-stimulated fibroblasts that had been transfected 
with the scrambled siRNA (Figure 4.8 [B]).   
The monocyte binding capacity of fibroblasts, following transfection with siRNA to 
CD44s, was subsequently assessed.  Fibroblast cultures that were transfected with scrambled 
siRNA had an increase in monocyte binding when stimulated with IL-1β, as expected (Figure 
4.9 [B]). Transfection of fibroblasts with a siRNA targeting CD44s significantly decreased 
monocyte binding, compared to fibroblasts transfected with a scrambled siRNA (Figure 4.9. 
[B]).  Together, these results suggest that the standard form of CD44 is the predominant CD44 
receptor involved in both IL-1β-induced monocyte binding and TGF-β1-induced myofibroblast 
differentiation.  
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Figure 4.8. – CD44s Knockdown Decreases α Smooth Muscle Actin mRNA Induction by TGF-β1 
Fibroblasts were cultured in 6-well culture plates, to 50-60% confluence.  Cells were growth-arrested for 24 h, before 
transfection with a siRNA to CD44s.  To ensure siRNA specificity, control cells were transfected with a negative 
scrambled siRNA. Cells were growth-arrested for a further 48 h, before being treated with TGF-β1 (10ng/ml) or serum- 
free medium alone for 72 h.  Figure [A] demonstrates the knockdown of CD44s in cells stimulated with TGF-β1 (white 
bars) or untreated cells (black bars)).  Figure [B] shows the expression of αSMA in control samples (black bars) and 
TGF-β1-stimulated samples (grey bars), following transfection with a siRNA to CD44s or a negative scrambled control.  
Data is displayed as the mean of three separate experiments ± SEM. Statistical analysis was performed using the one way 
ANOVA followed by unpaired Students t-test.   Data was deemed *P=<0.05, P***=<0.001. 
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Figure 4.9. – CD44s Knockdown Decreases Fibroblasts- Induced, Monocyte Binding by IL-1β 
Fibroblasts were sub-cultured in 6-well plates, until 50-60% confluence. Cells were growth-arrested for 24 h, 
before transfection with a siRNA to CD44s.  To ensure siRNA specificity control cells were transfected with a 
negative scrambled siRNA.  Cells were growth-arrested for a further 48 h before, being treated with IL-1β (1ng/ml) 
or serum-free medium alone (control samples) for 72 h. Two sample sets were run side by side, the first was used 
to assess sufficient silencing of CD44s Figure [A] demonstrates a CD44 siRNA knockdown IL-1β (white bars); 
untreated controls (black  bars) as analysed by qPCR. Figure [B] shows the expression of CD45 following a 
incubation of fibroblasts with monocytes.  Data shows unstimulated fibroblasts (black bars) and IL-1β-stimulated 
samples (grey bars).  Data is displayed as the mean of three separate experiments ± SEM. Statistical analysis was 
performed one way ANOVA, followed by unpaired Students t-test.   *P<0.05, **P0.01. 
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4.4.5. - CD44s Mediates αSMA Stress Fibres Formation in TGF-β1 - Treated Fibroblasts 
 
Following 72 h stimulation, TGF-β1 induced the expression of αSMA stress fibres in 
myofibroblasts (Figure 4.2. [C]).  This supports previous research undertaken in our laboratory 
(Webber et al. 2009b).  To investigate the role CD44s plays in the formation of αSMA stress 
fibres, cells were transfected with siRNA to CD44s and visualised for αSMA stress fibres using 
ICC.  Observations of untreated control fibroblasts transfected with either a negative scrambled 
siRNA or a siRNA to CD44, had limited αSMA and no stress fibre formation (Figure 4.10 
[A&B]). This was to be expected, as αSMA is known to not be highly expressed in resting 
fibroblasts (Clayton et al. 1997).  (Figure 4.10 [C&D]) shows the effect of the siRNA targeting 
CD44s, compared to the siRNA scrambled controls, following 72 h of stimulation with TGF-
β1.  Fibroblasts transfected with the scrambled siRNA had the distinct stress fibre formation 
typical of differentiation to the myofibroblast phenotype (Figure 4.10 [C]).  However, in cells 
transfected with siRNA to CD44s, the majority of cells visualised maintained the fibroblast 
phenotype and had limited stress fibre formation (Figure 4.10. [D]). These data correspond 
with previously observed data in this chapter and confirm the reduced mRNA expression data 
shown above. Together, these data imply that CD44s has a significant role in the regulation of 
αSMA stress fibre formation in myofibroblasts.  
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Figure 4.9 Silencing CD44s Prevents Stress Fibre Formation in Myofibroblasts  
To assess the role of CD44s in the formation of αSMA stress fibres, fibroblasts were grown to 50% 
confluence in chamber slide wells. Cells were then transfected with siRNA to CD44s or a siRNA negative 
scrambled control. Following a growth arrest period of 48 h cells were treated with serum-free medium 
(controls) or serum free medium containing TGF- β1 (10ng/ml). Cell cultures were then analysed using ICC.  
Cells were visualised for αSMA stress fibres by a florescent microscopy.  A representative picture was taken 
of each cell populations under each condition.   [A&C] are cells transfected with scrambled siRNA.  Picture 
[A] represents unstimulated fibroblasts [C] represents TGF-β1 pictures [B&D] represents cells transfected 
with siRNA to CD44s, unstimulated fibroblasts [B] and TGF-β1 stimulated [D]. Original magnification x 
400. 
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4.4.6. - Silencing CD44s Has No Effect on Other CD44 Spliced Variant Expression. 
 
It has previously been documented that increased proteolytic cleavage of CD44 at the 
ectodomain and within the intracellular domain, results in increased cellular migration and pro-
oncogenic activity (Okamoto et al. 2001). Whilst cleavage at the ecdodomain results in the 
shedding of CD44 and the formation of soluble CD44, cleavage of the intracellular domain 
results in the release of intracellular domain fragment (ICD), which can translocate to the 
nucleus and regulates gene transcription.  It has been suggested that ICD translocation 
upregulates CD44 transcripts as a positive feedback loop (Nagano and Saya 2004). 
Furthermore, CD44s has been shown to associate with other CD44 variants, changing their 
interactions and thereby indirectly altering cellular function (Iida and Bourguignon 1997).  It 
was, therefore, important to assess the possibility that CD44s regulates other CD44 spliced 
variants. Furthermore, the siRNA that targeted CD44s potentially could target other variants.  
Therefore, there were two main aims to this investigation:-  
1. To determine if CD44s resulted in a change of other CD44 variant expression levels. 
2. To validate the specificity of the custom designed siRNA targeting CD44s and 
eliminate the possibility of unwanted targeting of other variants.  
Figure 4.11. [A-E] and Figure 4.12 [A-E] show the effect of siRNA CD44s on the mRNA 
expression of the other CD44 variants.  This data shows the expression of CD44v3 [A], v6 [B], 
v7/8 [C], v8 [D] and v10 [E], following knockdown of CD44s, compared to scrambled control. 
The effect of TGF-β1 and IL-1β stimulation was also analysed.  Silencing CD44s had no effect 
on the expression of any of the CD44 variants under investigation, compared to the scrambled 
controls.  Furthermore, the expression patterns observed were similar to those observed in 
chapter 3. This preliminary data indicated that silencing CD44s did not affect transcription of 
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the other CD44 variants or altered their expression following TGF-β1 or IL-1β stimulation. 
Furthermore, this data demonstrated the specificity of the siRNA designed to target CD44s.   
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Figure 4.11 – Silencing CD44s had no Effect on other CD44 Spliced Variants in Fibroblasts or Myofibroblasts 
To assess the effects of silencing CD44s on CD44 spliced variant transcription, fibroblasts were grown to 50-60% confluence. Cells were transfected with either a scrambled control 
siRNA (Scrambled CT) or siRNA targeting CD44s (siRNA CD44 standard). Following growth arrest cells were treated with TGF-β1 (10ng/ml) or serum free medium alone (control 
fibroblasts).  The mRNA expression of CD44v3 [A], v6 [B], v7/8 [C], v8[D] and v10 [E] in fibroblasts (white bars) and TGF-β- treated fibroblasts (black bars), following siRNA to 
CD44s.  Data is representative of one experiment (sample N=3) and data is displayed as ±S.D. 
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Figure 4.12 – Silencing CD44s Had no Effect on Other CD44 Spliced Variants Expression in Control Fibroblasts or IL-1β-Stimulated Fibroblasts 
To assess the effects of CD44s on the ability of CD44 spliced variant transcription, fibroblasts were grown until 50-60% confluence.  Cells were transfected with either a 
scrambled negative control (scrambled CT) or siRNA targeting CD44s (siRNA CD44 standard).  Following growth arrest, cells were treated with IL-1β (1ng/ml) or serum- 
free medium alone (control fibroblasts).  Figures show the mRNA expression of CD44v3 [A], v6 [B], v7/8 [C], v8[D] and v10 [E] by fibroblasts (white bars) and IL-1β-  
induced fibroblasts (black bars), following transfection with siRNA to CD44s samples were analysed using qPCR.  Samples transfected with siRNA to CD44s were compared 
to samples transfected with a negative scrambled control. Data is representative of one experiment with a sample N=3. Data is displayed as ±S.D. 
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4.5. – Discussion 
 
In the previous chapter, the effects of TGF-β1 and IL-1β stimulation on the expression of CD44 
variants were investigated.  This chapter aimed to investigate which of the CD44 variants were 
involved in the TGF-β1-induced, HA/CD44 dependent upregulation of αSMA in 
myofibroblasts and the IL-1β-induced, HA/CD44 dependent monocyte binding. Using a 
process of elimination, the CD44 variants with the highest expression were silenced using a 
panel of custom-designed siRNAs (Figure 4.3.) The results show that the standard form of 
CD44 (CD44s) is essential for the upregulation of αSMA and the maintenance of the 
myofibroblast phenotype. Furthermore, CD44s was also found to be the principal mediator for 
fibroblast-monocyte binding, following IL-1β induction.  
 The important role of CD44 in fibrosis has been demonstrated in previous research 
(Rouschop et al. 2004). Mice deficient in CD44 (Cd44-/-) underwent unilateral ureter 
obstruction (UUO), resulting in a marked decrease in collagen and αSMA expression.  This 
was suggested to be the result of a downregulation of TGF-β1 and a decreased myofibroblast 
presence.  The mechanism of fibroblast to myofibroblast differentiation is well-defined and the 
role of CD44 in this process is also well understood.  TGF-β1 stimulation activates the re-
localisation of CD44 in the cell membrane, resulting in CD44 clusters within cholesterol-rich 
lipid rafts.  In these lipid raft regions, CD44 associates with EGFR and results in downstream 
activation of extracellular signalling receptor kinase 1/2 (ERK1/2) and calmodulin kinase II 
(CaMKII) (Midgley et al. 2013). In turn, HAS2 and αSMA expression is upregulated and both 
are also fundamental to the myofibroblast phenotype. The movement of CD44 is modulated by 
hyaluronan (HA) and is essential for HA-rich, peri-cellular coat formation and for maintenance 
of the myofibroblast phenotype.  
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 The presence of immune cells within the pro-fibrotic environment is central to the 
initiation of fibrotic progression, due to a constant release of cytokines into the immediate 
region. This leads to a continuous influx of fibrotic mediators and an aberrant wound healing 
response. Stimulation of fibroblasts with the pro-inflammatory cytokine, IL-1β, mediates a 
change in the cell membrane, which forms protrusions.  HA mediates the movement of CD44 
into these protrusions, where CD44 co-localises with ICAM-1. This HA/CD44/ICAM-1 
complex activates intracellular signalling ERK1/2 (Meran et al. 2013).  Silencing total CD44 
expression in IL-1β-stimulated fibroblasts decreased their ability to bind monocytes (Meran et 
al. 2013). Unlike TGF-β1 activation, however, HA does not form a peri-cellular coat, instead it 
is arranged in spiked formations on the cell membrane protrusions.  These are the areas shown 
to bind monocytes.  To elucidate which of the CD44 variants mediated the TGF-β1 and IL-1β 
responses, custom siRNAs were designed to target CD44s and variants, v3, v6, v8, v10 and 
v6-10.  
Silencing CD44v3 had no effect on TGF-β1 induced αSMA mRNA expression Figure 
4.4 [C] or IL-1β-induced monocyte binding Figure 4.5[C], suggesting that CD44v3 was not 
involved in activation of αSMA expression or monocyte adhesion.  CD44v3 is well-described 
and identified to contain a heparan sulfate (HS) binding domain, known to favour association 
with heparin binding proteins, such as bone morphogenetic protein (BMP-7) and hepatocyte 
growth factor (HGF). These growth factors are well-documented for their ability to 
counterbalance the effects of pro-fibrotic cytokine, TGF-β1 (Zeisberg et al. 2003; Narmada et 
al. 2013; Midgley et al. 2015). Overexpression of CD44v3 in transgenic mice subjected to 
UUO, propagated an increase in bone morphogenic protein-7 (BMP-7) and a decrease in TGF-
β1 (Rampanelli et al. 2014). Therefore, CD44v3 was suggested to have an anti-fibrotic role. An 
upregulation of CD44v3 in inflammatory diseases, such as ulcerative colitis (Rosenberg et al. 
1995b), along with the identified binding of HS motifs to act as an adhesion ligands in cell-cell 
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associations, suggested that CD44v3 may have a role in fibroblast–monocyte binding.  
However, here it was found that silencing this variant had no effect on IL1-β-induced monocyte 
binding.  One explanation for this is that HS motifs are abundant, diverse and cell specific and 
known to be associated with different cell-cell recognition patterns (Coombe et al. 1994).  
Furthermore, HS is a polyanionic molecule that can be altered depending on cell type, resulting 
in cell-specific function (Parish 2006).  HS is a GAG exhibiting different consensus sequences 
that mediate interactions within the ECM.  Different consensus sequences have been reported 
to alter binding affinity (Hileman et al. 1998).   Therefore, a possible suggestion for CD44v3 
not being involved in monocyte binding may be due to HS modifications that prevent its 
association with HA. 
 Most of the current research has found the CD44v8 encoding exon to be present in 
large/multiple exon isoforms, with multiple exons between common regions, e.g. within the 
epithelial form, CD44v8-10 (Bourguignon and Iida 1994). In the previous chapter, it was 
identified that CD44v8 containing solely v8/exon12 was expressed in fibroblasts, however, it 
was not as highly expressed as some of the other identified variants. Silencing CD44v8 did not 
prevent the expression of αSMA, following TGF-β1 stimulation (Figure4.4 [D]). Although, 
interestingly silencing CD44v8 significantly increased fibroblast-monocyte binding in control 
samples, compared to scrambled controls (Figure 4.6 [D]). A further increase in monocyte 
binding was observed in fibroblasts stimulated with IL-1β, compared to scrambled controls.  
These data suggest that CD44 variants containing v8/exon 12 may have a negative regulatory 
role on monocyte binding.   However, the analysis of the only larger variant identified in this 
study containing v8/exon 12 (CD44v6-10), did not suggest that this variant played a role in 
monocyte to fibroblast binding. Therefore, CD44v8 may have an independent role from the 
larger CD44 isoform, which also contain the v8 segment of the variable domain. Research in 
our laboratory has also identified CD44v7/8 expression in fibroblasts (Midgley et al. 2013). 
132 
 
However, siRNA to v7/8 did not show any effect on monocyte binding in control or IL-1β- 
stimulated fibroblasts, eliminating its involvement and further confirming that CD44v6-10 was 
not involved.  Why silencing CD44v8 increased monocyte binding and not TGF-β1 induced 
αSMA expression is not understood and would need to be further investigated. 
 In this study, transfection of fibroblasts with siRNA to CD44v6 or v10 had no effect on 
the induction of αSMA by TGF-β1 or IL-1β-induced monocyte binding, respectively.  CD44v6 
is one of the most studied CD44 variants, due to its association with c-Met, the receptor for 
HGF.  In some inflammatory diseases CD44v6 has an increased expression (Rosenberg et al. 
1995a).  However, there is limited evidence that it co-localises with either EGFR or ICAM-1.  
In a study by Ghatak et al. (2014), it was found that interstitial lung disease fibroblasts (ILDFbs) 
had a persistently upregulation of CD44v6 and c-Met, which promoted sustained auto-
induction of TGF-β1 and increased collagen I and αSMA expression.  Furthermore, the 
increased expression of TGF-β1 supressed HGF expression by ILDFbs. Interestingly, the 
addition of exogenous HGF suppressed the TGF-β1 fibrotic effects and reversed the fibrotic 
process. Therefore, it could be assumed that silencing CD44v6 would attenuate its interaction 
with c-Met and decreasing the fibrotic role of CD44v6/c-MET and decrease fibrotic 
progression. However, this study demonstrated that silencing v6 had no effect on αSMA 
upregulation, suggesting that the anti-fibrotic effects of CD44v6/c-Met association may be 
dependent on signalling pathways distinct from the TGF-β1-mediated HA/CD44/EGFR 
pathway. An essential role of CD44v6 has previously been defined. CD44v6 was required for 
the activation of the c-Met/HGF complex and cytoskeletal association with ezrin. This suggests 
that in fibroblasts, the CD44v6/c-Met/HGF complex is associated with cytoskeletal re-
organisation instead, of αSMA upregulation or monocyte binding.  
CD44v10 is commonly described as having modifications, such as the addition of N-
/O-linked glycosylation containing unique chondroitin sulphate (CS) motifs.  Moreover, this 
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variant has a specific binding sequence, B[X7]B, which modulates interactions with other 
chondroitin sulfate and serine-glycine motifs (Hayes et al. 2002). This motif also allows for the 
association with other CD44 receptors and mediation of cell-cell adhesion properties. However, 
the overexpression of v10 in breast cancer cells decreased CD44 cluster formation and it is 
speculated that the increased presence of CS reduced the CD44/HA binding affinity, due to 
lack of cluster formation, leading to limited cellular adhesion and contributing towards cancer 
metastasis (Iida and Bourguignon 1997; Bourguignon et al. 1998). This was confirmed in a 
more recent study by Ruffell et al. (2011), which demonstrated that the presence of CS motifs 
correlated inversely with CD44/HA binding by mouse bone marrow macrophages. This was 
demonstrated by the addition of various inflammatory mediators that altered CS expression.  
For example, tumour necrosis factor-α (TNFα) limited the presence of CS motifs and increased 
CD44/HA binding affinity. Conversely, interleukin-4 (IL-4) stimulation increased CS motifs 
and decreased CD44/HA affinity. Previously, it was demonstrated that CD44 was re-localised 
in the membrane and formed clusters when stimulated with TGF-β1 or IL-1β in a HA-
dependent manner; suggesting that the HA/CD44 binding affinity was increased (Meran et al. 
2013). That different stimuli modulate the HA/CD44v10 binding affinity by the addition of CS 
motifs may have suggested that these stimuli both limit the HA binding affinity, by reduced 
presence of posttranslational CS motifs. However, the results in this study demonstrated that 
using a siRNA targeting CD44v10 did not affect fibroblast αSMA expression or monocyte 
binding. 
The involvement of the larger variant CD44v6-10 in differentiation or monocyte 
binding was assessed previously, using individual siRNAs targeting CD44v6, v8 and v10.  The 
effects of silencing these variants had no effect on αSMA expression or monocyte binding.  A 
siRNA targeting CD44v7/8 confirmed these data, leading to the conclusion that the larger 
CD44v6-10 isoform had no role in these two activation pathways.  That CD44v7/8 was not 
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involved in these pathways is in line with previous research in our laboratory, which has shown 
that CD44v7/8 had an anti-fibrotic role when induced by BMP-7; and was able to reverse 
fibrotic progression that resulted from TGF-β1 through the internalization of HA (Midgley et 
al. 2015).  
Silencing CD44s significantly decreased the expression of αSMA mRNA and the 
formation of αSMA stress fibres.  It is not understood why this standard form of CD44 controls 
αSMA expression.  However, it had previously been determined in chapter 3, that CD44s had 
the highest expression of all CD44 variants in fibroblasts, suggesting it may be responsible for 
multiple gene regulations. For example, it was previously demonstrated that CD44s was 
responsible for the upregulation of matrix metalloproteinase-9 (MMP-9), resulting from 
intracellular proteolytic cleavage of the cytoplasmic tail by the enzyme presinillin (γ-secretase); 
and nuclear translocation of the signal peptide (PDZ) (Miletti-González et al. 2012).  This 
cleavage of intramembranous CD44 results in a CD44 intracellular domain (ICD) fragment, 
that translocate to the nucleus and activates MMP-9 expression. It has previously been reported 
that CD44 acts as a docking site for MMP-9 and MMP-2, both known to activate pro-TGF-β1 
into its active form (Yu and Stamenkovic 2000).  Furthermore, past research demonstrated that 
autocrine induction of TGF-β1 was important for maintaining the myofibroblast phenotype. It 
was shown that preventing the expression of SMAD2/3 (the downstream signalling pathway 
of TGF-β1), reduced TGF-β1-induced αSMA expression in myofibroblasts (Webber et al. 
2009a).  Therefore, decreasing CD44s in this study may have decreased the ICD formation 
leading to decreased MMP-9 expression and limited activation of TGF-β1; leading to reduced 
αSMA induction. 
 Furthermore, maintenance of the myofibroblast phenotype is dependent on the 
formation of the HA peri-cellular coat that is anchored into position by CD44. This HA/CD44 
association mediates the movement of CD44 through the membrane into lipid raft regions, 
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where it associates with co-receptor, EGFR.  Eliminating the variant involved in this process 
would prevent downstream intracellular signalling of ERK1/2 and activation of αSMA gene 
expression. CD44s has previously been identified to be the CD44 variant with the highest 
binding affinity to HA, making it an ideal candidate for this mechanism (Bartolazzi et al. 1994). 
The CD44 association with cytoskeletal proteins mediates multiple cellular functions, 
including directional cell migration and stress fibre formation (Hall 1998; Legg et al. 2002).  
(Figure 4.9[D]) shows a lack of αSMA stress fibre formation in TGF-β1-induced, 
myofibroblasts that were transfected with siRNA targeting CD44s. The decreased expression 
of CD44s prevented the incorporation and formation of αSMA into stress fibres.  Moreover, 
cells transfected with siRNA targeting CD44s retained the spindle morphology typical of the 
fibroblast, suggesting differentiation was inhibited.  This lack of morphological change may 
suggest that silencing CD44s reduced cytoskeletal/CD44 association required for 
differentiation.     
 IL-1β stimulation of keratinocytes upregulated CD44 expression and increased de-
phosphorylation of a Ser-325 residue in the cytoplasmic tail region. This Ser-325 residue was 
identified to be directly dephosphorylated by CaMK-II in fibroblasts.  The subsequent de-
phosphorylation of this region is upstream of the phosphorylation of Ser-291, which increases 
CD44/Ezrin association and mediates CD44 cluster formation. Furthermore, inhibition of 
caMK-II increased CD44 cluster formation (Jokela et al. 2015).  Our research has demonstrated 
that IL-1β stimulation increased monocyte binding, by activating the formation of a spiculated 
HA coat.  This was dependent on CD44 forming clusters that increased HA binding affinity 
(Meran et al. 2013).  The HA coat important for monocyte binding differs to the HA peri-
cellular coat formed around myofibroblasts following TGF-β1 stimulation. For example, the 
hyaldherin, tumour necrosis factor stimulating gene-6 (TSG6), is not required for the formation 
of IL-1β-induced HA protrusions, but is essential for forming and maintaining the 
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myofibroblast peri-cellular coat (Meran et al. 2013).  Therefore, the formation of the monocyte- 
specific, HA coat commonly induced under inflammatory conditions, seems to be HA/CD44- 
driven by a different mechanism.  This study determined that decreased CD44s expression 
prevented fibroblast–monocyte binding (Figure 4.10 [B]).  These data indicate the importance 
of CD44s in this process, suggesting that CD44s modulates the formation of the specific HA 
coat essential for monocyte binding by forming clusters, that increase HA binding affinity.  
Furthermore, it is known that CD44/ICAM association is essential for monocyte binding. A 
possible suggested mechanism for the involvement of CD44s in this process is that the binding 
of CD44s with HA activates downstream de-phosphorylation of the Ser-325 residue on the 
cytoplasmic region, by CaMK-II.  In turn, the de-phosphorylation activates CD44/ezrin 
association which mediates cytoskeletal re-arrangement and CD44s reorganisation, resulting 
in CD44s forming clusters and ICAM-1 association.  However, to confirm this, further research 
would be required. 
 Finally, transfection with siRNA targeting CD44s did not affect the expression of other 
CD44 variants investigated.  These preliminary data suggest that CD44s was not mediating the 
expression of other CD44 variants by ICD translocation to the nucleus; and that the siRNA 
targeting CD44s did not target other CD44 variants. Therefore, this preliminary data suggested 
that of the variants identified only CD44s is involved in modulating αSMA expression and 
monocyte binding. 
 In summary, this chapter shows that silencing the mRNA expression of CD44s prevents 
TGF-β1 induced αSMA expression and IL-1β-induced monocyte binding. None of the other 
variants had a role in this process, with the possible exception of v8.  This CD44 variant was 
observed to have an opposite role to CD44s and decreased CD44v8 expression was associated 
with increased monocyte binding, suggesting a regulatory for this variant in monocyte binding.  
Determining the exact mechanisms involved, however, would require further research.  
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Chapter 5-The Role of CD147 in Fibroblast Differentiation 
and Monocyte Binding 
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5.1- Introduction 
 
5.1.1. - CD147 Discovery and Overview 
 
CD147 is a type-1 transmembrane glycoprotein and a member of the immunoglobulin 
superfamily. Also known as extracellular matrix metalloproteinase inducer (EMMPRIN) or 
Basigin (Bsg), CD147 was originally discovered in the plasma membrane of  human LX-1 lung 
carcinoma cells (Biswas 1982).  It was further identified in multiple species and was designated 
several names, including, mouse gp42 (Altruda et al. 1989), neurothelin (Schlosshauer and 
Herzog 1990), rat OX-47 (Fossum et al. 1991); and chicken HT7 (Seulberger et al. 1990). It 
was later discovered that these proteins were all the same glycoprotein with different names in 
various species (Seulberger et al. 1992).  CD147 was firstly identified as either an antigen or 
its carrier, however, further research discovered that CD147 had a functional role.  It was 
observed that a membrane-bound protein mediated increased collagenase production by 
fibroblasts that were co-cultured with the human LX-1 carcinoma cell line and was originally 
named, tumour cell derived collagenase stimulatory factor (TCSF) (Biswas 1984; Biswas and 
Nugent 1987).  Later research discovered that TCSF expression on tumour cells increased 
fibroblast expression of other MMPs, including gelatinase (MMP-2) and stromolysin-1 (MMP-
3) (Kataoka et al. 1993).  It was renamed  EMMPRIN. Later studies discovered that EMMPRIN 
and Bsg had identical cDNA sequences and were identical proteins (Biswas et al. 1995).  
 The majority of CD147 research is focused on its upregulation in tumour cells and the 
implications in tumour development (Gabison et al. 2005; Zheng et al. 2006).  However, 
CD147 has a role in several other pathological diseases, including rheumatoid arthritis.  In this 
inflammatory disease, CD147 is upregulated on the cell surface of monocytes/macrophages 
and induces resident fibroblasts to produce MMPs (Zhu et al. 2005).  The upregulation of 
CD147 is also associated with pathogenic infections, including human immunodeficiency virus 
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(HIV) (Pushkarsky et al. 2001) and hepatitis B (Tian et al. 2010). Involvement of CD147 in 
disease is commonly associated with its interaction with multiple surface receptors and ligands. 
These include integrins, cyclophilins, caveolin-1 and monocarboxylate transporters (MCTs) 
(reviewed by Xiong et al. 2014).  Independent from MMP production, CD147 is 
multifunctional and has functional roles in cell metabolism (Kirk et al. 2000), spermatogenesis 
(Chen et al. 2011), lymphocyte activation (Chiampanichayakul et al. 2006); and cell-cell 
contact (Fadool and Linser 1993).  
5.1.2. - CD147 Gene and Protein Structure 
 
CD147 is a member of the immunoglobulin superfamily (IgSF), composed of a large group of 
proteins involved in cell recognition, association and adhesion, which are all dependent on a 
putative immunoglobulin domain (Williams and Barclay 1988).  It is encoded by 1797 base 
pairs on the CD147 gene at chromosome position 19P13.3 (Kaname et al. 1993).  The 5’ 
promotor region contains a 30bp site from -142bp to -112bp  that codes for a binding site for 
specific protein 1 (Sp1), AP1TFII and early growth response 2 (EGR-2); all important nuclear 
factors involved in CD147 transcription (Liang et al. 2002).   The CD147 gene encodes for a 
185 amino acid extracellular region, a 24 amino acid highly-conserved, transmembrane region; 
and a 39 amino acid cytoplasmic domain (Fossum et al. 1991; Biswas et al. 1995). The 
extracellular region is composed of two Ig domains (Figure 5.1); and it is these domains that 
have similar characteristics to other members of the immunoglobulin superfamily.  The 
transmembrane region contains mainly hydrophobic residues, with the exception of one 
charged glutamic acid residue, thought to increase protein-protein affinity. The translated 
CD147 protein is 28kDa, however, the molecular range of the protein is between 32-66kDa, 
due to post-translational glycosylation.  There are four alternative spliced variants of 
CD147/Bsg identified, they are CD147/Bsg 1, 2, 3 and 4. The most recently discovered, 
CD147/Bsg-1 is retina specific and has an additional unglycosylated Ig domain, thought to be 
140 
 
associated with homophilic binding (Hanna et al. 2003). CD147/Bsg-3 and 4 have a single Ig 
domain.  CD147/Bsg- 2 contains two Ig domains (Figure 5.1.).  CD147/Bsg-2 is the most 
characterised form of CD147, due to its ubiquitous expression and regulation of MMPs 
(Nabeshima et al. 2006; Belton et al. 2008).  As CD147/Bsg-2 is the most studied CD147 
variant, it will be the focus of this introduction.  Here on, it will be referred to as CD147 in 
humans and BSG in murine, unless stated otherwise.  
5.1.3. - CD147 Glycosylation 
 
The crystal structure of CD147 revealed three different asparagine (Asn) sites for glycosylation 
within the proximal Ig domain: Asn 44 within the distal Ig domain, Asn 152 and Asn 186 (see 
Figure 5.1) (Yu et al. 2008).  Most glycosylation studies on CD147 demonstrate that CD147 
is mainly an N-linked glycosylated glycoprotein, which varies between species and cell type. 
The three glycosylation domains give rise to multiple glycosylated forms of CD147 that are 
categorised into two groups. A lower glycosylated CD147 (LG-CD147) form, that has a 
molecular weight of ~32kDa; and multiple higher glycosylated CD147 (HG-CD147) that have 
a molecular mass range between ~40-66kDa (Tang et al. 2004).  It is suggested that a high 
mannose form of LG-CD147 glycosylated in the endoplasmic reticulum (ER), is a precursor to 
HG-CD147, which is modified in the Golgi apparatus  (Bai et al. 2014).  Once modified, HG-
CD147 is translocated to the membrane.   
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5.1.4.-CD147-Protein Interactions 
 
CD147 also associates with integrins α3β1 and α6β1; and mediates their reorganisation and 
distribution around points of cellular contact (Berditchevski et al. 1997). These integrins bind 
to laminin, which is a major components of the basement membrane and CD147 regulates 
integrin/laminin associations which are fundamental to processes such as foetal development, 
cell adhesion and angiogenesis (reviewed by Iacono et al. 2007).  The association of CD147 
with integrin α6β1 has been demonstrated to upregulate hepatoma cellular invasion and 
metastasis, by increased MMP production and activation of intracellular signalling 
phosphatidylinositol 3-kinase (Pl3K), a known integrin-induced pathway (Guinebault et al. 
1995; Dai et al. 2009).  Similarly, CD147 association with integrin α3β1 was linked to 
invadapodia and metastasis in hepatoma cells and the deletion of either CD147 or inhibition of 
α3β1, decreased focal adhesions, MMP expression and altered cytoskeletal arrangement.  
Extracellular Ig 
Domains 
Transmembrane 
Region 
Cytoplasmic Tail 
Glycosylation 
Regions 
Asn 44  
Asn 152  
Asn 186  
Figure 5.1 – CD147 Structure and Glycosylation 
Schematic demonstrates the extracellular Ig arrangement of CD147 variant 2.  The isoform contains two Ig domains with 
glycosylation sites at amino acid positions, Asn 44 in the distal domain and Asn152 and 186 within the proximal domain. 
Diagram is modified from review article (Xiong et al. 2014)  
142 
 
Overexpressing CD147 did not increase the overall expression of α3β1, but did increase its 
activity and its association with the adhesion-associated proteins, focal adhesion kinase (FAK) 
and paxillin (a protein that associates with FAK); and increased cellular metastatic potential 
(Tang et al. 2008b).      
Caveolin exists as three isoforms Cav-1, -2 and -3. Cav-1 and Cav-2 are expressed in 
multiple cell types, whereas Cav-3 is the only isoform expressed in skeletal muscle tissue, 
cardiac myocytes and smooth muscle cells (Song et al. 1996; Okamoto et al. 1998). Caveolin-
1 is also a major component of caveolae rafts. These are dynamic invaginated domains in the 
plasma membrane that often also contain multiple proteins and lipids (Parton and Simons 
2007).   Caveolins have multiple functions, including organising signalling receptors, 
cholesterol homeostasis, tumour suppression and endocytosis (reviewed by Okamoto et al. 
1998; Williams and Lisanti 2004).   Only Cav-1 has been documented to associate with CD147, 
but the research has been controversial.  For example, Cav-1 negatively regulated CD147 and 
preventing CD147/Cav-1 association, promoted CD147 self-clustering and increased MMP 
induction. Further, only the lower glycosylated form of CD147 was identified to associate with 
Cav-1 in multiple carcinoma cell lines; and it was suggested that regulation starts in the Golgi 
apparatus and that the CD147-Cav 1 association prevents further glycosylation and formation 
of the HG-CD147 (Tang et al. 2004). Conversely, in a hepatocarcinoma cell line, it was 
identified that increased Cav-1 upregulated the expression of HG-CD147 and MMP-11; and 
that these increases upregulated tumour invasion (Jia et al. 2006).  This conflicting research 
into Cav-1 and its interaction with CD147 suggests that the association with different 
glycosylated forms of CD147 molecular weights may be cell-type specific.  
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5.1.5. - CD147 in Disease 
 
CD147/EMMPRIN is an MMP inducer, commonly documented to be associated with cancer 
progression.  The upregulated MMP production mediated by CD147 degrade the surrounding 
ECM, to allow for cellular movement and cancer progression (Donadio et al. 2008).  Much of 
the current research investigating the involvement of CD147 in cancer progression focuses on 
tumour cell expression of CD147, induction of stroma fibroblasts to express and activate 
MMPs (Kanekura et al. 2002; Gabison et al. 2005).  In specific cancer types, CD147 induction 
of MMPs correlates with the intracellular signalling of protein kinases.  For example, the 
induction of MMP-1 (collagenase) secreted by fibroblasts through the phosphorylation of 
tyrosine kinase p-38 was associated with high levels of CD147 expressed on lung tumour cells 
(Lim et al. 1998).  More recently, the upregulation of CD147 expression was linked to an 
increased mitogen-activated protein kinase (MAPK) signalling, including extracellular 
signalling kinase (ERK), p38 and c-Jun N terminal kinase (JNK), in metastatic ovarian cancer.  
The observed increase of CD147 and MAPK signalling was determined to increase MMP-2 
(Davidson et al. 2003).  
 Although well-researched in tumourgenesis, CD147 has also been associated with 
several other diseases.  For example, Alzhemier’s disease is a neurodegenerative disease, 
resulting from the formation of amyloid plagues and neurofibrillary tangles, within cortical 
regions of the brain. These proteins damage nerve cells and prevent cell-cell contact at synapses 
regions (Cummings and Cotman 1995). The multi-protein, γ-secretase complex, consisting of 
presenilin 1, nicastrin, anterior pharynx defective 1 (APH-1) and presenilin enhancer 2 (PEN-
2), exists within cell membrane regions and cleaves membrane bound, β-amyloid precursor 
protein (APP). The cleavage of APP firstly by β-secretase, followed by γ-secretase, forms Aβ-
peptides. These are sticky proteins units that form amyloid plaques between neurons. CD147 
has been demonstrated to co-immunoprecipitate with γ-secretase and silencing CD147 
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increased the expression of Aβ-peptides, suggesting that CD147  has a regulatory role in the 
disease (Zhou et al. 2005).  Furthermore, CD147 has been widely associated with inflammatory 
disease through its interaction with cyclophilin A (CypA), a ubiquitously expressed member 
of the intracellular peptidyl-prolyl cis-trans isomerase family.  The principle function of these 
enzymes is to convert the cis and trans forms of proline by facilitating protein folding.  
However, these enzymes are also secreted extracellularly in response to inflammatory stimuli 
and act in a chemotactic manner, attracting leukocytes to the region.  Moreover, CD147 is a 
known receptor for CypA and is expressed highly expressed on the membrane of leukocytes 
under inflammatory conditions  (Yurchenko et al. 2002).    In rheumatoid arthritis (RA), it has 
been identified that the chemotactic function of CypA and its interaction with CD147, has an 
essential role in collagen-induced RA in mice.  Blocking CD147 expression with an anti-
CD147 monoclonal antibody prevented leukocytes, such as neutrophils and T-cells, migrating 
in response to CypA and inhibited the inflammatory response (Damsker et al. 2009). Therefore, 
CD147 also has a role in inflammatory responses.  
5.1.6 – CD147 in Wound Healing and Fibrosis 
 
The overexpression of CD147 in corneal fibroblasts upregulates αSMA expression and the 
subsequent contractile potential of these fibroblasts.  Furthermore, silencing CD147 in these 
cells reduced αSMA presence and the contractile phenotype, following TGF-β1 induction (Huet 
et al. 2008b). Similarly, the involvement of CD147 in fibrotic progression was demonstrated 
in CD147/Bsg deficient mice, Bsg-/-, that were subjected to a unilateral ureteral obstruction 
(UUO).  Extracted tissue showed that Bsg-/- mice had a decreased collagen and hyaluronan 
deposition, αSMA expression and MMP production.  Furthermore, they had a lower 
macrophage infiltration, compared to Bsg+/+mice, suggesting a role for CD147 in regulating an 
immune response (Kato et al. 2011).   
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It has been well-documented that CD147 has an increased expression on immune cells 
in inflammatory diseases, including antigen-presenting cells and T cells (Woodhead et al. 
2000); and an increased immune response is associated with fibrotic progression.  However, 
the regulation of CD147 by IL-1β is not understood.    The upregulation of IL-1β in periodontal 
ligaments has been demonstrated to increase mRNA expression of MMP-1 and -2, which, 
contributed to the inflammation and eventual detachment of periodontal ligaments.  However, 
the increased MMP expression did not correlate with an increase in CD147 expression, leading 
to the assumption that CD147 had no role in the IL-1β induction of MMPs in periodontal 
disease (Xiang et al. 2009).  Although it is understood that IL-1β stimulation facilitates 
fibroblast–monocyte binding, the role of CD147 is unknown. Both CD147 and IL-1β have 
previously been observed to become upregulated in inflammatory diseases (Kolb et al. 2001; 
Yang et al. 2008). However, only IL-1β has been implicated in increased monocyte binding by 
fibroblasts in fibrotic disease (Yang et al. 2008; Meran et al. 2013).  Therefore, a further aim 
of this study is to investigate the effect of IL-1β stimulation on CD147 expression in fibroblasts 
and determine if the pro-inflammatory cytokine, IL-1β; and CD147 have synergistic roles in 
the IL-1β/HA/CD44/ICAM-1-dependent monocyte binding by fibroblasts. 
 
5.2. – Chapter Aims 
 
 Determine the expression of CD147 in fibroblasts, TGF-β1-induced myofibroblasts and 
IL-1β-fibroblasts. 
 Analyse the role of TGF-β1 induction on CD147 and determine if CD147 has a role in 
HA/CD44/EGFR fibroblast to myofibroblast differentiation. 
 Investigate the role of IL-1β on CD147 induction and determine if CD147 has a role in 
HA/CD44/ICAM-1-mediated, monocyte binding. 
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5.3. – Methods 
 
5.3.1. – Effective Knockdown of CD147 at the mRNA and Protein Level. 
 
To investigate the importance of CD147 in fibroblasts to myofibroblast differentiation and in 
monocyte binding, a siRNA targeting was used. In order to identify the sufficient knockdown 
of CD147 mRNA and protein expression for the use in future experiments, a timecouse of 24-
144 h was used.  
Preliminary assessment demonstrated that as early as 24 h following transfection with 
the siRNA targeting CD147, fibroblasts had a decreased CD147 mRNA expression by 
approximately 50%, compared to fibroblasts transfected with the scrambled control (Figure 
5.2. [A]). The decreased CD147 mRNA expression was maintained at all subsequent time- 
points.  It had previously been identified and clarified again in this study that myofibroblasts 
are terminally differentiated following 72 h of TGF-β1 stimulation (Figure 4.1[A&B]).  
Similarly, IL-1β significantly increased monocyte binding following 72 h of stimulation 
(Figure 4.2. [B]).  Therefore, combining this earlier data with the data gathered here, which 
demonstrated the maintained knockdown of CD147 mRNA expression by the siRNA, it was 
decided that all experiments investigating CD147 function at the mRNA level would be carried 
out 72 h following transfection. 
  Figure 5.2 [B] shows the protein expression of CD147 over a time course of 144 h.  
Samples were transfected with either a siRNA targeting CD147 or a scrambled control. Total 
protein expression for CD147 was completely inhibited following 144 h transfection with the 
siRNA to CD147.  Therefore, all experiments which investigated the role of CD147 protein in 
fibroblast differentiation and monocyte binding were carried out 144 h following transfection 
with the siRNA targeting CD147, as shown in Figure 5.2. [C]. 
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Figure 5.2. – Time Course to Determine Knockdown of CD147 at mRNA and Protein Level Using siRNA 
to CD147 
In order to determine sufficient knockdown of CD147 at the mRNA and protein level, a siRNA to CD147 was used and its 
effects analysed over a time course of 144 h (figure [A]). Fibroblasts were grown to 50-60% confluence and growth- arrested 
for 24 h, prior to transfection.  Fibroblasts were transfected with a siRNA targeting CD147 (black bars) or a scrambled 
control siRNA (white bars).  Fibroblasts were incubated for 6 h in the transfection medium.  DMEM/F12 containing 20% 
v/v foetal calf serum (FCS) was added to samples, which were further incubated for 24 h. The medium was removed fresh 
serum-free DMEM/F12 was added.   The time course was initiated at this point.  Following 24h incubation and for every 
consecutive 24 h period, samples were extracted and analysed using qPCR .Data represents ± S.D. of a single experiment 
sample n=3.  Figure [B] shows the effective knockdown of CD147 protein expression. Fibroblasts were transfected with a 
siRNA targeting CD147 (Si) or a scrambled control (Sc), as described above.  Figure [C] shows the effective knockdown 
of CD147 following 144 h of transfection with an siRNA that targeted CD147. 
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5.3.2. Assessment of Experimental Conditions 
 
Due to the extended time required for the CD147 protein expression to be silenced, an analysis 
of the experimental conditions was required.  This was carried out to validate that cells were 
still metabolically active and viable. The florescent intensity of the cellular medium treated 
with AlamarBlue was used to analyse cellular metabolism.  The experiment was carried out 
using a negative untransfected control, a scrambled siRNA control and a siRNA targeting 
CD147. To analyse all experimental conditions cells, were stimulated with TGF-β1 or IL-1β in 
two separate assays (Figure 5.3. [A&B]). The AlamarBlue assay was carried out 144 h 
following transfection, as this was the time point that CD147 protein levels were previously 
observed to be totally silenced (Figure 5.1. [B]).   Cells were stimulated with either TGF-β1 or 
IL-1β stimulation 72 h after the experimental start time, they were then extracted at 144 h. 
Therefore, this enabled total protein to be knocked down and a stimulation time of 72 h, which 
had been previously identified to be the time-point of interest. Unstimulated fibroblasts 
transfected with siRNA to CD147 had a similar florescent intensity to untransfected fibroblasts 
and fibroblasts transfected with siRNA to CD147.   Silencing the protein expression of CD147 
had no effect on cell viability, when stimulated with TGF-β1 or IL-1β; and florescent intensity 
was consistent with those observed under the control conditions.  These data suggest that the 
experimental conditions did not have an effect on cellular viability. 
 
 
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] 
[B] 
Figure 5.3. – Assessment of Experimental Conditions 
Analyse of experimental conditions was carried out using an AlamarBlue assay.  Fibroblasts were grown until 
50-60% confluence, before being growth-arrested for 24 h.  Fibroblasts were treated with transfection 
medium alone (untransfected cells), a scrambled control siRNA an siRNA targeting CD147. Following a 6 h 
incubation period, fibroblasts were treated with fresh DMEM/F12 containing 20% v/v FCS and incubated for 
a further 24 h.  Fresh serum-free medium was added and cells were incubated for 72 h.  Samples were them 
treated with fresh serum-free medium containing TGF-β1 (10ng/ml) [A] or IL-1β (1ng/ml) [B]. Unstimulated 
samples were treated with fresh serum-free DMEM/F12 alone. An AlamarBlue assay was carried out 
according to the manufactures protocol. Data shows the fluorescence units displayed by fibroblasts treated 
with medium alone (untransfected) and fibroblasts transfected with a scrambled siRNA or a siRNA targeting 
CD147.  Samples stimulated with either TGF-β1 or IL-1β (black bars),were compared to control samples (white 
bars),under all three conditions.  Data represents 3 separate samples ± S.D. 
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5.4. – Results 
 
5.4.1. – CD147 mRNA Expression in Fibroblasts and Myofibroblasts 
 
Primarily, the mRNA expression of CD147 in quiescent fibroblasts and fibroblast-stimulated 
with either TGF-β1 (Figure 5.4. [A]) or IL-1β (Figure 5.4. [B]) was investigated. The 
expression of CD147 in quiescent fibroblasts was relatively high.  Stimulation with TGF-β1 
did not significantly alter the overall expression of CD147 by myofibroblasts.  The effects of 
IL-1β on CD147 were assessed over a time course of 0-72 h.  IL-1β-stimulated fibroblasts had 
a significant increase of CD147 expression at 72 h, compared to fibroblasts treated with serum- 
free medium alone (control fibroblasts). There was no difference in expression of CD147 at 
any of the earlier time-points, compared to control fibroblasts.  
 
Figure 5.4. - CD147 mRNA Expression in Quiescent Fibroblasts, TGF-β1-Induced Myofibroblasts and 
IL-1β-Stimulated Fibroblasts. 
Figure demonstrates CD147 mRNA expression by TGF-β1-induced myofibroblasts [A] and IL-1β-stimulated fibroblasts 
[B].  Briefly, fibroblasts were grown to 80%.  Following growth arrest, fibroblasts were treated with fresh serum-free 
DMEM/F12 containing TGF-β1 (10ng/ml) [A] or IL-1β (1ng/ml) [B], for 72 h. Control samples were treated with serum 
free DMEM alone. Analysis was carried out using qPCR. The expression of CD147 either TGF-β1-  or  IL-1β-stimulated 
fibroblasts (black bars), were compared to control unstimulated fibroblasts (white bars). Data is displayed as ±SEM 
from 3 separate experiments. Statistical analysis was carried out using one way ANOVA, followed by the unpaired 
student’s t test *P>0.05, N/S (not significant).  
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5.4.2. - Co-localisation of CD147 With CD44 
 
Central to TGF-β1-induced differentiation and IL-1β-induced monocyte binding 
pathways, is HA association with the receptor, CD44 (Webber et al. 2009b; Meran et al. 2013; 
Midgley et al. 2013).  An initial assessment investigated the association of CD147 with CD44 
and the effects of TGF-β1 and IL-1β stimulation were analysed.  Immunoprecipitation (IP) of 
CD147 was used to extract CD147 and a SDS-PAGE Western blot analysis was carried out to 
identify CD44 association.  CD147 was identified to co-localise with CD44 in control 
fibroblasts (Figure 5.5. [A&B]).  TGF-β1 stimulation increased co-localisation of 
CD147/CD44 in terminally differentiated myofibroblasts (Figure 5.5. [A]).  However, there 
was no increased observed in the CD147/CD44 association in fibroblasts stimulated with IL-
1β, compared to unstimulated fibroblasts (Figure 5.5. [B]).  The Western blot analysis was 
carried out using a pan-CD44 antibody that targets all CD44 variants.  The detection of a single 
CD44 band was identified to co-precipitate with CD147 in quiescent, TGF-β1-and IL-1β- 
stimulated fibroblasts. The band was observed at approximately 85-90kDa, the molecular mass 
range expected for the standard form of CD44 (CD44s).  Therefore, these data suggest that the 
CD44 variant observed to co-localise with CD147 in this study is CD44s and that this co-
localisation increases in TGF-β1 induced, myofibroblasts. 
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Figure 5.5. - Co-localisation of CD147/CD44 and the effects of TGF-β
1
- and IL-1β-Stimulated 
Fibroblasts. 
Images show CD147 co-localisation with CD44 in fibroblasts Figure [A&B], (Lane 1), TGF-β
1
 induced, 
myofibroblasts [A] (Lane 2) and IL-1β-stimulated fibroblasts [B] (Lane 2). Briefly, cells were grown to 
80% confluence.  Following growth arrest samples were treated with serum-free DMEM/F12, containing 
either TGF-β
1
 (10ng/ml) or IL-1β (1ng/ml).  Control fibroblasts were treated with fresh serum-free medium 
alone. Total cell lysate was extracted and analysis was carried out using immunoprecipitation of CD147, 
followed by Western blot analysis for CD44 and CD147. Figures [C&D] demonstrate the densitometry analysis 
of co-localisation following TGF-β1 [C] and IL-1β [D].  Data represents a single experiment using two samples ± S.D. 
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5.4.3. –CD147 Involvement in IL-1β Mediated Monocyte Binding 
 
CD147 was significantly upregulated in IL-1β-induced, fibroblasts (Figure 5.4. [B]), 
suggesting that CD147 may have a role in fibroblast-monocyte binding.  However, it is well- 
established that the HA/CD44 is central to monocyte binding and IL-1β stimulation did not 
increase co-localisation of CD147 with CD44 in fibroblasts (Figure5.5. [B]).  However, 
monocyte binding is not solely HA/CD44-dependent, it also involves the increased co-
localisation of CD44 with ICAM-1, a cell adhesion molecule previously shown to be important 
for leukocyte binding and signalling (Walpola et al. 1995). Therefore, it may be assumed that 
ICAM-1 associates with CD147; and not CD44.  To investigate this possibility, two separate 
co-IP experiments were carried out for CD147 and ICAM-1.   The co-IP for ICAM-1 and 
Western blot analysis of CD147 determined that ICAM-1 did associate with CD147 (Figure 
5.6. [A]).  This was confirmed by the reciprocal experiment, where a co-IP was carried out for 
CD147, followed by a Western blot analysis for ICAM-1 (Figure 5.6. [B]). There was no 
difference observed in the CD147/ICAM-1 co-localisation by IL-1β-stimulated fibroblasts, 
compared to unstimulated fibroblasts. Therefore, although CD147 mRNA expression increased 
in IL-1β stimulated fibroblasts (Figure 5.4. [B]), the lack of increased CD147/CD44 or  
CD147/ICAM-1 association, suggests it is unlikely to have a role in monocyte binding. A final 
experiment which knocked down CD147 expression was carried out, to determine if CD147 
had a functional role in monocyte binding, which may be mediated through a different 
mechanism.  Knockdown was achieved using a siRNA targeting CD147 (Figure 5.6. [C]) and 
monocyte binding was assessed using CD45 (Figure 5.6. [D]). Silencing CD147 did not have 
any effect on IL-1β induction of fibroblast-monocyte binding.  Therefore, combining all the 
data from (Figure 5.3.), it has been concluded that CD147 does not seem to have a role in IL-
1β-induced monocyte binding, through the pre-determined HA/CD44/ICAM-1 pathway or any 
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other mechanism.  Therefore, the effects of CD147 on monocyte binding has not been further 
analysed in this study. 
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Figure 5.6. – CD147 has no Role in IL-1β/HA/CD44/ICAM-1 Fibroblast -Monocyte Binding 
Fibroblasts were grown to approximately 80% confluence and growth-arrested, before being treated with fresh 
serum-free DMEM/F12, containing IL-1β (1ng/ml) or serum-free DMEM/F12 alone for 72 h. The protein was 
extracted and co-localisation was assess using immunoprecipitation and Western blot analysis.     Figure [A] shows 
the IP of ICAM-1 followed by a Western blot analysis for CD147.  Figure [B] is the reciprocal experiment, with 
an IP carried out for CD147 and a Western blot analysis for ICAM-1. Figure[C] shows the decreased expression 
of CD147 in fibroblasts following transfection with a siRNA to CD147.  A scrambled siRNA was used as a control.  
Following transfection, fibroblasts were growth-arrested and treated with fresh medium alone (control samples) 
(White bars) or medium containing IL-1β (1ng/ml) (black bars) for 72 h. Fresh DMEM/F12 containing 1x106/ml 
of U937/monocytes was added and incubated for 4 h.  Cultures were carefully washed before analysis. CD147 
knockdown was confirmed Figure 5.5[C], before assessment of monocyte binding by qPCR Figure 5.5[D]. Data 
represents a single experiment 3 separate samples ±S.D.  
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5.4.4. – Further Evidence for CD147/CD44 Co-localisation in Myofibroblasts. 
 Previously, it was determined that there was an increased CD147/CD44 co-localisation in 
myofibroblast compared to fibroblasts (Figure 5.5).  Recent research by Grass et al. (2013) 
implicated CD147 in breast cancer invasion, by promoting EGFR downstream activation of 
ERK1/2 signalling; a process dependent on HA/CD44 association. It was determined that 
CD147 formed a complex with CD44 and EGFR in lipid raft regions. This is similar to previous 
research in our laboratory that showed the importance of the CD44/EGFR association in lipid 
rafts and subsequent downstream activation of ERK1/2, for complete fibroblast to 
myofibroblast differentiation (Midgley et al. 2013).  
The co-localisation of CD147/CD44 previously observed was confirmed using 
immunocytochemistry (ICC).  Figure 5.7 shows the ICC analysis used to investigate the 
association of CD147 (green stain) with CD44 (red stain).  Both CD147 and CD44 were 
abundantly expressed throughout the cell membrane in fibroblasts [A-B] and myofibroblasts 
[C-D].  Merger of the two images showed two distinct populations in fibroblasts. The first 
showed CD147/CD44 merging (Figure 5.7. [C-D]; yellow regions). The second had CD147 
(green regions) alone diffusely spread throughout the membrane (Figure 5.7. [C-D]; white 
arrow).  Conversely, myofibroblasts had complete CD147/CD44 co-localisation (Figure 5.7. 
[G-H]); and separate populations were no longer observed. These data confirm co-IP results 
previous obtained (Figure 5.4. [A]); and demonstrate an increased CD147/CD44 co-
localisation in myofibroblasts. 
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Figure 5.7. – Confirmation of CD147/CD44 Co-localisation in Myofibroblasts 
Immunocytochemistry analysis, demonstrating CD147/CD44 co-localisation on the membrane of fibroblasts [A-D] and myofibroblasts [E-H]. Fibroblasts were grown 
to approximately 50% confluence in DMEM, containing 20% v/v FCS.  Following growth arrest, cells were treated with serum-free DMEM containing TGF-β1 
(10ng/ml) or fresh serum-free DMEM/F12 alone (control fibroblasts), for 72 h.  Cells were fixed and analyse using immunocytochemistry. Images show ICC florescence 
staining of: CD147 green stain [A&E], CD44 (red stain [B&E]; and merged staining [C, D, G and H].  Original magnification x400 
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5.4.5. – Assessment of CD147 Association With EGFR in Myofibroblasts  
 
Previously, it was reported that CD147 co-localised with CD44 and EGFR in TGF-β1- 
stimulated, breast cancer cells.  The co-localisation of these three surface receptors contributed 
to increased invadapodia, dependent on ERK1/2 (Toole and Slomiany 2008).  Investigation of 
CD147/EGFR co-localisation in fibroblasts (green stain) and myofibroblasts (red stain) was 
carried out by ICC.  Following merger of CD147 (Figure 5.8. [A]) with CD44 (Figure 5.8. 
[B]), fibroblasts demonstrated total CD147/CD44 co-localisation (Figure 5.8. [C&D]; yellow 
merge).  Conversely, myofibroblasts (Figure 5.8. [D-G]) showed no co-localisation of CD147 
(green stain) (Figure 5.8. [E]) with EGFR (red stain) (Figure 5.8. [F]); and two distinct 
populations were observed throughout the plasma membrane (Figure 5.8. [G-H]).    
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Figure 5.8. - CD147 Co-localises With EGFR in Fibroblasts, But Not Myofibroblasts 
Immunocytochemistry analysis demonstrating CD147/EGFR co-localisation on the membrane of fibroblasts [A-D] and myofibroblasts [E-H]. Fibroblasts were grown to 
approximately 50% confluence in DMEM containing 20% v/v FCS.  Following growth arrest cells were treated with serum-free DMEM, containing TGF-β1 (10ng/ml) or fresh 
serum-free DMEM/F12 alone (control fibroblasts), for 72 h.  Cells were fixed and analyse using immunocytochemistry. Images show ICC florescence staining of: CD147 (green 
stain [A&E]), EGFR (red stain [B&E]); and merged staining [C, D, G and H].  Original magnification x400 
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5.4.6. – Expression of CD147 Glycosylated Forms in Fibroblasts and Myofibrobasts 
 
CD147 exists in multiple glycosylated forms that mediate different functions and are variable 
expressed between cell types (Bai et al. 2014). Therefore, it may be speculated that a specific 
glycosylated form of CD147 co-localises with CD147 in myofibroblasts.  Identification of the 
glycosylated forms could also suggest a specific functional role. Western blot analysis of 
fibroblasts and myofibroblasts identified two bands of a 32 and 44kDa molecular mass (Figure 
5.9. [A]); suggesting that a LG-CD147 (32 kDa) and a HG-CD147 (44 kDa) form of CD147 
was expressed in fibroblasts and myofibroblasts.  Quantification of the bands using 
densitometry analysis (sample density was normalised using a corresponding GAPDH control), 
compared the expression of each glycosylated CD147 form between fibroblasts and 
myofibroblasts (Figure 5.9. [B]). There was no significant difference of LG-CD147 between 
fibroblasts and myofibroblasts, suggesting that this LG-CD147 is equally expressed in both 
cell types.  Analysis of HG-CD147, however, showed a significantly increased expression in 
myofibroblasts, compared to fibroblasts.  Therefore, it may be assumed from this data the 
higher glycosylated form of CD147 out of the two forms identified, has an increased expression 
in TGF-β1-induced myofibroblasts.   
 
 
 
 
 
 
 
 
 
 
~32kDa 
Figure 5.9. Expression of Glycosylated Forms of CD147 in Fibroblasts and Myofibroblasts 
Analysis of glycosylated forms of CD147 expressed by fibroblasts and myofibroblasts. Fibroblasts were grown to approximately 
80% and growth-arrested.  Fresh serum-free DMEM/F12 alone (control samples) or containing TGF-β1 (10ng/ml), was the added 
for 72 h.  Total protein was extracted and samples were separated using SDS-PAGE and analysed by Western blot.  Figure [A] 
shows the Western blot identification of 2 bands LG-CD147 (~32kDa) and HG-CD147 (~44kDa).  Figure [B] is the 
densitometry analysis of CD147 bands normalised to the corresponding GAPDH control. Graph shows the density analysis of 
both the HG-CD147 (higher bands) and LG-CD147 (lower bands) of CD147, in both fibroblasts (white bars) and myofibroblasts 
(black bars).  Data is displayed as ±SEM from 3 separate experiments. Statistical analysis was carried out using One way 
ANOVA, followed by the student’s unpaired t test  *P <0.05. 
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5.4.7. – CD147 Distribution Throughout the Plasma Membrane 
The HA mediated co-localisation of CD44/EGFR in lipid raft regions has been demonstrated 
as essential for αSMA induction and terminal myofibroblast differentiation (Midgley et al. 
2013). This study has identified that CD147/CD44 association is increased in myofibroblasts, 
compared to fibroblasts (Figure 5.5. and 5.7.). To determine the association of CD147 with 
lipid raft regions within the cell membrane, ICC was used to analyse CD147 distribution in the 
plasma membrane of fibroblasts and myofibroblasts (Figure 5.10. [A-H]).   
  ICC analysis using cholera toxin B (CTX-B), a lipid raft marker (red stain); and 
CD147 (green stain), was carried out in fibroblasts (Figure 5.10. A-D) and myofibroblasts 
(Figure 5.10. E-H).  CD147 was situated mainly in lipid raft regions in fibroblasts and merger 
of CD147 (Figure 5.10. [A]) with CTX-B (Figure 5.10. [B]), observed almost complete co-
localisation (Figure 5.10. [C-D]; yellow merge). Myofibroblasts had partial CD147/CTX-B 
co-localisation and merger of CD147 (Figure 5.10. [E]) with CTX-B (Figure 5.10. [F]), 
revealed small clusters of co-localisation (white arrows) (Figure 5.10. [G-H]), compared to the 
complete co-localisation observed in fibroblasts.   These data suggest that a population of 
CD147 may relocate from raft regions to non-raft regions when TGF-β1-stimulated, to give 2 
distinct populations of CD147.  
 One form of lipid raft that has previously been identified as important for CD44/EGFR 
co-localisation in myofibroblasts, are caveolae. These are abundantly expressed flask-shaped, 
lipid rafts, containing various lipids and caveolin (Quest et al. 2004; Tang et al. 2004).  CD147 
is widely accepted to associate with Cav-1 and it  has been demonstrated that the association 
regulates CD147 functions (Tang et al. 2004).  To investigate CD147 association with Cav-1 
in fibroblasts and myofibroblasts, a gradient fractional analysis of the membrane was 
performed.  Fractions 5-10 were identified as containing CAV-1 (band MW ~21kDa). 
Fractions 9-10 were identified as non-lipid raft regions, using early endosomal antigen 1 (EEA-
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1) as a marker (band MW ~170 kDa).  The position of CD147 within the membrane was 
assessed in fibroblasts (Figure 5.11. [A]) and myofibroblast (Figure 5.9. [B]). 
 CD147 was observed to be situated in fractions 5-8 in fibroblasts, these were all Cav-
1 associated regions.  Fractions 5-7 were previously determined to be lipid raft regions.  This 
suggests that the majority of CD147 is present in lipid raft regions in fibroblasts.  There were 
two distinct populations of CD147 throughout the membrane observed in myofibroblasts. The 
first was detected by a single band in fraction 7 (a pre-determined raft region). Two further 
bands were located within fractions 9 and 10 (both pre-determined non-raft regions) (Figure 
5.11 [B]).  These data are consistent with the previous ICC analysis in (Figure 5.5 [A]), that 
also identified two distinct populations of CD147; that existed in and out of lipid raft regions.   
It was previously identified that there were two glycosylated forms of CD147 in 
fibroblasts and myofibroblasts (Figure 5.9 [A-B]).  Interestingly, fibroblasts and myofibroblast 
analysis observed a single band with a molecular mass of approximately 44kDa.  This 
suggested that is the HG-CD147 form that associates with the plasma membrane. It was 
previously demonstrated that CD44 is expressed diffusely throughout the plasma membrane in 
fibroblasts, but is more associated with caveolae rafts in myofibroblasts.  Moreover, the CD44 
identified had a molecular mass between 80-95kDa, suggesting it was CD44s (Midgley et al. 
2013). Previously in this study, it was suggested that it was CD44s that co-localised with 
CD147 (Figure 5.5 [A]).   Analysis of CD44s (bands 80-95kDa) in fibroblasts and 
myofibroblasts were consistent with previous findings and the majority of CD44s was observed 
to be present within caveolin regions in myofibroblasts (Figure 5.11 [B]).  However, there was 
a small proportion of CD44 in fraction 10 (a pre-determined non-raft region).  Interestingly, 
these data observed CD147 and CD44s to be situated in the same membrane fractions, in and 
out of caveolae regions, in myofibroblasts. 
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Figure 5.10 – CD147 Association With Lipid Rafts 
 
CD147 association with lipid rafts was analysed using ICC. Fibroblasts were grown to 80% and growth-arrested. Cells were then treated with serum-free DMEM/F12, 
containing TGF-β1 (10ng/ml) or serum-free DMEM/F12 alone (control fibroblasts); and incubated for 72 h.  Cells were fixed and stained before analysis...Images show 
CD147 (green stain) and CTX-B (red stain) in fibroblasts [A-D] and myofibroblasts [E-H]. Co-localisation can be observed as yellow stain, resulting from image merger. 
White arrow [H] show regions of CD147/CTX co-localisation. Images are representative pictures of cell populations Magnification x 400.  
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Figure 5.11 – CD147 Association with Caveolae Rafts 
The caveolae raft isolation was performed using a Caveolae/Raft Isolation Kit (Sigma-Aldrich). Fibroblasts were 
grown to 80% confluence and growth-arrested, before being treated with in serum-free medium containing TGF-β1 
(10ng/ml) or fresh serum-free medium alone (control fibroblasts), for 72 h. Fractions were separated using SDS-
PAGE. Images show Western /blot analysis for fractions 2-10 in fibroblasts [A] and myofibroblasts [B]  
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5.4.8. - CD147 Regulation of αSMA  
 
Previous studies demonstrated that silencing total CD44 decreased αSMA mRNA and protein 
expression, preventing fibroblast differentiation (Simpson et al. 2009; Midgley et al. 2013).  
This study has identified that CD44/CD147 co-localisation increased in myofibroblasts, 
suggesting that the CD147/CD44 co-localisation may also be essential for αSMA expression. 
Following knockdown of CD147, the mRNA and protein expression of αSMA was analysed. 
A scrambled siRNA was used as a control.  
Silencing CD147 mRNA (Figure 5.12 [A]) expression had no significant effect on 
myofibroblasts αSMA expression (Figure 5.12 [B]), when compared to myofibroblasts 
transfected with the scrambled control.   
Fibroblasts transfected with the siRNA to CD147 did not express large amounts of 
αSMA protein and had identical morphology to fibroblasts transfected with the scrambled 
control siRNA (Figure5.13 [A&C]).  Myofibroblasts transfected with the scrambled siRNA 
formed distinct αSMA stress fibres, commonly associated with the myofibroblasts phenotype 
Figure 5.13[B].  Interestingly, myofibroblasts that had previously been transfected with a 
siRNA to CD147 had an increased αSMA expression, compared to fibroblasts. However, 
αSMA stress fibres that are a common characteristic of myofibroblasts did not form in the usual 
uniform manner and αSMA was randomly situated throughout the myofibroblasts, leading to 
incomplete fibre formation (Figure 5.13[D].  Interestingly, total αSMA protein expression did 
not decrease following silencing of CD147 in myofibroblasts transfected with the siRNA, 
compared to those transfected with the scrambled siRNA (Figures 13 [E-F]).  These data, 
therefore, indicate that CD147 does not have a role in αSMA transcription or translation, but 
is more associated with the incorporation and polymerization of αSMA into stress fibre 
bundles. 
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Figure 5.12. - Silencing CD147 Had no Effect on αSMA mRNA Expression 
Data compares the expression of αSMA in fibroblasts (white bars) and myofibroblasts (black bars), following transfection 
with a siRNA targeting CD147.  Control fibroblasts were transfected with a scrambled control siRNA. Following 
transfection, the cells were treated with serum-free DMEM/F12 (control fibroblasts) or serum-free DMEM/F12 containing 
TGF-β1 (10ng/ml), for 72 h. Samples were analysed using qPCR.   Figure [A] demonstrates the significant knock down of 
CD147 mRNA expression and [B] shows the expression of αSMA expression.  Data is representative of 3 individual 
experiments ± SEM. Statistical analysis was carried out using the one way ANOVA, followed by the unpaired student’s t 
test.  **P<0.01, ***P<0.001, N/S (not significant). 
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Figure 5.13 – siCD147 Prevents the Formation of αSMA Stress Fibres 
To visualise αSMA stress fibres, fibroblasts were grown to 50% confluence before growth arrest. Cells were then transfected with siRNA to CD147 or a 
siRNA scrambled control for 72 h, before being treated with serum-free DMEM (controls) or serum-free DMEM containing TGF- β1 (10ng/ml).  
Following a further 72 h incubation period, cells were fixed and analysed using ICC or extracted for Western blot analysis.  A representative picture 
was taken of each cell population under each condition. Images show fibroblasts transfected with [A] scrambled control or [C] siRNA to CD147 and 
myofibroblasts transfected with [B] scrambled control and [D] siRNA to CD147.  Data is representative of two individual experiments. Original 
magnification x 400.  Figure [E] shows Western blot analysis of αSMA and GAPDH used as a loading control. Densitometry analysis was carried out 
normalising αSMA density to GAPDH density [F].  Experiment represents three individual experiments ± SEM.   N/S (not significant).   
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5.4.9. -CD147 Transcriptional Regulation of Differentiation Mediators 
Silencing CD147 failed to prevent αSMA transcription or translation.  Combining this data 
with previous data that identified a lack of CD147/EGFR association, suggests CD147 does 
not have a role in the TGF-β1-induced pathway.  To confirm this, the transcriptional regulation 
of another mediator known to be essential for terminal differentiation were assessed.  Both 
TSG-6 and TGF-β1 have an increased expression, following TGF-β1 activation (Simpson et al. 
2009; Webber et al. 2009b).  Following knockdown of CD147 (Figure 5.14. [A]), the 
expression of these two mediator were assessed. There was no effect on the auto-induction of 
TGF-β1 (Figure 5.14. [B]) or TSG-6 mRNA expression (Figure 5.14. [C]) in fibroblasts 
transfected with the siRNA to CD147, compared to fibroblasts transfected with a scrambled 
control.  A further analysis examined the role of CD147 on the transcriptional regulation of 
EGFR. The analysis determined that CD147 did not regulate EGFR transcription (Figure 5.14. 
[D]).  These data conclude that CD147 does not seem to directly induce the TGF-β1-dependent 
differentiation pathway.  Therefore, the lack of stress fibre formation following CD147 
knockdown and the CD147/CD44 co-localisation previously observed, suggest that CD147 
may have a more indirect regulation of differentiation, by mediating the correct mechanical 
tension required for SMA incorporation.  Therefore, the rest of this study focused on the 
involvement of CD147 a mechanotransduction mediator.  
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5.4.10. - CD147 Mediation of Myofibroblast Contraction 
 
The expression of αSMA stress fibres and is often associated with the contractile phenotype of 
myofibroblasts (Hinz et al. 2001).  The lack of uniform stress fibre formation in myofibroblasts 
transfected with siRNA targeting CD147, suggested that the contractile ability of the 
myofibroblasts would be impaired.  Using collagen gels, the effect of silencing CD147 on the 
contractile ability of myofibroblasts was assessed. The percentage decrease of the collage area 
was calculated at each time point by subtracting the total area from untreated fibroblasts at 0 
R
e
la
t
iv
e
 
E
x
p
r
e
s
s
io
n
o
f
 
E
G
F
R
 
m
R
N
A
S c ra m b le d  
s iR N A
s iR N A C D 1 4 7
0 .0
0 .5
1 .0
1 .5
2 .0
R
e
la
t
iv
e
 
E
x
p
r
e
s
s
io
n
 
o
f
 
T
S
G
6
 
m
R
N
A
S c ra m b le d  
s iR N A
s iR N A C D 1 4 7
0
5
1 0
1 5
2 0
R
e
la
t
iv
e
 
e
x
p
r
e
s
s
io
n
o
f
 
T
G
F
-

1
 
m
R
N
A
S c ra m b le d  
s iR N A
s iR N A C D 1 4 7
0
2
4
6
8
R
e
la
t
iv
e
 
E
x
p
r
e
s
s
io
n
o
f
 
C
D
1
4
7
 
m
R
N
A
S c ra m b le d  
s iR N A
s iR N A C D 1 4 7
0 .0
0 .5
1 .0
1 .5
2 .0
[A] [B] 
[C] [D] 
Figure 5.14. – CD147 Does Not Regulate TGF-β1-Induced Mediators 
Analysis of CD147 knockdown [A] on TGF-β1-induced differentiation mediators, TGF-β1 [B], TSG-6 [C] and EGFR 
[D]. Data compares their expression in fibroblasts (white bars) and myofibroblasts (black bars), following transfection 
with a siRNA targeting CD147.  Control fibroblasts were transfected with a scrambled control siRNA. Following 
transfection the cells were treated with serum-free DMEM/F12 (control fibroblasts) or serum-free DMEM/F12, 
containing TGF-β1 (10ng/ml), for 72 h. Samples were analysed using qPCR.   Data is representative of a single 
experiment consisting of 3 separate samples ± S.D.  
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h.  Figure 5.15. shows the images of the contraction gels that were seeded with fibroblasts and 
transfected with a scrambled control siRNA [A-C] or a siRNA targeting CD147 [D-E].  
Following 72 h of TGF-β1 stimulation, there was a decrease area of ~14.5% in collagen gels 
transfected with the scramble control siRNA (Figure 5.15.[B]). A further 18.5% decrease was 
observed between 72 h and 144 h of TGF-β1 stimulation, giving a total percentage decrease of 
~33% compared to unstimulated fibroblasts at 0 h (Figure 5.15. [C]). Cells transfected with 
the siRNA targeting CD147 had a decreased gel area of ~22.5% following 72 h of TGF-β1 
stimulation (Figure 5.15. [E]).  A small decrease observed of 2.8% was observed between 72 
h and 144 h of stimulation with TGF-β1, indicating that contraction ability had been reduced in 
fibroblasts transfected with a siRNA to CD147, when compared to fibroblasts transfected with 
the scrambled siRNA Figure 5.15. [F].  The protein expression of CD147 is not totally silenced 
until 144 h, following transfection with the siRNA (Figure 5.2 [B]). Therefore, that contraction 
ability was functional at 72 h, suggests that the CD147 protein was no totally knocked down.  
The lack of uniform αSMA stress fibre formation in myofibroblast was also observed at 144 h, 
following transfection with siRNA to CD147 (Figure 5.13. [D]).  It may, therefore, be assumed 
that the lack of contraction observed between 72 h and 144 h of TGF-β1 stimulation, was the 
result of a decreased CD147 protein expression that limited αSMA stress fibres formation and 
functional contraction.  Figure 5.15. [G] shows the percentage decrease of collagen gels seeded 
with fibroblasts that were transfected with either the scrambled control siRNA or a siRNA to 
CD147 at 72 and 144 h timepoints.   
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Figure 5.15. - Silencing CD147 Regulates Myofibroblast Contraction Ability 
To assess the role of CD147 in the contraction ability of myofibroblasts, fibroblasts were seeded onto pre-made 
collagen gels and grown to 50-60% confluence.  Following growth arrest, fibroblasts were transfected with a 
siRNA targeting CD147 or a scrambled control siRNA.  Fibroblasts were further growth-arrested before being 
treated with serum-free DMEM/F12 alone (controls) or serum-free DMEM/F12, containing TGF- β1 (10ng/ml). 
Collagen gels were photographed at 0h, 72 h and 144 h, following TGF-β1 stimulation.  [A-C] show contraction 
gel of fibroblasts transfected with a scrambled control siRNA. [D-F] show fibroblasts transfected with a siRNA 
targeting CD147 [G] shows the percentage decrease at 72 h (black bars) and 144 h (white bars), compared to 0 h. 
Data represents a single experiment.    
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5.4.11. - CD147 and F-Actin Arrangement by Fibroblasts and Myofibroblasts 
 
It is necessary for the F-actin cytoskeleton to remain intact and maintain the correct mechanical 
tension for αSMA subunits to become incorporated. HA/CD44 association mediates changes 
in the cytoskeleton arrangement and mechanical tension, through interaction with intracellular 
extracellular matrix (ERM) proteins, which mediates multiple cellular processes (Ponta et al. 
2003). This study has shown an increased CD147/CD44 association and a distinct lack of 
αSMA stress fibre formation in fibroblasts, transfected with a siRNA to CD147. Therefore, it 
was hypothesised that silencing CD147 protein expression may alter the cytoskeletal 
interaction of CD44 with F-actin, resulting in a dysregulation of F-actin which prevented the 
effective polymerisation and incorporation of αSMA. To investigate this, F-actin arrangement 
was analyses in fibroblasts and myofibroblasts, following transfection with siRNA to CD147.  
The arrangement of F-actin fibres alters from fibroblast to myofibroblast.  F-actin fibres in 
fibroblasts are arranged around the peripheral edge of the cell. Myofibroblast F-actin has a 
more cortical distribution of F-actin fibres.  This can be observed in Figure 5.16. [A&B],which 
show the F-actin arrangement in fibroblasts [A] and myofibroblasts [B]. 
 Fibroblasts and myofibroblasts transfected with the siRNA to CD147 (Figure 5.16. 
[C-D]) respectively, showed no difference in F-actin arrangement, compared to fibroblasts or 
myofibroblasts transfected with the scrambled control.   The lack of disruption to the F-actin 
filaments suggests that silencing CD147 expression does not alter F-actin arrangement in 
myofibroblasts.  This suggests that CD147/CD44 co-localisation is not central to CD44/F-actin 
association and does not contribute to the lack of αSMA incorporation into stress fibres.  
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Figure 5.16. - Silencing CD147 Has no Effect on F-actin Arrangement 
The effects of siRNA to CD147 on the cytoskeletal arrangement of F-actin arrangement was investigated. Fibroblasts were grown to 50% confluence in chamber and growth-arrested. 
Cells were transfected with siRNA to CD147 or a scrambled control siRNA.  Following transfection and a further growth-arrested period, fibroblasts were treated with serum-free 
DMEM/F12 (controls) or serum-free DMEM/F12, containing TGF β1 (10ng/ml), for 72 h. Cells were then fixed and analysed using ICC.  Cells were visualised by florescent 
microscopy.  A representative picture was taken of each cell populations under each condition.   Images show fibroblasts transfected with [A] scrambled control or [C] siRNA to 
CD147 and myofibroblasts transfected with [B] scrambled control and [D] siRNA to CD147.  Original magnification x 400. 
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5.4.12. – Investigation into CD147 Regulation of CD44s  
   
Previously, it was identified that CD147/CD44 co-localisation increased in myofibroblasts 
(Figure 5.5. [A]). Further, the molecular weight of the CD44 at ~80-95kDa, suggested it was 
an increased CD147/CD44s co-localisation.   It has been shown that CD44s can be cleaved 
within the transmembrane region, producing an intracellular domain (ICD) that regulates its 
own gene transcription and the gene expression of  multiple other genes, including gelatinase 
(MMP-9) (Miletti-González et al. 2012).  Moreover, MMP-9 cleaves CD44, resulting in the 
release of extracellular domains (ECDs) and ICDs (Chetty et al. 2012).  CD147 is an inducer 
of MMP-9, suggesting that CD147/CD44s co-localisation upregulates MMP-9 activation and 
increases CD44s cleavage and elevates gene transcription from ICDs.  More recently, TGF-β1 
stimulation has been shown to increase CD147 intracellular signalling of known fibrotic 
transcription factors, including SMAD2, co-SMAD4 and ERK1/2 (Li et al. 2015). Therefore, 
it could be suggested that CD44s and CD147 regulate the gene transcription of each other.  To 
investigate this, the mRNA expression of CD147 and CD44s here analysed, following 
transfection with either a siRNA to CD44s or CD147 (Figure 5.17. [A-D]).  
Following the significant knockdown of CD147 (Figure 5.17. [A]) and CD44s (Figure 
5.17. [C]), the expression of CD44s (Figure 5.17. [B]) and CD147 (Figure 5.17. [D]) was 
assessed. There was no effect on CD44s mRNA expression following silencing of CD147, 
compared to the scrambled controls. Similarly, there was no effect on CD44s expression in 
cells transfected with the siRNA targeting CD147. This concludes that the previously observed 
CD147/CD147 co-localisation is not central to mediating ICD regulation of each other. 
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Figure 5.17. Analysis of CD147 and CD44s Gene Transcription 
Fibroblasts were sub-cultured until 50-60% confluence and growth-arrested.  Fibroblasts were transfected with siRNA 
targeting CD147 or siCD44s. A negative scrambled siRNA was used in control samples.   Following a further growth arrest 
period, cells were treated with serum-free DMEM/F12 containing TGF-β1 (10ng/ml) or serum free DMEM/F12 alone (control 
samples), for 72 h.  Samples were analysed by qPCR. Figures [A&C] show the knockdown of CD147 and CD44s, respectively. 
Figure [D] shows the relative expression mRNA of CD44s, following transfection with siRNA to CD147. All data were 
comparative to scramble controls.  Control fibroblasts (white bars) were compared to myofibroblasts (black bars). Data is 
displayed as ±SEM of three individual experiments. Statistical analysis was carried out using one way ANOVA followed by 
the unpaired student’s t test. *P<0.05, **P<0.01, ***P<0.001, N/S (not significant). 
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5.4.13. – CD147 Regulation of TGF-β1 Induced EDA-Fibronectin Expression 
 
Mechanical tension is an important factor regulating fibroblast to myofibroblast differentiation. 
A combination of supermature focal adhesion formation and increased cell-ECM and cell-cell 
contact increases the tensile strength of F-actin.  The correct tension is essential for 
incorporation and polymerisation of αSMA, through its NH2-terminal sequence, Ac-EEED 
(Chaponnier et al. 1995).   EDA-fibronectin (EDA-FN) is essential for myofibroblast terminal 
differentiation, its upregulation precedes that of αSMA in proto-myofibroblasts. Lack of EDA-
FN association prevents differentiation (Serini et al. 1998).  Therefore, the CD147 regulation 
of EDA-FN was investigated. 
Following significant knockdown of CD147 mRNA expression (Figure 5.18. [A]), the 
effects on EDA-FN expression were observed. Silencing CD147 did not have an effect on 
EDA-FN and a similar increase was observed in myofibroblasts transfected with the siRNA to 
CD147 that were observed in the scrambled controls (Figure 5.18. [B]). 
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Figure 5.18. Knockdown of CD147 Does Not Affect TGF-β
1
 Induction of EDA-Fibronectin by Myofibroblasts 
To investigate CD147 regulation of EDA-FN, fibroblasts were grown to 50-60% confluence and growth-arrested. 
Cells were transfected with a siRNA targeting CD147 or a scrambled control siRNA.  Following a further growth 
arrest period, fibroblasts were treated with serum-free DMEM, containing TGF-β
1
 (10ng/ml) or serum-free 
DMEM/F12 alone (control samples).  Samples were analysed using qPCR.  [A] demonstrates the knockdown of 
CD147 mRNA expression in fibroblasts (white bars) and myofibroblast (black bars).  [B] shows the mRNA 
expression of EDA-FN, following CD147 knockdown. Data is displayed as ±SEM of three individual experiments. 
Statistical analysis was carried out using one way ANOVA, followed by the student unpaired t test. **P<0.01, 
***P<0.001, N/S (not significant). 
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5.4.14. - CD147 Co-localises with Integrin α4β7 in Myofibroblasts 
 
The mechanical tension resulting from supermature focal adhesions is dependent on ECM-cell 
contact, for which EDA-FN/integrin  association is essential (Hinz 2007).  Recently, integrin 
α4β7/EDA-FN association was shown to mediated fibroblast to myofibroblast differentiation 
in an FAK- and ERK1/2-dependent manner (Kohan et al. 2010). CD147 is known to associate 
with and mediate the interactions of integrins, including their association with FAK (Tang et 
al. 2008b). Therefore, a CD147 association with integrin α4β7 was investigated using ICC 
(Figure 5.19 [A-F]).  
CD147 was highly expressed in fibroblasts and myofibroblast (green stain) (Figures 
5.19 [A&D]).  Integrin α4β7 was also expressed in both fibroblasts and myofibroblasts 
(Figures 5.19. [B&E]. To identify CD147/α4β7 association, the images were merged. The 
merger of CD147 and integrin α4β7 in fibroblasts showed no co-localisation.  This was 
confirmed by an Intensity Scattergram, that showed a mainly green intensity of the merged 
images (Figure 5.19. [G]).  This suggests that there is a higher expression of CD147 in 
fibroblasts, compared to myofibroblasts. Merger of myofibroblast images, however, did have 
a degree of co-localisation (Figure 5.19 [F]) and the corresponding Intensity Scattergram had 
an equal expression of red and green intensity (Figure 5.19. [H]).  That CD147/α4β7 co-
localised in myofibroblasts, suggests that the association may contribute to maintaining the 
correct tension for αSMA incorporation into F-actin fibers.    
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Figure 5.19.  CD147 and Integrin α4β7 Co-localise in Myofibroblasts 
CD147 co-localisation with integrin α4β7 was investigated using ICC. Cells were grown to 50% confluence and growth-arrested, before being treated with serum-free DMEM/F12, containing 
TGF-β1 (10ng/ml) or serum-free DMEM/F12 alone (control), for 72 h. Figure [A-F] show the ICC analysis of fibroblasts [A-C] and myofibroblasts [D-F] and the analysis of CD147 (green 
stain) and integrin α4β7 (red stain).  Intensity scatterplots were used to analyse merged images [C&F].  Images are representative pictures of three individual experiments.  Magnification  x 
400.
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5.4.15. CD147 Regulates Intracellular ERK1/2 Activation 
 
CD147, CD44 and integrin α4β7, have been identified to mediate downstream ERK1/2 
following certain activation stimuli (Tolg et al. 2006; Toole and Slomiany 2008; Kohan et al. 
2010; Midgley et al. 2013).   Phospho-ERK1/2 activation has also been associated with 
mechanical tension, through HA/CD44 association with the cytoskeleton (Kawamura et al. 
2003).  This study has identified a decreased incorporation of αSMA into stress fibres, when 
CD147 expression is silenced.  This may suggest that the association of CD147 with CD44 or 
α4β7, may regulate essential downstream signalling mediators that are important for the correct 
mechanical tension. Previous research in our laboratory demonstrated p-ERK1/2 to activate in 
a biphasic manner following TGF-β1 stimulation, over a timecourse of 0-3 h.  Therefore, these 
times have been used in this study. 
ERK1/2 activation was investigated using Western blot of fibroblasts, transfected with a siRNA 
targeting CD147 or a scrambled control siRNA.  Samples transfected with the scrambled 
control siRNA had a similar biphasic peak that was previously described (Meran et al. 2011a).  
There was an activation of p-ERK1/2 at 5 and 10 min, followed by a decreased p-ERK1/2 
expression at 30 min.  The second activation was observed at the 1 h time-point and was still 
present at 3 h.  Silencing CD147 decreased p-ERK1/2 expression at all time-points, compared 
to the scrambled control, suggesting that CD147 has a regulatory role in p-ERK activation.   
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Figure 5.19. - CD147 Regulates Intracellular p-ERK1/2 Activation 
Investigation of CD147 activation of p-ERK1/2.  Fibroblasts were grown to 50-60% confluence and growth- 
arrested, before being transfected with a siRNA to CD147 or a scrambled siRNA for 144 h. Fibroblasts were 
stimulated with TGF-β1 (10ng/ml), over a time course of 0-3 h.  Samples were analysed using SDS-PAGE, 
followed by Western blot.  Image shows p-ERK1/2 activation, following TGF-β1 induction in fibroblasts 
transfected with a scrambled control siRNA (Sc) or a siRNA targeting CD147 (Si).  Data is representative of 
1 experiment. 
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5.5. -Discussion. 
 
Chapters 3 and 4 identified which CD44 spliced variants were expressed by fibroblasts and 
determined that CD44s was the principle CD44 variant involved in TGF-β1-induced, fibroblast 
differentiation and IL-1β-induced, monocyte binding.  Central to both these mechanisms is 
CD44. This chapter investigated the association of CD44 with CD147/EMMPRIN, a MMP 
inducer, previously identified to induce breast cancer invasiveness through association with 
CD44 and EGFR in lipid rafts (Grass et al. 2013). Similarly, both CD44 and CD147 have an 
increased expression in prostate cancer and promote cell growth and metastasis, via 
intracellular ERK1/2 (Hao et al. 2012).  Separately, CD44 and CD147 have been identified as 
mediators of fibrotic progression (Kato et al. 2011; Meran et al. 2013; Midgley et al. 2013).  
However, it is not known if CD147 has a role in the TGF-β1-induced, HA/CD44/EGFR or IL-
1β induction of HA/CD44/ICAM-1 pathways.  This chapter investigates the role of CD147 in 
these two pathways.  
 This study identified that CD147 was highly expression in fibroblasts, however, this 
expression did not increase following stimulation with TGF-β1.  This suggested that TGF-β1 
did not regulate CD147 transcription in fibroblast differentiation.  This is in contrast to previous 
reports that TGF-β1 induced CD147 expression in corneal fibroblasts (Huet et al. 2008b). 
Interestingly, CD147 mRNA expression increased following IL-1β treatment. This study and 
previous studies have shown that fibroblast-monocyte binding is increased following IL-1β 
activation (Meran et al. 2013). Therefore, this suggests that the increased CD147 mRNA may 
be associated with monocyte binding. 
CD147 and CD44 have both previously been associated with the activation of 
intracellular ERK1/2, which is known to be a mediator of cellular growth and survival 
(Roskoski Jr 2012). In prostate cancer cells, silencing the expression of either CD147 or CD44 
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separately, reduced invadapodia and intracellular ERK1/2 signaling (Hao et al. 2012).  Further, 
the HA/CD44 association along with CD147 have been found to be fundamental in chemo-
resistant treatments in some cancer cell lines and more recently, it has been shown that the 
increased growth and invasive properties of cancer cells is associated with a CD147/CD44 co-
localisation (Toole and Slomiany 2008; Grass et al. 2013). This study determined that 
CD147/CD44 co-localised in fibroblasts. Interestingly, this association was increased in 
myofibroblasts, suggesting a regulatory role for TGF-β1 in the association of these two 
receptors.  Stimulation with IL-1β did not increase the CD147/CD44 co-localisation from that 
observed in quiescent fibroblasts.  A pan-CD44 antibody that recognised all CD44 spliced 
variants determined that CD44s co-localised with CD147 preceding TGF-β1stimulation.   The 
CD147/CD44s co-localisation had previously been reported in pancreatic cancer. The study 
found that the CD147/CD44s association was observed in lipid raft regions of the plasma 
membrane and both receptors were required for intracellular activation for tumor growth (Li et 
al. 2013).  Chapter 4 in this study identified CD44s as the principle CD44 variant involved in 
the TGF-β1-induced, HA/CD44/EGFR and IL-1β-induced HA/CD44/ICAM-1 mechanisms.  
The CD147/CD44s co-localisation observed in this study suggests that CD44s associates with 
multiple other surface receptors in fibroblasts and myofibroblasts. 
  CD147/CD44 co-localisation was not effected by IL-1β stimulation. CD147 has been 
shown to co-localise with ICAM-1 in the U397 cell line and activation of CD147 was important 
for activation of ICAM-1 signaling and cell binding properties (Khunkeawla et al. 2001). This 
suggested that it could be CD147 association with ICAM-1 that mediates monocyte binding by 
fibroblasts.  This study identified that CD147/ICAM-1 co-localised in fibroblasts and IL-1β 
stimulated fibroblasts, however, no difference in the co-localisation was observed. That CD147 
co-localised with both CD44 and ICAM-1, both of which are central adhesion molecules to 
monocyte binding; the functional role of CD147 was investigated. Silencing CD147 had no 
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effect on IL-1β-induced, monocyte binding, suggesting it had no role in the IL-1β-induced 
HA/CD44/ICAM-1 pathway.  Although CD147 failed to be associated with monocyte binding 
by fibroblasts, does not eliminate its involvement.  For example, in a study by Khunkeawla et 
al. (2001), CD147 was found to be essential for homotypic aggregation in the U397 cell line. 
Therefore, CD147 may involve the monocytes ability to bind HA on fibroblasts and not 
fibroblasts ability to bind monocytes.  As CD147 expression was not silenced in U397 cells, it 
cannot be concluded that it has no involvement, although from the results in this study, it seems 
it does not regulate fibroblasts ability to bind monocytes.   
The increased co-localisation of CD147/CD44 following TGF-β1 stimulation was 
further confirmed by ICC.  Interesting, CD147 did not co-localise with EGFR, following TGF-
β1 stimulation. Our previous research has shown that fibroblast to myofibroblast differentiation 
requires HA to move CD44 through the membrane, where it associates with EGFR in caveolin 
rafts (Midgley et al. 2013).  As CD147 did not co-localise with EGFR it suggests that CD147 
has a role in fibroblast to myofibroblast differentiation in a CD44-dependent manner.  For 
example, CD44 and CD147 are both known to regulate MMP transcription and activation (Sun 
and Hemler 2001; Murray et al. 2004).  Further CD44 has been documented to act as a platform 
for MMPs (Seiki 2002). The association of CD44 with CD147 (a known MMP inducer) may 
allow for a synergistic relationship, where CD44 positions the MMPs and mediates CD147 
activation.  MMPs are known to be ECM regulators, therefore, an increased production may 
result in an ECM re-arrangement that allows HA to associate with and move CD44 through the 
membrane to associate with EGFR in lipid raft regions.  Interestingly, it has been previously 
observed in gland epithelium that CD44v3 is a platform for MMP-7, which activates the 
epidermal growth factor receptor 4 (ErbB4) (Yu et al. 2002).  This may suggest that CD147 
regulates the activation of MMPs positioned on the CD44, which then activate EGFR in the 
HA/CD44/EGFR complex. TGF-β1 and TSG-6 are essential differentiation mediators.  
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Silencing CD147 had no effect on the transcription of these two mediators again suggesting 
that CD147 has no role in the TGF-β1/HA/CD44/EGFR pathway. 
High and low glycosylated forms of CD147 have been reported to associate with lipid 
rafts (Tang et al. 2004). This study found that both high and low glycosylated forms of CD147 
were expressed by fibroblast and myofibroblasts. It was also determined that there was an 
increased expression of the HG-CD147, following TGF-β1 stimulation. The HG-CD147 form 
has previously been identified to have increased expression under fibrotic conditions. For 
example, rats treated with the antibiotic, bleomycin (which results in a fibrotic response and 
fibrosis), had an increased expression of a CD147 glycosylated form of 55kDa (Barth et al. 
2006). This is also in line with the observations by Tang et al. (2004), that shows that the higher 
glycosylated form of CD147 is an activator of MMPs. Although the pathology of fibrosis is the 
result of an imbalance between ECM production and degradation, some MMPs have been 
shown to be upregulated in fibrotic conditions.  For example, the increased expression of both 
MMP-9 and MMP-2 has been reported to be associated with fibrotic progression. Increased 
MMP-9 expression has been reported to degrade the tubular basement membrane, therefore, 
activating epithelial cells to undergo EMT in obstructive nephrology (Liu 2006). Further, 
MMP-2 has also been shown to be required for tubular EMT (Cheng and Lovett 2003). 
Therefore, the increase expression of a higher glycosylated form of CD147 in myofibroblasts 
in this study may be associated with MMP activation and upregulation in fibrosis. 
Fibroblasts had a total co-localisation of CD147 with lipid raft regions, however, 
myofibroblasts had a sub-population situated outside of raft regions. Therefore, TGF-β1 
activation re-localised CD147 to form two populations throughout the membrane.  
Interestingly, CD147 was identified to be situated mainly in CAV-1 regions in the membrane 
in fibroblasts (these regions were identified lipid raft regions known as caveolae rafts).  CD147 
was situated in CAV-1 regions and non-raft regions in myofibroblasts.   CD44 was also present 
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in and out of CAV-1 regions in fibroblasts, which re-localised in myofibroblasts to become 
mainly situated in CAV-1 regions, this is in line with previous research. A population of CD44 
was observed to be associated with non-raft regions. That both CD44 and CD147 were present 
in the same membrane regions suggests that the increased CD147/CD44 co-localisation, 
previously observed in myofibroblasts could be in or out of raft regions or both. In a study by, 
Tang and Hemler (2004), it was observed that overexpression of CAV-1 had a negative effect 
on CD147 regulation of MMP-1; and the increased presence of CAV-1 resulted in decreased 
CD147 self-clustering and MMP-1 induction in three different cell types. This was confirmed 
in a study that silenced CAV-1 protein expression and found and increased expression of MMP-
1 and intracellular ERK1/2 in dermal fibroblasts (Haines et al. 2011).  Therefore, the presence 
of a population of CD147 outside of raft regions in myofibroblasts may contribute to increased 
cluster formation and MMP production via its association with CD44.  
Only HG-CD147 was observed in the membrane fractions. This is in line with the cell 
type, as fibroblasts and myofibroblasts are known for MMP induction to mediate ECM 
degradation and turnover.  The high glycosylated form of CD147 is mainly associated with 
MMP production and, therefore, it would be expected in a cell that has MMP production as a 
specific function to express this glycosylated form of CD147 (Tang et al. 2004).  It was 
previously observed that there were two glycosylated forms of CD147 in fibroblasts and 
myofibroblast total lysate. An explanation for this is that LG-CD147 form is a precursor to HG-
CD147 and is only present within the Golgi; although it has previously been observed to exist 
on the plasma membrane, it seems this is cell-specific.  For example, in lung cancer cells in a 
study by Huang et al. (2013), only the high molecular form of CD147 was expressed on the 
plasma membrane, compared to the presence of two glycosylated forms in the total cell lysate; 
this is in line with observation made in this study. 
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CD44 is well established to be a regulator of the actin cytoskeleton.  Furthermore, it 
has been shown that the association of CD44 with the cytoskeleton is lipid raft-dependent 
(Oliferenko et al. 1999).  Interestingly, silencing CD147 has shown to alter the cytoskeletal 
architecture in human hepatocellular cancer cells (Qian et al. 2008).  The CD147/CD44 co-
localisation and the presence of a population within lipid rafts may, therefore, indicate a 
regulatory role of CD44/CD147 in mediating the cytoskeleton.   Myofibroblasts can be 
characterized by the increased expression of αSMA and its incorporation into F-actin to form 
αSMA stress fibers. That silencing CD147 did not have an effect on αSMA transcription or 
translation following TGF-β1 activation, further suggests that it is not involved in the classical 
HA/CD44/EGFR induction of differentiation. Interestingly, silencing CD147 prevented αSMA 
incorporation into F-actin and form stress fiber formation.  The incorporation of αSMA into 
stress fibers is highly dependent on mechanical tension. A decrease in mechanical tension limits 
αSMA stress fibre formation and the contractile ability of myofibroblasts (Hinz et al. 2001). 
Preliminary data from this study identified that following total knockdown of CD147, the 
contractile ability of myofibroblast was decreased. These data combined suggests that CD147 
may be involved in maintaining the correct mechanical tension required for αSMA stress fibre 
formation.  
It is well-established that CD44 regulates the movement of F-actin through the 
association with ERM proteins and regulates cellular migration, proliferation and 
differentiation, through its activation by HA (Ponta et al. 2003).  Moreover, CD147 has also 
been associated with cytoskeletal re-arrangement by the upregulation of integrins, focal 
adhesion kinase (FAK) and other focal adhesion proteins, through the activation of Ras 
homolog gene family, member A (RhoA), which has also been associated to be downstream 
from CD44 (Zhao et al. 2011).  Therefore, it could be assumed that the removing CD147 protein 
expression may prevent CD44/F-actin re-arrangement and differentiation. However, silencing 
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CD147 did not alter the F-actin re-arrangement and it was observed to move from peripheral 
regions of fibroblasts and to a more cortical arrangement in myofibroblasts.  
This study found that CD44s co-localised with CD147. CD44s has previously shown 
to regulate its own transcription and to regulate MMP-9 expression, through cleaving and 
release of the ICD.  Further, CD147 is well-documented to increase the expression of many 
MMPs as well as vascular endothelial growth factor (VEGF) and HA (Nabeshima et al. 2006).  
Therefore, it was thought to be important to determine if these two associated receptor 
regulated the transcription of each other.  There was no evidence to suggest that these two 
receptors regulate transcription of each other.  
EDA–FN is essential for fibroblast to myofibroblast differentiation and its up-
regulation precedes that of αSMA and collagen in the intermediate proto-myofibroblast stage.  
Further, its expression is greatly upregulated under fibrotic condition.  The importance of EDA-
FN in fibrosis can be shown in a study carried out by Muro et al.(2008).  The study showed 
that EDA–FN-deficient mice treated with bleomycin (a fibrotic inducer) failed to induce 
fibrosis, compared to wild-type mice.  EDA-FN has been associated with the formation of focal 
adhesions, through the association with integrins and other FA proteins.  Moreover, the 
inhibition of EDA-FN prevents supermature focal adhesions formation. These are essential for 
αSMA stress fibre formation in myofibroblasts and for creating the correct tensile strength for 
αSMA incorporation into F-actin (Dugina et al. 2001). This study showed that CD147 does not 
regulate transcription of EDA-FN.  However, the fact that CD147 does not regulate 
transcription of EDA-FN, does not exclude it from regulating EDA-FN interactions with 
integrins. 
CD147 associates with multiple integrins, which are associated with cell adhesion and 
are essential mediators of mechanical tension.  The association of CD147 with integrin α3β1 
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in human hepatoma cells has been shown to be important for cell adhesion, invasion and MMP 
production; as well as a reduction in focal adhesion (FA) quality and defective actin 
cytoskeletal  re-arrangement (Tang et al. 2008b). This study investigated the association of 
CD147 with integrin α4β7 which had previously, through its association with EDA-FN, been 
identified to mediate fibroblast differentiation. It was identified that CD147/ α4β7 co-localised 
in myofibroblasts. Through this association, CD147 may mediate integrin α4β7 interaction 
with EDA-FN, making it an essential mediator for obtaining the correct mechanical tension 
and αSMA incorporation.  However, further research into this hypothesis is required. 
 CD147, CD44 and multiple integrins have all been identified to activate downstream 
p-ERK1/2. Interestingly, ERK1/2 has previously been shown to be involved in 
mechanotransduction signaling, cytoskeletal re-arrangement and upregulation of 
differentiation mediators, including HAS2, EGFR and αSMA (Kawamura et al. 2003; Shi et al. 
2011; Midgley et al. 2013). This study identified that CD147 has a regulatory role in p-ERK1/2 
activation and silencing CD147 expression decreased p-ERK1/2 activation.  This suggests that 
CD147 mediates mechanotransduction in a p-ERK1/2-dependent manner, although to clarify 
this, further research is required. 
In conclusion, this chapter has identified a possible role for CD147 in maintaining the 
correct mechanical tension for αSMA incorporation and terminal myofibroblast differentiation. 
However, more research is required to determine if the CD147/CD44 association or the 
CD147/α4β7 association are central to this process. This study has elucidated that CD147 is 
unlikely to play a role in the classical TGF-β1-driven differentiation through the 
HA/CD44/EGFR pathway. Similarly, CD147 was not identified to have a role in regulating 
monocyte binding by fibroblasts.  
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Chapter 6-General Discussion 
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6.1 General Discussion 
 
This thesis investigated the roles of CD44 variants and the MMP inducer, CD147, in pro-
fibrotic and pro-inflammatory phenotypic changes in myofibroblast. Multiple CD44 variants 
were expressed in fibroblasts and it was that these existed as both single exon or multiple exons 
spliced, between the two common regions. Ten CD44 variants were identified preceding 
stimulation with transforming growth factor-β1 (TGF-β1) (which decreased expression of all 
the variants) and interleukin-1β (IL-1β) (which increased all variant expression). The standard 
form of CD44 (CD44s) was identified as essential for TGF-β1-driven, fibroblast to 
myofibroblast differentiation (Figure 6.1[A]) and the IL-1β induction of fibroblast-monocyte 
binding (Figure 6.2[B]).  The study also determined that CD147 was essential for αSMA 
incorporation into F-actin stress fibres in myofibroblasts, suggesting a control mechanism for 
the cells’ contractile ability.  A regulatory role for CD147 was also determined in the activation 
of the intracellular signalling kinase extracellular signal-regulated kinase1/2 (ERK1/2). CD147 
associated with two key differentiating mediators, CD44 and the EDA-fibronectin (EDA-FN) 
associated integrin, α4β7, following TGF-β1 induction.   The investigation also determined that 
it was most probably CD44s that was co-localised with CD147, suggesting a dual role for the 
simplest CD44 variant in fibrotic progression.  
Combining data from this study and previous research from our laboratory suggests that 
association of hyaluronan (HA) with CD44s is central to the TGF-β1-mediated, 
HA/CD44/EGFR and the IL-1β activation of the HA/CD44/ICAM-1 pathways (Figure 6.1[A-
B]). The peri-cellular HA arrangements resulting from these two pathways differ and are 
specific to their function. One suggestion for this variation in HA arrangement is the nature of 
the association of CD44s in the plasma membrane.  The CD44/EGFR association observed in 
myofibroblasts requires association with CAV-1 lipid rafts (caveolae). However, the CD44s/ 
intracellular adhesion molecule-1 (ICAM-1) co-localisation resulting from IL-1β stimulation 
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happens within non-lipid raft regions (Meran et al. 2013).   Downstream intracellular signalling 
is mediated through the association of receptors with different cell membrane components and 
receptor interactions.  Both the TGF-β1 and IL-1β pathways investigated in our laboratory 
activate downstream ERK1/2.  These protein kinases have been identified to regulate multiple 
signalling pathways and transcription factors (Roskoski 2012).  Therefore, the activation of 
ERK1/2 via different regions of the plasma membrane may mediate HA re-arrangements by 
promoting different gene transcription. For example, recently it has been identified that the 
hyaldherin, tumour necrosis factor-inducible gene 6 (TSG-6), is essential for myofibroblast 
TGF-β1 induced, HA peri-cellular coat formation, but is not required for the formation of the 
HA spikes induced by IL-1β.   This suggests that the protein transcription required for the HA 
coat assembly differs following different stimuli. A further explanation as to why the same 
CD44 variant can mediate different HA arrangement is the varied post-translational 
modifications which can effect HA interaction and signalling (Bartolazzi et al. 1996). 
Therefore, to examine the varied functional role of CD44s in mediating different HA 
arrangements requires further investigation. 
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That none of the other CD44 spliced variants were identified to have a role in TGF-β1- 
induced, differentiation or IL-1β-induced, monocyte binding, does not eliminate their 
involvement.  A recent fibrotic reversal model identified in our laboratory has shown 
CD44v7/8 to be essential for preventing TGF-β1-induced, fibrosis, through its induction by the 
anti-fibrotic growth factor, bone morphogenic protein-7 (BMP-7) (Midgley et al. 2015).  The 
study examined the effect of silencing CD44v7/8 expression on the ability of BMP-7 to prevent 
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Figure 6.1. - Schematics [A&B] illustrate the role of CD44s and its re-location in TGF-β1- 
induced fibroblast differentiation and IL-1β induced monocyte binding, respectively.  
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or reverse the fibrotic response induced by TGF-β1. It was shown that decreasing the expression 
of CD44v7/8 prevented the anti-fibrotic effects of BMP-7 on fibroblast differentiation and 
upregulated αSMA expression.  Further, it was suggested that the dampened fibrotic response 
by BMP-7 was the result of a CD44v7/8 specific function that initiated the internalisation of 
HA and prevented the formation of the myofibroblast HA coat (Midgley et al. 2015).  A similar 
response was observed in this study, which identified that a decreased expression of CD44v8 
increased fibroblast-monocyte binding.  This CD44 variant shares a partial exonic sequence 
with CD44v7/8, suggesting that the v8/exon 12 may have a functional role in the internalisation 
of HA.   
The majority of fibroblast populations undergo differentiation to become 
myofibroblasts following TGF-β1 stimulation, including lung and dermal fibroblasts 
(Desmoulière et al. 1993).  However, TGF-β1 stimulation of oral mucosal fibroblasts results in 
an anti-fibrotic phenotype that resists differentiation and a proliferative response (Stephens et 
al. 1996; Szpaderska et al. 2003; Meran et al. 2007; Meran et al. 2008a).  Furthermore, the 
TGF-β1 induction of proliferation of dermal fibroblasts is CD44-dependent, however, the anti-
proliferative response of oral fibroblasts is CD44 independent, resulting from a HA-deficient 
environment (Meran et al. 2011b).  Interestingly, preliminary data analysing CD44 mRNA 
variant expression in oral and dermal cells undertaken in our laboratory, suggests that oral cells 
have a high expression of v7 (see appendix 2).  This may suggest that non-scarring cells express 
a HA regulating CD44 variant, which contributes to the non-scarring properties.   Therefore, 
for future investigations, it may be interesting to analyse the inhibitory effects of CD44 variant 
expression on HA regulation in non-scarring cell types.  
Analysing the protein involvement of CD44s is restricted due to the limitations of 
available antibodies.  Although there are specific antibodies that target variant-specific stem 
regions, antibodies that target CD44s, target the amino domain that is common to all variants.  
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Therefore, using conventional protein methods, such as immunocytochemistry (ICC) and 
Confocal Microscopy, to confirm CD44s co-localisation with either epidermal growth factor 
receptor (EGFR) or intercellular adhesion molecule-1 (ICAM-1) is not possible and conclusive 
results would require more advanced techniques, such as Florescence Resonance Emission 
Transfer (FRET). 
CD147 is a major contributor to cancer invadapodia, through its ability to induce and 
activate matrix metalloproteinases (MMPs); and contribute to the re-arrangement of the ECM.  
However, it has also previously been associated with fibrotic progression (Huet et al. 2008b; 
Kato et al. 2011; Li et al. 2015). The current study identified that CD147 had an increased co-
localisation in TGF-β1-induced myofibroblasts, with CD44s and EDA-FN associated integrin, 
α4β7. CD44 and EDA-FN are essential mediators of myofibroblast terminal differentiation 
(Serini et al. 1998; Muro et al. 2008; Webber et al. 2009b; Meran and Steadman 2011; Midgley 
et al. 2013). Downregulation of the CD147 mRNA expression did not affect the mRNA 
expression of αSMA following TGF-β1 stimulation. However, the incorporation of αSMA into 
F-actin stress fibres was prevented.  Further, a decreased contractile ability was observed in 
TGF-β1-induced, myofibroblasts, when CD147 protein expression was completely silenced. 
The incorporation of αSMA into the F-actin cytoskeleton by the NH2-terminal motif AC-EED, 
requires the correct mechanical tension mediated by the combination of mature focal adhesion 
formation, cell-cell contact, cell-ECM contact and cytoskeletal re-arrangement (Hinz et al. 
2002; Clement et al. 2005).  EDA-FN is central to focal adhesion formation and fundamental 
for the correct mechanical tension required for differentiation (Hinz et al. 2001). That CD147 
was also found to co-localise with the EDA-FN-associated integrin, α4β7; and CD44, suggests 
that CD147 has a role in mediating the required tension for αSMA incorporation.  
Combining the findings of this thesis with previously published data, three possible 
mechanism for the function of CD147 differentiation are given below:    
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1) CD147 forms a complex with both CD44 and integrin α4β7, which links the ECM  
Integrin α4β7 has been determined to associate with a small GTPase known as, Ras Homolog 
Gene Family Member A (RhoA)(Abdi et al. 2013).  This signalling protein is activated when 
HA associates with CD44 and mediates intracellular cytoskeletal re-organisation (Bourguignon 
2008). Interestingly, in a study by Kawamura et al. (2003),  RhoA activation was upstream 
from ERK1/2 in a signalling mechanism that was determined to be CAV-1-dependent.  The 
current study also determined that silencing CD147 prevented TGF-β1-dependent, ERK1/2 
signalling. Furthermore a sub-population of CD147 was observed in lipid raft regions that 
contained CAV-1 in myofibroblasts.  Combining these data suggests that the intracellular 
activation of RhoA may depend on all three membrane proteins forming a CD44/CD147/α4β7 
complex.  However, to confirm this, an analysis of RhoA and ERK1/2 signalling by 
myofibroblast would be required, following inhibition of all the proteins separately.  The 
association of integrin α4β7 with EDA-FN is essential to myofibroblast formation (Kohan et 
al. 2010).  Therefore, the proposed CD44/CD147/α4β7 complex may contribute to mechanical 
tension by an intracellular and extracellular contractile force (Figure 6.3).  However, to 
confirm this hypothesis a more extensive analysis into CD44/CD147/α4β7 co-localisation and 
their position within the plasma membrane would be required.  
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2) CD147 mediates the correct mechanical tension for αSMA incorporation through 
separate association with integrin α4β7 and CD44s 
 
A further proposal for the role of CD147 in differentiation is that it associates with integrin 
α4β7 and CD44 independently; and mediates two separate functional properties.  CD44 is 
known to be essential for re-arrangement of the cytoskeleton that mediates multiple cellular 
functions, including differentiation, proliferation and migration (Thomas et al. 1993; Trochon 
et al. 1996; Meran et al. 2011b; Pham et al. 2011; Midgley et al. 2013).  Furthermore,  RhoA 
activates downstream mediator Rho-associated coiled coil containing kinase (ROCK), a 
serine/threonine kinase, known to be involved in actin contraction and stress fibre formation 
(Riento and Ridley 2003).  ROCK has been shown to phosphorylate myosin light chains of 
non-muscle myosin II (NM-II) and cofilin, both of which are actin binding proteins that play a 
pivotal role in stress fibre contraction and actin polymerisation, respectively.  CD147 also 
mediates the RhoA/ROCK pathway in cancer cell migration (Zhao et al. 2011).  Members of 
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Figure 6.3 – Schematic demonstrates possible CD44/CD147/α4β7 complex formation 
that may contribute towards the essential mechanical tension required for αSMA 
incorporation into F-actin stress fibres.  The signalling pathway shows the downstream 
activation of RhoA and ERK1/2, following TGF-β1 activation within CAV-1 lipid raft 
regions. 
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the Rho family have also been identified as essential for integrin signalling complexes to form 
and decreased Rho expression prevents downstream activation of ERK1/2 (Hotchin and Hall 
1995). 
Integrins are associated with cell-cell, cell-ECM and focal adhesion formation, all of 
which contribute to mechanotransduction signalling (Chen et al. 2004).   CD147 is primarily a 
MMP inducer and has been identified to accumulate around regions of cell-cell contact (Ma et 
al. 2010). It is widely identified to be associated with cell-ECM contact, due to its remodelling 
properties, facilitated by MMPs (Huet et al. 2008a; Ma et al. 2010).  The functional role of 
CD147 association with the integrin α3β1 has previously been identified as essential for cell 
adhesion, invasion, MMP induction and ECM remodelling; and the subsequent inhibition of 
α3β1 decreased these CD147 dependent responses (Dai et al. 2009). Similarly, in hepatoma 
cells, it was identified that FAK and paxillin, both essential downstream mediators of integrin 
function, were CD147-dependent (Tang et al. 2008a).  
That this study determined that silencing CD147 inhibited ERK1/2 activation may 
suggest that ERK1/2 is downstream from CD147/CD44 signalling or CD147/α4β7 signalling. 
Furthermore, previous studies have shown inhibiting CD44 or α4β7 decreases ERK1/2 
signalling, suggesting all are required for ERK1/2 activation (Kohan et al. 2010). Interestingly, 
ERK1/2 activation is also regulated through mechanical tension, therefore, the decreased 
ERK1/2 expression observed in this study may also result from CD147 reduction of mechanical 
tension from both pathways (Zou et al. 1998).   (Figure 6.4) shows the hypothetical roles of 
CD147/CD44 and CD147/α4β7 independently in mecahnotransduction and possible signalling 
regulation by each complex.  However, to confirm this hypothesis, further research is required. 
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3) CD147 mediates α4β7/EDA-FN and HA/CD44 association through the re-
arrangement of the ECM, via MMP induction. 
A final hypothesis suggests that CD147 mediates the receptor association with ECM 
components by induction and activation of MMPs which mediate ECM re-arrangement; 
facilitating receptor-ligand association.  In fact, one major area of research for CD147 
induction of MMPs examines the ECM re-arrangement to facilitate metastasis and 
invasiveness in cancer biology (Kanekura et al. 2002; Gabison et al. 2005).  In multiple 
tumour studies, CD147 requires association with integrins for MMP activation (Tang et al. 
2008b; Dai et al. 2009).  Therefore, the CD147/integrin α4β7 association observed in this 
F-Actin 
Figure 6.3 – Schematic to demonstrate hypothetical role of CD147 in 
mecahnotransduction signalling through mediation of two individual pathways.  [A] 
shows a possible intracellular signalling mechanisms that may result from 
HA/CD44/CD147 association. [B] represents a hypothetical role for CD147 
association with the EDA-FN integrin, α4β7.  
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study may be required for MMP induction and facilitate the EDA-FN/integrin α4β7 
association. Similarly, for terminal differentiation, the association of HA/CD44 is required 
for intracellular signalling and cytoskeletal re-arrangement (Ponta et al. 2003).  CD147 is 
thought to associate with CAV-1 in the membrane through its lower proximal Ig domain. 
Furthermore, this association is thought to promote clustering and induce MMP production 
(Tang and Hemler 2004).  The distal Ig domain of CD147 is well-recognised as an MMP 
activator (Iacono et al. 2007). The current study identified a population of CD147 in CAV-
1 raft regions. This may suggest that CD147 also anchors co-localised receptors within raft 
regions; which are commonly associated with essential intracellular signalling (Figure 
6.4). Therefore, silencing CD147 in this study may have prevented, firstly, the ECM re-
arrangement and secondly anchorage to the plasma membrane within raft regions; both 
reported to be essential for receptor ligand association and signalling (Simons and Toomre 
2000; Stivarou and Patsavoudi 2015).  Importantly failure of receptor ligand association 
and intracellular signalling would prevent the contractile response required for αSMA 
incorporation, as was observed in this study. 
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In conclusion CD147 and CD44s have both been identified to have a role in fibroblast 
differentiation.  However, these two abundantly expressed receptors are essential mediators for 
multiple cellular function and therefore, could not be used directly as a target for therapeutic 
treatments.    
 This study determined that CD147 was only important in TGF-β1 differentiation, but 
was not observed to mediate the IL-1β pro-inflammatory pathway.  One distinct difference 
between TGF-β1 and IL-1β pathways is the association with lipid raft regions.  The 
CD44/ICAM-1 association is independent of lipid raft regions, which may suggest that the pro-
fibrotic role observed by CD147 is raft-dependent. A more detailed examination of ICAM-1 
and its interaction/associations with the plasma membrane, may lead to a better understanding 
of cell membrane mediated signalling.  This current study identified separate populations of 
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Figure 6.4. - Schematic to show a possible role for CD147 in differentiation.  It is 
hypothesised that CD147 mediates ECM re-arrangement, via MMP induction by the distal Ig 
domain and anchorage to CAV-1 lipid rafts, via CD147 proximal domain.   
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CD147 in and out of raft regions in myofibroblasts.  Intracellular activation by CD147 has 
previously shown to be lipid raft-dependent, with an essential role for CAV-1 association (Tang 
and Hemler 2004).  A further investigation to this study may benefit from sorting lipid raft and 
non-raft populations of CD147, with an aim to determine which population is mediating the 
mechanical tension demonstrated in this thesis.  This may lead to identification of more specific 
targets that may be useful as a therapeutic treatment.  Indeed, some research has targeted lipid 
rafts directly and found that disruption of these regions prevented activation of downstream 
mediators (Parpal et al. 2001; Mollinedo et al. 2010).  However, for this to be a useful the 
treatment would need to specifically target diseased areas.  
Similarly a much more specific target would be required for therapeutic treatments of 
fibrotic and inflammatory responses than targeting HA/CD44s association directly. CD44v7 
has been shown to be highly expressed in non-differentiating, anti-fibrotic oral cells (See 
Appendix 2).  This study also determined that CD44v8 had a pro-inflammatory response. 
Furthermore, our recent studies have found that BMP-7 induction of CD44v7/8 in lung 
fibroblast prevents and reverses fibroblast differentiation.   
Future work may well identify therapeutic targets associated with the expression of 
these variants and their potential interactions. 
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Appendix 1 - CD44v6-10 sequence 
CD44v6 -Forward primer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v8/v9 
v9/v10 
v7/v8 
v6/v10 
Consensus sequence is shown on the top row.  The reference sequence is shown on the 
second row.  The sequence for CD44v6-10 is shown on the bottom row.  Exon-exon 
boundaries are indicated with arrows and annotations.  
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Appendix 2- Comparison of CD44 Variant expression in Dermal and Oral Fibroblasts 
ibroblasFibroblastsibroblasts 
Data demonstrates CD44 variant expression by unstimulated dermal and oral fibroblast and TGF-β1 induced 
fibroblasts.  Data shows independent experiments with each CD44 variant being relative to its Dermal 
fibroblast control.  Analysis was carried out by Sian Gardiner under my supervision. 
